# Title page

**Title**: AI in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against CLAIM and FUTURE-AI guidelines

**Authors**: Douwe J. Spaanderman MSc<sup>1\*</sup>, Matthew Marzetti MSc<sup>2,3\*</sup>, Xinyi Wan MSc<sup>1\*</sup>, Andrew F. Scarsbrook MD<sup>4,5</sup>, Philip Robinson MD<sup>4</sup>, Edwin H.G. Oei MD, PhD<sup>1</sup>, Jacob J. Visser MD, PhD<sup>1</sup>, Robert Hemke MD, PhD<sup>6</sup>, Kirsten van Langevelde MD, PhD<sup>7</sup>, David F. Hanff MD<sup>1</sup>, Geert J.L.H. van Leenders MD, PhD<sup>8</sup>, Cornelis Verhoef MD, PhD<sup>9</sup>, Dirk J. Grünhagen MD, PhD<sup>9</sup>, Wiro J. Niessen PhD<sup>1,10</sup>, Stefan Klein PhD<sup>1,†</sup>, Martijn P.A. Starmans PhD<sup>1,8,†</sup>
\*Shared first author

#### **Affiliations**:

†Shared last author

- 1. Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
- 2. Department of Medical Physics, Leeds Teaching Hospitals NHS Trust, UK
- 3. Leeds Biomedical Research Centre, University of Leeds, UK
- 4. Department of Radiology, Leeds Teaching Hospitals NHS Trust, UK
- 5. Leeds Institute of Medical Research, University of Leeds, UK
- 6. Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands
- 7. Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands
- 8. Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
- 9. Department of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands
- 10. Faculty of Medical Sciences, University of Groningen, Groningen, the Netherlands

# **Corresponding author**

Douwe J. Spaanderman

Internal postal address: P.O. Box 2040, 3000 CA Rotterdam, the Netherlands, Na-2624 Visiting address: office Na-2624, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands d.spaanderman@erasmusmc.nl

+31-10-7041026

#### **Authors addresses**

Douwe J. Spaanderman

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Matthew Marzetti

Department of Medical Physics, Level 1, Bexley Wing, St James's University Hospital, Beckett Street, Leeds, West Yorkshire, LS9 7TF, United Kingdom

#### Xinyi Wan

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Andrew F. Scarsbrook

Department of Nuclear Medicine, Level 1, Bexley Wing, St James's University Hospital, Beckett Street, Leeds, West Yorkshire, LS9 7TF, United Kingdom

#### Philip Robinson

Leeds Biomedical Research Centre, University of Leeds, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, United Kingdom

#### Edwin H.G. Oei

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Jacob J. Visser

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

## Robert Hemke

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center Meibergdreef 9, 1105AZ Amsterdam, the Netherlands

#### Kirsten van Langevelde

Department of Radiology, Leiden University Medical Center Albinusdreef 2, 2333 ZA Leiden, the Netherlands

#### David F. Hanff

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Geert J.L.H. van Leenders

Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Cornelis Verhoef

Department of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam,

Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

## Dirk J. Grünhagen

Department of Surgical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Wiro J. Niessen

Faculty of Medical Sciences, University of Groningen Antonius Deusinglaan 1, 9713 AV Groningen, the Netherlands

## Martijn P.A. Starmans

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Stefan Klein

Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands

#### Title:

AI in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against CLAIM and FUTURE-AI guidelines

# Summary

#### Background:

Soft-tissue and bone tumours (STBT) are rare, diagnostically challenging lesions with variable clinical behaviours and treatment approaches. This systematic review aims to provide an overview of Artificial Intelligence (AI) methods using radiological imaging for diagnosis and prognosis of these tumours, highlighting challenges in clinical translation, and evaluating study alignment with the Checklist for AI in Medical Imaging (CLAIM) and the FUTURE-AI international consensus guidelines for trustworthy and deployable AI to promote the clinical translation of AI methods.

#### Methods:

The systematic review identified literature from several bibliographic databases, covering papers published before 17/07/2024. Original research published in peer-reviewed journals, focused on radiology-based AI for diagnosis or prognosis of primary STBT was included. Exclusion criteria were animal, cadaveric, or laboratory studies, and non-English papers. Abstracts were screened by two of three independent reviewers to determine eligibility. Included papers were assessed against the two guidelines by one of three independent reviewers. The review protocol was registered with PROSPERO (CRD42023467970).

## Findings:

The search identified 15,015 abstracts, from which 325 articles were included for evaluation. Most studies performed moderately on CLAIM, averaging a score of  $28.9\pm7.5$  out of 53, but poorly on FUTURE-AI, averaging  $5.1\pm2.1$  out of 30.

## Interpretations:

Imaging-AI tools for STBT remain at the proof-of-concept stage, indicating significant room for improvement. Future efforts by AI developers should focus on design (e.g. define unmet clinical need, intended clinical setting and how AI would be integrated in clinical workflow), development (e.g. build on previous work, training with data that reflect real-world usage, explainability), evaluation (e.g. ensuring biases are evaluated and addressed, evaluating AI against current best practices), and the awareness of data reproducibility and availability (making documented code and data publicly available). Following these recommendations could improve clinical translation of AI methods.

## Funding:

Hanarth Fonds, ICAI Lab, NIHR, EuCanImage.

### Keywords:

Systematic Review; Soft-tissue and bone tumours; Radiological imaging; Artificial Intelligence; Medical Image Analysis, FUTURE-AI, CLAIM.

#### Panel 1

#### Research in context

#### Evidence before this study

Research on the use of AI in diagnosing and predicting the outcomes of soft-tissue and bone tumours (STBT) is becoming more prevalent. However, the clinical adoption of AI methods in this field remains limited, highlighting a significant gap between AI development and its practical implementation in healthcare settings. Previous reviews focused on the accuracy and performance of published STBT tools, however, did not investigate the quality of research. Recent efforts have introduced guidelines with comprehensive criteria specifically designed for structured reporting and responsible development, deployment, and governance of trustworthy AI in healthcare.

#### Added value of this study

This review examines the methodological quality of published literature by assessing it against two best-practice guidelines, which were chosen to complement each other and cover a wide range of criteria. Aspects related to study quality, study design, and trustworthy and deployable AI, as assessed in this review using the CLAIM and FUTURE-AI guidelines, may be even more important factors than their performance for assessing their potential translation to the clinic. This review highlights what the field is doing well and where future research should focus. The review includes all research using AI methods investigating STBT, giving it a far wider scope than previous reviews. Furthermore, this is a fast-moving field, hence updates on previous reviews are required.

## Implications of all the available evidence

Currently published AI methods are producing promising proof-of-concept results but are not ready for clinical application. This work highlights opportunities and provides recommendations for AI developers and clinical professionals for future research to drive clinical implementation.

#### Introduction

Primary soft-tissue and bone tumours (STBT) are among the rarest neoplasms in humans, comprising both benign and malignant lesions. Malignant STBT, i.e. sarcoma, account for approximately 1% of all neoplasms. These tumours may occur at any age and almost any anatomical site, arising from cells of the connective tissue, including muscles, fat, blood vessels, cartilage, and bones. The rarity of STBT, along with their diverse subtypes and varied clinical behaviour, poses substantial challenges in accurate diagnosis and prognosis.

Radiological imaging (including nuclear medicine) is crucial in evaluating and monitoring STBT. Technological advancements in imaging modalities have led to a substantial increase data volume, along with a corresponding growth in the expertise required for its interpretation. The growing utilisation of radiological imaging and complexity of analysis has increased radiologists' workload. Therefore, developing intelligent computer-aided systems and algorithms for automated image analysis that can achieve faster and more accurate results is crucial. For STBT, intelligent systems may help non-specialised radiologists in diagnosing rare cancers more effectively. Furthermore, an increased caseload is associated with higher interpretive error, which can be avoided with computer-aided diagnostic tools. 4,5

Artificial intelligence (AI) has become increasingly prevalent in medical image analysis. Over the last 7 years, the number of FDA-approved medical imaging AI products for radiology has substantially increased.<sup>6</sup> However, while medical imaging AI research in STBT has also substantially increased, there are no products developed for STBT among the FDA-approved list.<sup>7</sup> Hence, instead of purely developing novel technological solutions, more research should focus on aligning with areas of unmet clinical need.

Therefore, a systematic assessment of current published research is necessary to identify the issues required to overcome the translational barrier. This systematic review aims to evaluate the existing literature on AI for diagnosis and prognosis of STBT using radiological imaging against two best practice guidelines; CLAIM and FUTURE-AI.<sup>8,9</sup> CLAIM, endorsed by the Radiological Society of North America (RSNA), promotes comprehensive reporting of radiological research that uses AI. FUTURE-AI proposes ethical and technical standards to ensure responsible development, deployment, and governance of trustworthy AI in healthcare. Utilising both guidelines allows for comprehensive coverage of different aspects of AI research.<sup>10</sup> Additionally, this review discusses opportunities for future research to bridge the identified gap between AI research and clinical use in STBT.

#### **Methods**

This systematic review was prospectively registered with PROSPERO (CRD42023467970) and adheres to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines.<sup>11</sup> The full study protocol can be found online .<sup>12</sup>

#### Search strategy and selection criteria

Medline, Embase, Web of Science core collection, Google Scholar, and Cochrane Central Register of Controlled Trials were systematically searched for relevant studies. All papers published before 27/09/2023 were included in the initial search; the starting date depended on the coverage of the respective database searched. The detailed search strategy is listed in Appendix 1. The literature search was conducted by the Medical Library, Erasmus MC, Rotterdam, the Netherlands. The database search was repeated on 17/07/2024 to update publications.

Inclusion criteria were: (1) original research papers published in peer-reviewed journals, and (2) studies focusing on radiology-based AI or radiomics characterisation of primary tumours located in bone and/or soft tissues for tasks related to diagnosis or prognosis, e.g. no pure segmentation studies. Exclusion criteria were: (1) animal, cadaveric, or laboratory studies, and (2) not written in English language.

The complete reviewing methodology is illustrated in Figure 1. Three independent reviewers participated in title-and-abstract screening (DS, MM, XW). Retrieved papers were randomly divided into three batches. Reviewers 1 and 2 reviewed one batch, Reviewers 1 and 3 reviewed a second batch, and Reviewers 2 and 3 reviewed the final batch. In cases where there were disagreements in the screening of an abstract, the third reviewer who was not initially involved in reviewing the specific abstract, adjudicated any conflicts.

#### Data analysis

Each paper was scored according to CLAIM and FUTURE-AI guidelines. Checklists were developed based on each guideline. Blank checklists are available in Appendix 2. These guidelines were chosen for their complimentary nature and comprehensive coverage of clinical AI tool requirements.<sup>10</sup>

The CLAIM checklist was adapted from the checklist implemented by Si et. al. to contain more detail in some of the more general checklist items. 8,13,14 CLAIM consists of 44 items, covering the following sections: title, abstract, introduction, methods, results, discussion, and other information. The majority of items focus on the methods (30/44 items). The Methods section is further divided into the following subsections: Study design, Data, Ground truth, Data

partition, Testing data, Model, Training, and Evaluation. Similarly, the Results section is divided into Data and Model performance. We further divided three items into twelve sub-items to provide more detailed information. These were: (4) Study objectives and hypotheses (4a and 4b), (7) Data sources (7a-d), and (9) Data preprocessing steps (9a-f). The adapted CLAIM checklist totalled 53 items.

The FUTURE-AI checklist was created from the FUTURE-AI guideline and contains 30 items. These items are split according to the six FUTURE-AI principles: Fairness (3), Universality (4), Traceability (6), Usability (5), Robustness (3), Explainability (2), and General (7). Additionally, FUTURE-AI specifies guidelines for AI tools at various machine learning technology readiness levels (TRL). It recommends (+) or strongly recommends (++) specific guidelines for tools at the proof-of-concept stage (Research) and for those intended for clinical development (Deployable).

All items in both sets of guidelines were scored between 0 and 1, with 0 meaning the item was not addressed, 0.5 meaning it was partially addressed (where relevant and only in FUTURE-AI) and 1 meaning it was fully addressed.

To ensure consistency between scores among reviewers, a subset of papers (n=45) was selected for independent review by all three reviewers. The subset was selected by ordering the papers alphabetically based on the first author's name and choosing the first 45 papers from this order in the initial search. The number of disagreements for each item in either guideline was recorded, and inter-reader variability for each guideline was measured by calculating Fleiss' Kappa statistics (κ). Fleiss kappa statistics were interpreted according to the guidance given by Fleiss et al., with a score 0–0·4 indicating poor agreement, 0·41–0·75 showing good agreement and >0·75 showing excellent agreement. To construct 95% confidence intervals (95% CI) for the inter-reader variability, 1000× bootstrap resampling was employed. The percentage agreement between all three reviewers was calculated for each item. Following this a consensus discussion was conducted between all three reviewers, allowing discussion and resolution of any systematic differences in interpretation and scoring of specific items. Next, each reviewer re-scored the same subset a second time, several weeks after the first scoring. Kappa statistics and percentage agreements were re-calculated.

After consensus, the remaining included papers were equally divided between the three reviewers and reviewed by a single reviewer. If a reviewer was uncertain how to score a paper, they consulted one or more of the other reviewers for confirmation or discussion. In addition to scoring the CLAIM and FUTURE-AI checklists, the following information was recorded for each paper: (1) year of publication, (2) journal of publication, (3) disease type investigated (soft

tissue sarcoma, bone sarcoma, or gastrointestinal stromal tumour – GIST), (4) study design (retrospective or prospective – if a study used both retrospectively and prospectively acquired data it was recorded as being a prospective study), (5) outcome predicted (diagnosis, prognosis, or both), (6) imaging modality (MRI, CT, ultrasound, X-ray, PET-CT, PET-MRI, scintigraphy, or multiple imaging modalities), (7) data source (public, single centre, or multi-centre), and (8) availability of data and AI model source code.

The performance metrics of the corresponding AI models were collected for the top 20 performing papers, as determined by their combined CLAIM and FUTURE-AI scores, that performed external validation. Only the top 20 papers were included for this analysis as reported model performance cannot be reliably reproduced or considered clinically meaningful as low scoring studies lack methodological transparency or do not adhere to best scientific practices. For the same reason, only externally validated papers were selected to ensure robust assessment of model generalizability, reducing the risk of overfitting and dataset-specific bias, thus strengthening the clinical relevance of the reported findings.

#### **Statistics**

The number of papers adhering to each item of CLAIM/FUTURE-AI was calculated. Descriptive statistics of how well papers scored in each (sub)section/principle were calculated, including mean, standard deviation (SD), maximum, and minimum score, as well as the mean and SD of the guideline adherence rate (AR), which is the score divided by the maximum achievable score.

## Role of Funders

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

### Ethics

This study is a systematic review of published work and thus ethical approval was deemed unnecessary.

#### **Results**

Database searches identified 15,015 published studies, with 5,667 duplicates. After screening, 454 articles were retained for full-text review. After excluding 129 studies a total of 325 unique studies were included in the systematic review (Figure 2). Fifteen of the excluded papers were part of the reproducibility subgroup, meaning 30 articles were independently reviewed by all reviewers. A complete reference list of the final 325 included papers is provided in Appendix 3. Main reasons for exclusion were focusing on different entities (e.g. renal cancer), no use of radiological imaging, or lacking AI-based analysis.

Included studies were published between 2008 and 2024, mostly in the last five years (Figure 3). Of the 325 included studies, most AI methods used hand-crafted imaging features with machine learning (n=221, 68%). Recently, more AI methods used model-learned imaging features (n=62, 19%), i.e. deep learning, or a combination of model-learned and hand-crafted imaging features with machine learning (n=29, 9%). Thirteen studies used hand-crafted imaging features without machine learning.

Study characteristics are illustrated in Figure 4. Disease types included soft tissue tumours (n=125, 38·5%), bone tumours (n=114, 35·1%), and GIST (n=82, 25·2%). Only four studies included both soft tissue and bone tumours (1.2%). Study design was mostly retrospective (n=272, 83.7%), with fewer prospective studies (n=38, 11.7%), and a minority where study design was not clearly documented (n=15, 4.6%). The majority of reports focused on developing AI methods to predict diagnosis (n=206, 63·4%), 109 (33·5%) evaluated prognosis, and 10 (3.1%) studied a combination of diagnosis and prognosis of the disease. Various radiological techniques were evaluated, with 144 (44.3%) studies using MRI, 94 (28.9%) CT, 34 (10·5%) ultrasound, 30 (9·2%) X-ray, 10 (3·1%) PET-CT, 3 (0·9%) PET-MRI, and 1 (0·3%) scintigraphy, and 9 (2.8%) multiple modalities. One-hundred-and-ninety (58.5%) studies collected data from a single centre, whereas 93 (28.6%) utilised imaging from multiple centres. Nineteen studies did not clearly document data provenance (5.8%). Furthermore, 23 (7.1%) studies used publicly available data from two sources (Table 1). AI methods were most often validated with separate internal test data (n=214, 65.8%), and sometimes additionally with external test data (n=70, 21.5%). Several AI methods were not validated with independent data or validation was not clearly documented (n=41, 12.6%). Only 5 (1.5%) studies made data available, with 238 (73.2%) studies not providing or not specifying data availability, and 82 (25.2%) studies stating data would be made available on reasonable request. Similarly, AI source code to facilitate reproducibility was only made available in 23 (7·1%) studies, with 287 (88·3%) not providing or not specifying code availability, and 15 (4·6%) studies indicating code would be made available on reasonable request.

Kappa statistics for inter-reader variability increased from 0·58 (95% CI: [0·55, 0·62]) and 0·68 (95% CI: [0·61, 0·75]) for CLAIM and FUTURE-AI before consensus discussion, to 0·80 (95% CI: [0·78, 0·83]) and 0·92 (95% CI: [0·88, 0·95]) after, showing excellent agreement (Supplementary Figure S1 and S2).

Individual scores for each item in Figure 5 for CLAIM and 6 for FUTURE-AI. Section level scores are provided in Table 2 and 3. Scores by year are available in Supplementary Figure S3 and S4, both showing an increasing trend. Scores by tumour type, method type, and outcome are available in Supplementary Figures S5 and S6, all showing no clear distinction between groups. Individual paper scores for each item are documented in Supplementary Figures S7 and S8, and are also available online as interactive figures and tables.<sup>16</sup>

The included studies performed moderately on the CLAIM checklist, with a mean score of 28·9 out of 53 (SD: 7·5, min–max: 4·0–48·0, AR mean±SD: 55%±14%). All items were reported at least once, but several were only reported in less than 15% of the papers (n≤50 papers) including: define a study hypothesis at the design phase (CLAIM-4b, 13·8%), data deidentification methods (CLAIM-11, 3·4%), how missing data were handled (CLAIM-12, 8·2%), intended sample size and how it was determined (CLAIM-21, 4%), robustness or sensitivity analysis (CLAIM-30, 13·8%), methods for explainability or interpretability (CLAIM-31, 12·9%), registration number and name of registry (CLAIM-34, 2·8%), and documented where full study protocol can be accessed (CLAIM-42, 12·3%).

The included studies rarely adhered to FUTURE-AI, with a mean score of  $5\cdot1$  out of 30 (SD:  $2\cdot1$ , min-max:  $0-11\cdot5$ , AR:  $17\%\pm7\%$ ). From the 30 items, 5 were never reported. Only 6 items were partially reported in over half of the reviewed papers (n>162) including: collecting and reporting on individuals' attributes (Fairness-2,  $83\cdot1\%$ ), using community-defined standards (Universality-2, 56%), defining use and user requirements (Usability-1,  $85\cdot2\%$ ), engaging interdisciplinary stakeholders (General-1,  $86\cdot2\%$ ), implementing measures for data privacy and security (General-2,  $85\cdot2\%$ ), and defining an adequate evaluation plan (General-4,  $67\cdot7\%$ ).

Strongly recommended items by FUTURE-AI for proof-of-concept AI studies (Research), were reported more frequently than recommended items, with mean scores of 2·9 out of 12 (SD: 1·1, min–max: 0–7, AR: 24%±9%) and 2·3 out of 16 (SD: 1·2, min–max: 0–6·5, AR: 14%±8%), respectively. However, this trend was not observed in items intended to assess studies for clinical deployability (Deployable), where the mean scores were 3·8 out of 24 (SD: 1·7, min–max: 0–10, AR: 16%±7%) for strongly recommended items and 1·3 out of 4 (SD: 0·7, min–max: 0–3, AR: 33%±18%) for recommended items.

Performance measurements of the top 20 performing papers (summed score of both CLAIM and FUTURE-AI) which included external validation are provided in Table 4. These studies covered diverse disease types (soft-tissue tumours: n=9, bone tumours: n=8, GIST: n=3), imaging modalities (MRI: n=11, CT: n=4, X-ray: n=4, ultrasound: n=1), outcomes (diagnosis: n = 12, prognosis: n = 7 and both diagnosis and prognosis: n = 1), and AI methodologies (machine learning model using a combination of hand-crafted and model-learned imaging features: n=3; machine learning using model-learned features: n=6; machine learning using hand-crafted imaging features: n=11). Overall, AI methods demonstrated strong performance for their respective tasks, however there is a wide range in performance between models (AUC range: 0.64-0.95). However, most studies relied on a single centre for external validation (n=12), and only a few included prospective validation (n=2). These studies had a mean score of 40·4 out of 53 (SD: 3·0, AR mean±SD: 76%±5·8%) for CLAIM and 8·4 out of 30 (SD: 1·6, AR mean±SD: 28%±5·4%) for FUTURE-AI. Finally, among these top 20 studies, we explored potential associations between performance metrics, individual guideline scores, and three main study categories, as summarized in Supplementary Table S1. This showed no obvious differences in scores and performance metrics between any of the groups.

#### **Discussion**

This work has systematically identified and summarised radiological imaging-AI research on STBT and conducted comprehensive evaluation of published literature against two bestpractice guidelines: CLAIM and FUTURE-AI. These guidelines were developed to ensure that AI tools target unmet clinical needs, are transferrable, generalisable, and can be used in realworld clinical practice. Analysis revealed a rapid increase in experimental AI tools for imagingbased STBT evaluation over the past five years. Studies performed moderately against CLAIM  $(28.9\pm7.5 \text{ out of } 53)$  and poorly against FUTURE-AI evaluations  $(5.1\pm2.1 \text{ out of } 30)$ . The poor results in FUTURE-AI are expected as these guidelines are recent and set high requirements. Several papers do show higher scores in both CLAIM and FUTURE-AI (Table 4) and show promising results in external validation cohorts (AUC range: 0.784-0.948). However, the highest scoring paper achieved only a 11.5 out of 30 in FUTURE-AI, highlighting room for improvement. These results suggest that while progress has been made in developing AI tools for STBT, most studies are still at the proof-of-concept stage and there remains substantial room for improvement to guide future clinical translation. Panel 2 summarises the authors' recommendations, focusing on five keys topics: design, development, evaluation, reproducibility, and data availability.

In the design stage, several critical aspects warrant more attention. Intended clinical settings (Universality-1) and prior hypotheses (CLAIM-4b) should be reported. On a positive note, over 85% of studies involved interdisciplinary teams (Usability-1, General-1), which is recommended for effective AI tool development. However, most studies did not comprehensively identify possible sources of bias at an early stage (Fairness-1, Robustness-1), which could limit the applicability of these AI tools. To overcome this, interdisciplinary stakeholders should work together from the design stage to identify the clinical role of the AI tool, ensure it integrates into the clinical workflow, and any possible sources of bias.

In the development stage, studies generally reported dataset source and conducted research with appropriate ethical approvals (CLAIM-7). However, almost half of studies did not assess biases during AI development (Fairness-3) and very few studies trained with representative real-world data (Robustness-2), which can hinder the transferability of AI tools, especially given the highly heterogeneous imaging characteristics of STBT. Another notable gap is a lack of focus on explainability and traceability. Few studies addressed items under FUTURE-AI Explainability (1-2) and Traceability (1-3), similar shortcoming was observed in the CLAIM checklist (CLAIM-31). While accuracy is crucial in medical practice, it is often argued that AI methods should go beyond pure performance metrics by addressing other factors such as prediction uncertainties, explaining their outputs, and providing clinicians with detailed information. <sup>17</sup> For AI tools to be effective in clinical decision-making, explainability is vital to ensure clinicians

understand and can trust the AI's reasoning. Additionally, to assist with AI development, research should build on previous work where possible. To assist with this, researchers should continue to adhere to community-defined standards, which is currently done in over half of the reviewed papers, and ensure their code is available. This review shows that almost all included studies developed new models rather than adapting or enhancing existing ones, even when promising results were achieved. Finally, it is integral that AI tools are easy for the end-user to use in the clinical workflow, however only two studies developed a graphical user interface for user experience testing (Usability-3). 19,20

Regarding evaluation, while over 85% of studies adopted relevant metrics and reported AI algorithm performance (CLAIM-28 and 37), only 22% conducted external validation (CLAIM-33), and most used single-institute datasets (Universality-3). Furthermore, several studies lacked thorough internal validation (Robustness-3, General-4). AI tools should be tested against independent external data, ideally from multiple sources, to assess the tool's universality and prevent site-specific bias. Accuracy metrics should also be compared against current best-practice (i.e. compared to radiologists) to ensure AI tools offer improvements in outcomes. Less than 20% of studies reported failure analysis or incorrectly classified cases (CLAIM-39). Including failure analysis is crucial to identify potential pitfalls, helping users understand when it is appropriate to use the tool. Developers should also ensure that the tool is robust against the biases identified during the design stage.

Regarding reproducibility, most studies fail to provide adequate materials (code, model, and data) to reproduce published results. Only around 10% of studies offered a full study protocol, including comprehensive methodology or code. Making protocols and code available enables others to reproduce the study across multiple steps, such as data preprocessing, ground truth acquisition, model construction, and training procedure. The lack of accessible and reproducible AI research in STBT could impede the adoption of these tools, as sarcoma centres may struggle to reproduce the tools performance locally. Adhering to guidelines such as CLAIM could enhance the quality and accessibility of these protocols.

Regarding data availability, there is a lack of freely accessible annotated imaging datasets of STBT, as highlighted in Table 1. Although 25% of published research stated that data used was available by request, a recent study by Gabelica et al. (2022) investigating compliance with data sharing statements showed a response rate of 14%, with only 6·8% supplying the data.<sup>21</sup> One challenge in creating these datasets is the time required and the need for an easy-to-use format. Structured and standardised reporting in clinical practice could help reduce the effort needed for retrospective data collection. However, AI developers often struggle to collate data themselves, especially since STBT are rare and only treated at tertiary sarcoma centres. This

underscores the importance of collaborating with clinical professionals. Increasing data availability would accelerate AI tool development and allow for external validation of models. Potential solutions include hosting "grand challenges" where clinicians provide data for AI developers to tackle a real-world clinical problem, or employing federated learning, which has proven effective for training AI models on rare tumours across international networks.<sup>22-24</sup>

Several reviews described the use of AI or radiomics in STBT management.<sup>25-28</sup> This study expands and complements these previous reviews, including a substantially larger volume of included publications (325 vs. 21-52 reports) primarily due to our extended scope and search strategy, including benign soft-tissue tumours, bone tumours, and a broad range of AI methods (i.e. not limiting to radiomics with hand-crafted features). Furthermore, most previous reviews only examined the accuracy and performance of published AI tools in the field; the current systematic review instead examined the methodological quality of published literature by assessing this against best-practice guidelines. The only other systematic reviews that, to the authors knowledge, have assessed quality of AI research in radiology imaging for STBT are Crombé et al. (2020) (52 studies) and De Angelis et al. (2024) (49 studies), both scoring against the Radiomics Quality Score (RQS).<sup>25,26</sup> In this study, different scoring systems were deliberately chosen as CLAIM and FUTURE-AI are independent but complementary guidelines, providing a broader assessment of overall quality than using only one. 10 FUTURE-AI allows assessment of trustworthiness, deployability, and translation to clinical practice, while CLAIM guidelines, which are endorsed by the RSNA, ensures that studies are reported according to a standard set of information especially designed for medical imaging AI. Findings indicate that the field continues to produce promising proof-of-concept results but is not ready to make the jump to clinical application. This agrees with earlier work in the field.

To better understand the relationship between adherence to reporting guidelines and model performance, we examined the top 20 studies with the highest combined CLAIM and FUTURE-AI scores. Our analyses suggest that no particular subfield demonstrates consistently superior performance, with reported metrics varying widely—even among similar models. This underscores the need for further external validation and standardization. Whilst some studies show promising results, the overall heterogeneity highlights the complexity of AI performance assessment.

Subgroup analysis in which CLAIM and FUTURE-AI scores were investigated by tumour type, method type and outcome, showed no obvious differences between groups although papers performing statistics on hand crafted features scored worse than studies which used some form of machine learning. This is not surprising as the guidelines we chose focus on the use of AI. There was a general trend for a small increase in scores for both guidelines over time. This

implies that whilst the quality of AI-based research is improving over time no field assessed in this review is ahead than any other.

There are limitations to this study. First, due to the large volume of literature, most papers were scored by a single reviewer. However, a sub-group of papers were scored by three reviewers followed by consensus analysis, showing excellent agreement, and reviewers remained in discussion if they had doubts about how best to score a paper for a particular category. Two or more reviewers per paper might have provided more robust results but would have required a significant time investment for likely only marginal gains. Secondly, in the reproducibility study with subgroups, papers were selected by alphabetical order based on the first author's name. While this approach introduces a degree of randomness, a fully randomised selection process would have been more robust to minimise potential biases. Third, there are other scoring guidelines such as APPRAISE AI, TRIPOD-AI, or RQS.<sup>51-53</sup> Future studies could benefit from integrating other frameworks, other than CLAIM and FUTURE-AI, to provide a more comprehensive evaluation of both reporting adherence and study quality

In conclusion, this review discusses the growing volume of published work evaluating imaging-related AI tools to aid in diagnosis, prognosis, and management of soft tissue and bone tumours. The top performing papers, as determined by both guidelines, may represent encouraging steps toward bringing AI in radiology closer to clinical translation, however even these have some limitations. The identified limitations of the reviewed studies with respect to CLAIM and FUTURE-AI guidelines will need to be addressed before such tools can translate into the clinical domain. Several opportunities have been identified and the authors' recommendations to promote translation of AI methods into clinical practice are summarised in Panel 2. Addressing these points may help drive clinical adoption of AI tools into the radiology workflow in a responsible and effective way.

#### **Contributors**

D.J.S., M.M., X.W.: conceptualisation, data curation, formal analysis, investigation, methodology, project administration, visualisation, writing – original draft, and writing – review & editing; S.K., M.P.A.S: conceptualisation, investigation, methodology, supervision, writing – review & editing; A.F.S., P.R., E.H.G.O., J.J.V., R.H., K.L., D.F.H., G.J.L.H.L., C.V., D.J.G., W.J.N.: methodology, supervision, writing – review & editing; S.K., M.P.A.S., M.M., E.H.G.O., J.J.V., C.V., D.J.G., W.J.N.: funding acquisition. All authors read and approved the final version of the manuscript. D.J.S, M.M., X.W., S.K., M.P.A.S. have accessed and verified the data. D.J.S, M.M., X.W. have contributed equally. S.K. and M.P.A.S. have contributed equally.

## **Data Sharing Statement**

Empty checklists for this review are included in the supplementary material. All data collected and analysed in this study are available online. A website (https://douwespaanderman.github.io/AI-STTandBoneTumour-Review/) with interactive figures and tables with scores for each paper is also available online.

## **Declaration of Interests**

WJN is the founder of Quantib and was scientific lead until 31-1-2023. JJV received a grant to institution from Qure.ai / Enlitic; consulting fees from Tegus; payment to institution for lectures from Roche; travel grant from Qure.ai; participation on a data safety monitoring board or advisory board from Contextflow, Noaber Foundation, and NLC Ventures; leadership or fiduciary role on the steering committee of the PINPOINT Project (payment to institution from AstraZeneca) and RSNA Common Data Elements Steering Committee (unpaid); phantom shares in Contextflow and Quibim; chair scientific committee EuSoMII (unpaid); chair ESR value-based radiology subcommittee (unpaid); member editorial board European Journal of Radiology (unpaid). SK and EHGO are scientific directors of the ICAI lab "Trustworthy AI for MRI", a public-private research program partially funded by General Electric Healthcare. The other authors do not have any conflicts of interest.

## Acknowledgments

This research was supported by an unrestricted grant of Stichting Hanarth Fonds, The Netherlands. MPAS and SK acknowledge funding from the research project EuCanImage (European Union's Horizon 2020 research and innovation programme under grant agreement Nr. 95210). MPAS also acknowledges funding from a NGF AiNed Fellowship (NGF.1607.22.025). MM, Doctoral Clinical and Practitioner Academic Fellow, NIHR302901, is funded by Health Education England (HEE) / National Institute for Health and Research (NIHR) for this research project. This research was conducted within the "Trustworthy AI for

MRI" ICAI lab within the project ROBUST, funded by the Dutch Research Council (NWO), GE Healthcare, and the Dutch Ministry of Economic Affairs and Climate Policy (EZK). AS receives salary support from ICNIHR Leeds Biomedical Research Centre (NIHR203331). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The views expressed in this publication are those of the author and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.

# <u>Panel 2: Recommendations to promote clinical translation of AI methods for soft-tissue and bone tumours.</u>

#### Design

- Interdisciplinary stakeholders should define; (A) the unmet clinical need, (B) the intended use of AI, (C) intended clinical setting in which AI should operate, (D) the end-user requirements, (E) how AI would operate in clinical workflow.
- Possible types and sources of bias (e.g. sex, age, ethnicity, socioeconomics, geography) should be identified at the early design stage.

#### **Development**

- Data used for AI development should reflect real-world data used in the intended clinical setting or preferably retrieved from the clinical setting. Additionally, sources of variation and potential biases should be investigated early in the development process.
- Explainability of AI methods should be developed and implemented in a way that it is possible to understand why an AI tool has arrived at its predictions.
- AI development should build on previous work by: (A) adhering to community-defined standards, and (B) considering previous existing methods by validating or improving them whenever possible.
- Ensure that AI tools are easy for the end-user to use in a clinical setting.

#### **Evaluation**

- AI tools should be evaluated using independent external test data. Limits on universality of the external test sets should be discussed.
- AI tools should be evaluated against current best practices, e.g. classification by radiologist or histology results from biopsy, and evaluated with intended end-users.
- Failure analysis of incorrect classified cases should be conducted.
- The robustness and sensitivity to variations and biases in data, identified prior to AI development, should be thoroughly investigated.

## Reproducibility

- Code should be made publicly available, readable, usable and traceable to increase confidence in the method.
- The Methods section should comprehensively cover all aspects of AI development, including; (A) data preprocessing, (B) ground truth acquisition, (C) a detailed description of the AI methodology, and (D) the training procedures. To this end, the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) could be followed.

#### **Data availability**

- Structured and standardised reporting should be introduced in clinical practice to limit the manual work required in retrospective data collection.
- Tertiary sarcoma centres should collect labelled data and make this publicly available, preferably in the context of a "grand challenge", while protecting patient details and respecting privacy.
- To protect patient privacy and avoid excessive data-sharing, researchers could work together using a federated learning approach.

# **Tables**

 Table 1: Open-access datasets available with imaging for soft-tissue and bone tumours.

Data	Vallières el al. (2015) [29]	Starmans et al. (2021) [preprint - 30]	
Origin	Canada	the Netherlands	
Disease type	Various soft-tissue sarcoma (Extremities)	sarcoma Various soft-tissue tumours	
Imaging modality	MR and PET-CT	MR or CT	
Number of patients	51	564	
Additional data	Tumour segmentation and clinical outcome (lung metastasis)	Tumour segmentation and clinical outcome (phenotype)	

**Table 2**: Summary scores of the included studies for each (sub)section of the Checklist for Artificial Intelligence in Medical Imaging (CLAIM).

(Sub)section Maximum achievable score		Score (Mean ± SD) Max scor		Min score	Adherence rate (Mean ± SD)	
Title / Abstract	tle / Abstract $2 \cdot 0$ $2 \cdot 0 \pm 0 \cdot 2$		2.0	0.0	98% ± 12%	
Introduction	3.0	2·1 ± 0·4	3.0	0.0	70% ± 14%	
Methods	38.0	19·8 ± 5·8	34.0	0.0	52% ± 15%	
Study design	2.0	$1.8 \pm 0.5$	2.0	0.0	$89\% \pm 24\%$	
Data	15.0	$8{\cdot}0\pm2{\cdot}8$	14.0	0.0	$54\% \pm 18\%$	
<b>Ground truth</b>	5.0	$2.9 \pm 1.4$	5.0	0.0	57% ± 29%	
<b>Data partitions</b> 2.0		$1.7\pm0.6$	2.0	0.0	$87\% \pm 30\%$	
Testing data 1.0		$0.0 \pm 0.2$ 1.0		0.0	$4\%\pm20\%$	
Model	3.0	$1.5 \pm 1.0$	3.0	0.0	51% ± 33%	
Training 3.0		$1.2 \pm 0.9$	3.0	0.0	40% ± 31%	
Evaluation	7.0	$2.7 \pm 1.3$	6.0	0.0	$38\% \pm 18\%$	
Results	5.0	2·6 ± 1·2	5.0	0.0	52% ± 24%	
Data	2.0	$1.0 \pm 0.8$	2.0	0.0	50% ± 39%	
Model 3·0		$1.6 \pm 0.8$	3.0	0.0	53% ± 25%	
Discussion	2.0	1·3 ± 0·6	2.0	0.0	66% ± 32%	
Other information	3.0	1·2 ± 0·9	3.0	0.0	39% ± 31%	
Overall	53.0	28·9 ± 7·5	48.0	4.0	55% ± 14%	

**Table 3**: Summary scores of the included studies for each principle from the FUTURE-AI international consensus guideline for trustworthy and deployable AI.

Principle	Maximum	Score (Mean ±	Max	Min	Adherence rate
Frincipie	achievable score	SD	Score	Score	$(Mean \pm SD)$
Fairness	3.0	1·1 ± 0·7	2.5	0.0	37% ± 22%
Universality	4.0	$0.8 \pm 0.7$	3.0	0.0	$20\% \pm 17\%$
Traceability	6.0	$0.1 \pm 0.2$	1.0	0.0	$1\% \pm 3\%$
Usability	5.0	$0.5 \pm 0.3$	3.0	0.0	$10\% \pm 7\%$
Robustness	3.0	$0.4 \pm 0.4$	2.5	0.0	$14\% \pm 12\%$
Explainability	2.0	$0.1 \pm 0.2$	1.5	0.0	$4\% \pm 12\%$
General	<b>7·0</b>	$2 \cdot 2 \pm 0 \cdot 8$	3.5	0.0	32% ± 11%
Overall	30.0	5·1 ± 2·1	11.5	0.0	17% ± 7%

**Table 4:** Performance measurements of the top 20 performing papers, as determined by their combined CLAIM and FUTURE-AI scores, among those that performed external validation. AUC = area under the curve, CI = confidence interval, NPV = negative predictive value. \*AI development centre was also included as one of the eight external validation centres. † Values are mean ± standard deviation

Author	Short description	Validation	Performance (Proportion, 95% CI)
Ye et al. [31]	A multi-task machine learning model using learned imaging features (deep learning) for the segmentation, detection, and differentiation of malignant and benign primary bone tumours, as well as bone infections, leveraging multi-modal inputs including T1-weighted MRI, T2-weighted MRI, and clinical data.	External validation 53 patients from 1 centre	AUC: 0·900 (0·773–1·000) Accuracy: 0·783 (0·581–0·903) Sensitivity: 0·756 (0·552–0·886) Specificity: 0·886 (0·764–0·950)
Dong et al. [32]	Machine learning model using learned imaging features (deep learning) differentiating gastrointestinal stromal tumours (GISTs) and leiomyomas on endoscopic ultrasonography.	External validation 241 patients from 1 centre  Prospective validation 59 patients from 1 centre	External validation AUC: 0.948 (0.921–0.969) Accuracy: 0.917 (0.875–0.946) Sensitivity: 0.903 (0.834–0.945) Specificity: 0.930 (0.872–0.963) Precision: 0.919 (0.853–0.957) NPV: 0.915 (0.855–0.952)  Prospective validation (for GISTs and leiomyomas, respectively) AUC: 0.865 (0.782–0.977) and 0.864 (0.762–0.966) Accuracy: 0.865 and 0.864 Sensitivity: 0.897 and 0.857 Specificity: 0.833 and 0.871 Precision: 0.839 and 0.881
Xie et al. [33]	Machine learning model using learned imaging features (deep learning) to classify histological types of primary bone tumours on radiographs.	External validation 89 patients from 1 centre	AUC: 0.873 (0.812–0.920) Accuracy: 0.687 (0.614–0.783) Sensitivity: 0.572 (0.457–0.685) Specificity: 0.916 (0.893–0.938)
Xu et al. [34]	Machine learning model using a combination of hand-crafted and model-learned imaging features to differentiate between retroperitoneal lipomas and well-differentiated liposarcomas based on MDM2 status on contrast-enhanced CT.	External validation 63 patients from 2 centre	AUC: 0·861 (0·737–0·985) Accuracy: 0·810
Arthur et al. [35]	Machine learning model using hand- crafted imaging features classifying histological type and tumour grade in retroperitoneal sarcoma on CT.	External validation 89 patients from 8 centres*	Histology and Grade AUC: 0.928 and 0.882 Accuracy: 0.843 and 0.823 Sensitivity: 0.923 and 0.800 Specificity: 0.829 and 0.848 Precision: 0.480 and 0.865 NPV: 0.984, 0.778
Guo et al. [36]	Machine learning model using a combination of hand-crafted and model-learned imaging features to classify histological grade and predict prognosis of soft-tissue tumours on MRI.	External validation 125 and 44 patients from 2 centres  Prospective validation 12 patients from 1 centre	External validation (Centre 1 and Centre 2) AUC: 0.860 (0.787–0.916) and 0.838 (0.696–0.932) Accuracy: 0.840 and 0.750 Sensitivity: 0.835 and 0.840 Specificity: 0.794 and 0.737 Hazard ratio: 4.624 (1.924–11.110) and 2.920 (0.603–14.150)  Prospective validation AUC: 0.819 (0.501–0.974) Accuracy: 0.667 Sensitivity: 0.667 Specificity: 1.000

Gitto et	Machine learning model using hand-	External validation	AUC: 0.94 for atypical cartilaginous
al. [37]	crafted imaging features differentiating atypical cartilaginous tumour and grade II chondrosarcoma of long bones on MRI.	65 patients from 1 centre	tumour and 0·90 for grade II chondrosarcomal Accuracy: 0·92 Sensitivity: 0·92 Precision: 0·92
Von Schaky et al. [38]	Machine learning model using hand- crafted imaging features to distinguish between benign and malignant bone lesions on radiography.	External validation 96 patients from 1 centre	AUC: 0·90 Accuracy: 0·75 (0·65–0·83) Sensitivity: 0·90 (0·74–0·98) Specificity: 0·68 (0·55–0·79) Precision: 0·57 (0·42–0·71) NPV: 0·94 (0·82–0·99)
Gitto et al. [39]	Machine learning model using hand- crafted imaging features differentiating atypical cartilaginous tumour and high-grade chondrosarcoma of long bones on radiography.	External validation 30 patients from 1 centre	AUC: 0·90 Accuracy: 0·80 Sensitivity: 0·89 Specificity: 0·67
Cao et al. [40]	Machine learning model using hand- crafted imaging features predicting the local recurrence after surgical treatment of primary dermatofibrosarcoma protuberans, based on MRI.	External validation 42 patients from 1 centre	AUC: 0·865 (0·732–0·998) for 3- year and 0·931 (0·849–1·00) for 5 year C-index: 0·866 (0·786–0·946)
Yang et al. [41]	Machine learning model using hand- crafted imaging features predicting progression-free survival after imatinib therapy in patients with liver metastatic gastrointestinal stromal tumours on multi-sequence MRI.	External validation 45 patients from 1 centre	AUC: 0·766 for 1-year, 0·776 for 3-year, and 0·893 for 5-year C-index: 0·718 (0·618–0·818)
Chen et al. [42]	Machine learning model using hand- crafted imaging features predicting pathologic response to neoadjuvant chemotherapy (NAC) in patients with osteosarcoma on MRI.	External validation 34 patients from 3 centres	AUC: $0.842 (0.793-0.883)$ Accuracy: $0.765 \pm 0.020^{\dagger}$ Sensitivity: $0.739 \pm 0.032^{\dagger}$ Specificity: $0.909 \pm 0.026^{\dagger}$
Liang et al. [43]	Machine learning model using a combination of hand-crafted and model-learned imaging features for predicting lung metastases in patients with soft-tissue sarcoma on MRI.	External validation 126 patients from 2 centre	AUC: 0·833 (0·732–0·933) Accuracy: 0·897 Sensitivity: 0·474 Specificity: 0·972 Precision: 0·750 NPV: 0·912
Kang et al. [44]	Machine learning model using learned imaging features (deep learning) to predict preoperative risk of gastrointestinal stromal tumours on CT.	External validation 388 patients from 1 centre	Low-malignant, intermediate-malignant, and high-malignant AUC: 0.87 (0.83–0.91), 0.64 (0.60–0.68), and 0.85 (0.81–0.89) Accuracy: 0.81 (0.77–0.85), 0.75 (0.71–0.79), and 0.77 (0.73–0.81) Sensitivity: 0.72 (0.64–0.79), 0.24 (0.14–0.34), and 0.79 (0.73–0.85) Specificity: 0.86 (0.83–0.90), 0.86 (0.82–0.90), and 0.75 (0.70–0.81)
He et al. [45]	Machine learning model using learned imaging features (deep learning) for classification of benign, intermediate or malignant primary bone tumours on radiography.	External validation 291 patients from 2 centre	AUC: 0·877 (0·833–0·918) benign vs not benign and 0·916 (0·877–0·949) malignant vs not malignant Accuracy: 0·734
Peeken et al. [46]	Machine learning model using hand- crafted imaging features from different timepoints (delta radiomics) predicting pathologic complete response to neoadjuvant therapy in high grade soft tissue sarcoma of trunk and extremity, based on MRI.	External validation 53 patients from 1 centre	AUC: 0.75 (0.56–0.93) Accuracy: 0.86 Balanced accuracy: 0.57 Sensitivity: 0.20 Specificity: 0.95 Precision: 0.33 NPV: 0.90
Forema n et al. [47]	Machine learning model using hand- crafted imaging features predicting the MDM2 gene amplification status in order to differentiate between atypical lipomatous tumours (ALT) and lipomas on MRI.	External validation 50 patients from 1 centre	AUC: 0·88 (0·85–0·91) Accuracy: 0·76 Sensitivity: 0·70 Specificity: 0·81

Spraker	Machine learning model using hand-	External validation	Sensitivity: 0.79
et al.	crafted imaging features predicting	61 patients from 1	Specificity: 0.68
[48]	overall survival of grade II and III	centre	C-index: 0.78
	soft-tissue tumours on MRI.		Hazard ratio: 2·4
Fradet	Machine learning model using a	External validation	AUC: 0.80
et al.	combination of hand-crafted and	60 patients from 35	Specificity: 0.63
[49]	model-learned imaging features	centres	
	predicting malignancy for lipomatous		
	soft-tissue lesions on MRI.		
Gitto et	Machine learning model using hand-	External validation	AUC: 0.784
al. [50]	crafted imaging features	36 patients from 1	Accuracy: 0.75
	differentiating atypical cartilaginous	centre	-
	tumours and high-grade		
	chondrosarcomas of long bones on		
	CT.		

#### References

- 1. Cormier JN, Pollock RE. Soft Tissue Sarcomas. *CA: A Cancer Journal for Clinicians* 2004; **54**: 94–109.
- Kruiswijk AA, Dorleijn DMJ, Marang-an de Mheen PJ, van de Sande MAJ, van Bodegom-Vos L. Health-Related Quality of Life of Bone and Soft-Tissue Tumor Patients around the Time of Diagnosis. *Cancers* 2023; 15: 2804.
- 3. Zhang Z, Sejdić E. Radiological images and machine learning: trends, perspectives, and prospects. *Computers in biology and medicine* 2019; **108**: 354–70.
- Hanna TN, Lamoureux C, Krupinski EA, Weber S, Johnson J-O. Effect of Shift, Schedule, and Volume on Interpretive Accuracy: A Retrospective Analysis of 2.9 Million Radiologic Examinations. *Radiology* 2018; 287: 205–12.
- 5. Bechtold RE, Chen MYM, Ott DJ, Zagoria RJ, Scharling ES, Wolfman NT, et al. Interpretation of Abdominal CT: Analysis of Errors and Their Causes. *Journal of Computer Assisted Tomography* 1997; **21**: 681.
- 6. McNabb NK, Christensen EW, Rula EY, Coombs L, Drey K, Wald C, *et al.* Projected Growth in FDA-Approved Artificial Intelligence Products Given Venture Capital Funding. *Journal of the American College of Radiology: JACR* 2024; **21**: 617–23.
- Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices.
   FDA. 2024; published online Aug. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices (accessed Aug 2024).
- 8. Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, *et al.* Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update. *Radiology: Artificial Intelligence* 2024; **6**: e240300.
- 9. Lekadir K, Frangi AF, Porras AR, et al. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. *BMJ* 2025; **388**: e081554.
- 10. Klontzas ME, Gatti AA, Tejani AS, Kahn CE. AI Reporting Guidelines: How to Select the Best One for Your Research. *Radiology: Artificial Intelligence* 2023; **5**: e230055.
- 11. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, *et al.* The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; **372**: n71.
- 12. Spaanderman D, Marzetti M, Wan X, Scarsbrook A, Oei E, Visser J, *et al.* AI in radiological imaging of soft-tissue and bone tumors: a systematic review and evaluation against best-practice guidelines. PROSPERO International prospective

- register of systematic reviews. 2023; published online Oct 6. https://www.crd.york.ac.uk/prospero/display\_record.php?RecordID=467970 (accessed Aug 2024).
- 13. Si L, Zhong J, Huo J, Xuan K, Zhuang Z, Hu Y, *et al.* Deep learning in knee imaging: a systematic review utilizing a Checklist for Artificial Intelligence in Medical Imaging (CLAIM). *European Radiology* 2021; **32**: 1353–61.
- 14. Mongan J, Moy L, Kahn CE. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. *Radiology: Artificial Intelligence* 2020; **2**: e200029.
- 15. Fleiss JL, Levin B, Paik MC. The Measurement of Interrater Agreement. In: Statistical Methods for Rates and Proportions, 1st edn. Wiley, 2003: 598–626.
- 16. Spaanderman D, Marzetti M, Wan X, Starmans M, Klein S. AI in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against best-practice guidelines. Github. 2024; published online Aug 21. https://douwespaanderman.github.io/AI-STTandBoneTumour-Review (accessed Aug 21, 2024).
- 17. Abrantes J, Rouzrokh P. Explaining explainability: The role of XAI in medical imaging. *European Journal of Radiology* 2024; **173**. DOI:https://doi.org/10.1016/j.ejrad.2024.111389.
- 18. Amann J, Blasimme A, Vayena E, Frey D, Madai VI. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. *BMC Medical Informatics and Decision Making* 2020; **20**: 310.
- 19. Yang X, Wang H, Dong Q, Xu Y, Liu H, Ma X, *et al.* An artificial intelligence system for distinguishing between gastrointestinal stromal tumors and leiomyomas using endoscopic ultrasonography. *Endoscopy* 2022; **54**: 251–61.
- Dong Z, Zhao X, Zheng H, Zheng H, Chen D, Cao J, et al. Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study. eClinicalMedicine 2024; 73.
   DOI:https://doi.org/10.1016/j.eclinm.2024.102656.
- 21. Gabelica M, Bojčić R, Puljak L. Many researchers were not compliant with their published data sharing statement: a mixed-methods study. *Journal of Clinical Epidemiology* 2022; **150**: 33–41.
- 22. Dieuwertje Luitse, Blanke T, Poell T. AI competitions as infrastructures of power in medical imaging. *Information Communication & Society* 2024; 1–22.
- 23. Grand Challenge. grand-challenge.org. https://grand-challenge.org/.
- 24. Pati S, Baid U, Edwards B, Sheller M, Wang S, Reina GA, *et al.* Federated learning enables big data for rare cancer boundary detection. *Nature Communications* 2022; **13**: 7346.

- 25. Crombé A, Fadli D, Italiano A, Saut O, Buy X, Kind M. Systematic review of sarcomas radiomics studies: Bridging the gap between concepts and clinical applications? *European Journal of Radiology* 2020; **132**: 109283–3.
- 26. De Angelis R, Casale R, Coquelet N, Ikhlef S, Mokhtari A, Simoni P, *et al.* The impact of radiomics in the management of soft tissue sarcoma. *Discover Oncology* 2024; **15**. DOI:https://doi.org/10.1007/s12672-024-00908-2.
- 27. Crombé A, Spinnato P, Italiano A, Brisse HJ, Feydy A, Fadli D, *et al.* Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives. *Diagnostic and Interventional Imaging* 2023; **104**: 567–83.
- 28. Zhu N, Meng X, Wang Z, Hu Y, Zhao T, Fan H, *et al.* Radiomics in Diagnosis, Grading, and Treatment Response Assessment of Soft Tissue Sarcomas: A Systematic Review and Meta-analysis. *Academic Radiology* 2024; **0**. DOI:https://doi.org/10.1016/j.acra.2024.03.029.
- 29. Vallières M, Freeman CR, Skamene R, Naqa IEI. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Physics in Medicine & Biology* 2015; **60**: 5471.
- 30. [preprint] Starmans, MPA, Milea T, Vos M, Padmos GA, Grünhagen DJ, Verhoef C, *et al.* The WORC database: MRI and CT scans, segmentations, and clinical labels for 930 patients from six radiomics studies. *medRxiv* 2021; published online Aug. DOI:https://doi.org/10.1101/2021.08.19.21262238.
- 31. Ye Q, Yang H, Lin B, Wang M, Song L, Xie Z, *et al.* Automatic detection, segmentation, and classification of primary bone tumors and bone infections using an ensemble multi-task deep learning framework on multi-parametric MRIs: a multi-center study. *European Radiology* 2023; **34**: 4287–99.
- 32. Dong Z, Zhao X, Zheng H, Zheng H, Chen D, Cao J *et al.* Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study. *EClinicalMedicine* 2024; **73**: 102656–6.
- 33. Xie H, Hu J, Zhang X, Ma S, Liu Y, Wang X. Preliminary utilization of radiomics in differentiating uterine sarcoma from atypical leiomyoma: Comparison on diagnostic efficacy of MRI features and radiomic features. *European Journal of Radiology* 2019; **115**: 39–45.
- 34. Xu J, Miao L, Wang CX, Wang HH, Wang QZ, Li M, et al. Preoperative Contrast-Enhanced CT-Based Deep Learning Radiomics Model for Distinguishing Retroperitoneal Lipomas and Well-Differentiated Liposarcomas. Academic Radiology 2024; 31. DOI:https://doi.org/10.1016/j.acra.2024.06.035.

- 35. Arthur A, Orton MR, Emsley R, Vit S, Kelly-Morland C, Strauss D, *et al.* A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis. *The Lancet Oncology* 2023; **24**: 1277–86.
- 36. Guo J, Li Y, Guo H, Hao DP, Xu JX, Huang CC, *et al.* Parallel CNN-Deep Learning Clinical-Imaging Signature for Assessing Pathologic Grade and Prognosis of Soft Tissue Sarcoma Patients. *Journal of Magnetic Resonance Imaging* 2024; published online June 10. DOI:https://doi.org/10.1002/jmri.29474.
- 37. Gitto S, Cuocolo R, van Langevelde K, van de Sande MAJ, Parafioriti A, Luzzati A, *et al.* MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. *EBioMedicine* 2022; **75**: 103757–7.
- 38. von Schacky CE, Wilhelm NJ, Schäfer VS, Leonhardt Y, Jung M, Jungmann PM, *et al.* Development and evaluation of machine learning models based on X-ray radiomics for the classification and differentiation of malignant and benign bone tumors. *European Radiology* 2022; **32**: 6247–57.
- 39. Gitto S, Alessio Annovazzi, Nulle K, Interlenghi M, Salvatore C, Anelli V, *et al.* X-rays radiomics-based machine learning classification of atypical cartilaginous tumour and high-grade chondrosarcoma of long bones. *EBioMedicine* 2024; **101**: 105018–8.
- 40. Cao C, Yi Z, Xie M, Xie Y, Tang X, Tu B, *et al.* Machine learning-based radiomics analysis for predicting local recurrence of primary dermatofibrosarcoma protuberans after surgical treatment. *Radiotherapy and Oncology* 2023; **186**: 109737–7.
- 41. Yang L, Zhang D, Zheng T, Liu D, Fang Y. Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging. *Abdominal Radiology* 2023; **49**: 801–13.
- 42. Chen H, Zhang X, Wang X, Quan X, Deng Y, Lu M, *et al.* MRI-based radiomics signature for pretreatment prediction of pathological response to neoadjuvant chemotherapy in osteosarcoma: a multicenter study. *European Radiology* 2021; **31**: 7913–24.
- 43. Liang H, Yang S, Zou H, Hou F, Duan LS, Huang CC, et al. Deep Learning Radiomics Nomogram to Predict Lung Metastasis in Soft-Tissue Sarcoma: A Multi-Center Study. Frontiers in Oncology 2022; 12. DOI:https://doi.org/10.3389/fonc.2022.897676.
- 44. Kang B, Yuan X, Wang H, Qin S, Song X, Yu X, *et al.* Preoperative CT-Based Deep Learning Model for Predicting Risk Stratification in Patients With Gastrointestinal Stromal Tumors. *Frontiers in Oncology* 2021; **11**. DOI:https://doi.org/10.3389/fonc.2021.750875.

- 45. He Y, Pan I, Bao B, Halsey K, Chang M, Liu H, *et al.* Deep learning-based classification of primary bone tumors on radiographs: A preliminary study. *eBioMedicine* 2020; **62**: 103121.
- 46. Peeken JC, Asadpour R, Specht K, Chen EY, Klymenko O, Akinkuoroye V, et al. MRI-based delta-radiomics predicts pathologic complete response in high-grade softtissue sarcoma patients treated with neoadjuvant therapy. Radiotherapy and oncology 2021; 164: 73–82.
- 47. Foreman S, Llorián-Salvador O, David D, Rösner VKN, Rischewski JF, Feuerriegel GC, *et al.* Development and Evaluation of MR-Based Radiogenomic Models to Differentiate Atypical Lipomatous Tumors from Lipomas. *Cancers* 2023; **15**: 2150–0.
- 48. Spraker MB, Wootton L, Hippe DS, Ball KC, Peeken JC, Macomber MW, *et al.* MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma. *Advances in radiation oncology* 2019; **4**: 413–21.
- 49. Fradet G, Ayde R, Bottois H, El Harchaoui M, Khaled W, Drape JL, *et al.* Prediction of lipomatous soft tissue malignancy on MRI: comparison between machine learning applied to radiomics and deep learning. *European Radiology Experimental* 2022; **6**. DOI:https://doi.org/10.1186/s41747-022-00295-9.
- 50. Gitto S, Cuocolo R, Annovazzi A, Anelli V, Acquasanta M, Cincotta A, *et al.* CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomas. *EBioMedicine* 2021; **68**: 103407–7.
- 51. Kwong J, Khondker A, Lajkosz K, et al. APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support. *JAMA network open* 2023; **6**: e2335377–7.
- 52. Collins GS, Moons K, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. *BMJ* 2024; e078378–8.
- 53. Lambin P, Leijenaar R, Deist T, et al. Radiomics: the bridge between medical imaging and personalized medicine. *Nature Reviews Clinical Oncology* 2017; **14**: 749–62.

# **Supplementary Table**

**Table S1:** Score analysis for different predicted outcomes, disease types, and AI methods of the top 20 studies in terms of highest combined CLAIM and FUTURE-AI score.


Categories		N	Mean CLAIM score	Mean FUTURE -AI score	AUC range	Accuracy range	Sensitivity range	Specificity range
	Diagnosis	12	41.2	8.7	0.78-0.95	0.69-0.92	0.57-1.00	0.63-0.93
Outcome type	Prognosis	7	39.0	7.9	0.64-0.93	0.77-0.90	0.20-0.79	0.68-0.97
type	Both	1	40.0	9.0	0.82-0.86	0.67-0.84	0.67-0.84	0.74-1.00
	Bone tumour	8	41.4	8.1	0.78-0.94	0.69-0.92	0.57-0.90	0.67-0.92
Disease type <sup>a</sup>	Soft-tissue tumour	9	38.9	8.6	0.75-0.93	0.67-0.90	0.20-1.00	0.63-1.00
	GIST	3	42.0	8.7	0.64-0.95	0.75-0.92	0.24-0.90	0.75-0.93
	Hand-crafted features	11	39.5	7.6	0.75-0.94	0.75-0.92	0.20-0.92	0.67-0.95
Method type	Model-learned features	6	42.8	9.3	0.64-0.95	0.67-0.92	0.24-0.90	0.74-1.00
	Combined hand- crafted and model- learned features	3	38.3	9.5	0.80-0.86	0.80-0.86	0.47-1.00	0.63-0.97


The ranges presented in the table are derived from the minimum and maximum values reported for each metric across the selected studies. For the study categorized under 'both,' performance metrics were reported from three external validation sites, contributing to the observed ranges.

<sup>&</sup>lt;sup>a</sup> No papers investigating both Soft-tissue tumour (STT) and Bone tumours were in the top 20 scoring papers.


# **Figures**

**Figure 1:** Reviewing methodology.







**Figure 3:** Number of included studies (n=325) between 2008 and July 2024, color coded for the various AI methodologies used.




**Figure 4:** Characteristics of the studies included (n=325) as percentages.



**Figure 5:** Reported and unreported criteria for the included studies (n=325) from the Checklist for Artificial Intelligence in Medical Imaging (CLAIM). Gray bars between criteria within categories indicate subcategories.




**Figure 6:** Scores of the included studies (n=325) for each criterion from the FUTURE-AI international consensus guideline for trustworthy and deployable AI. For each criterion, expected compliance for both research (Res.) and deployable (Dep.) AI tools is reported. F = Fairness, U = Universality, T = Traceability, U = Usability, E = Robustness, E = Explainability, E = Robustness, E = Ex




# **Supplementary Figures**


**Figure S1:** Inter-reader variability sub-group analysis (n=30) for criteria of the Checklist for Artificial Intelligence in Medical Imaging (CLAIM). Agreement before (green) and after (orange) consensus discussion is reported between raters.




**Figure S2:** Inter-reader variability sub-group analysis (n=30) for criteria of the FUTURE-AI international consensus guideline for trustworthy and deployable AI. Agreement before (green) and after (orange) consensus discussion is reported between raters.




**Figure S3:** Trend of scores on the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) for each year across included studies (n=325). Red dots represent the mean score for each year, while each blue dot corresponds to a single study, with their positions slightly adjusted to avoid overlap. The regression line is calculated with the starting point (x = 0) set to 2008.




**Figure S4:** Trend of scores on the FUTURE-AI international consensus guideline for trustworthy and deployable AI for each year across included studies (n=325). Red dots represent the mean score for each year, while each blue dot corresponds to a single study, with their positions slightly adjusted to avoid overlap. The regression line is calculated with the starting point (x = 0) set to 2008.



**Figure S5:** Scores on the Checklist for Artificial Intelligence in Medical Imaging (CLAIM) for different AI methods, disease types and predicted outcomes across included studies (n=325).



**Figure S6:** Scores on the FUTURE-AI international consensus guideline for trustworthy and deployable AI for different AI methods, disease types and predicted outcomes across included studies (n=325).



**Figure S7:** Reported and unreported criteria for each study (n=325) from the Checklist for Artificial Intelligence in Medical Imaging (CLAIM). An interactive version of this plot can be found at: <a href="https://douwe-spaanderman.github.io/AI-STTandBoneTumour-Review/#">https://douwe-spaanderman.github.io/AI-STTandBoneTumour-Review/#</a>

**Figure S8:** Scores of each study (n=325) for each criterion from the FUTURE-AI international consensus guideline for trustworthy and deployable AI. An interactive version of this plot can be found at: https://douwe-spaanderman.github.io/AI-STTandBoneTumour-Review/#

# Appendix 1: Search strategy

Database searched	Platform	Coverage period		
Medline ALL	Ovid	1946 – 07/2024		
Embase	Embase.com	1971 - 07/2024		
Web of Science Core Collection*	Web of Knowledge	1975 - 07/2024		
Cochrane Central Register of Controlled Trials**	Wiley	1992 - 07/2024		
Additional Search Engines: Google Scholar***				
Total				

<sup>\*</sup>Science Citation Index Expanded (1975- 07/2024); Social Sciences Citation Index (1975- 07/2024); Arts & Humanities Citation Index (1975- 07/2024); Conference Proceedings Citation Index- Social Science & Humanities (1990- 07/2024); Emerging Sources Citation Index (2005- 07/2024)

No other database limits were used than those specified in the search strategies

#### **Embase**

('artificial intelligence'/exp OR 'machine learning'/exp OR 'pattern recognition'/exp OR 'radiomics'/exp OR (CNN OR (artificial\* NEAR/3 intelligen\*) OR ((machine OR deep) NEAR/3 learning) OR (neural\* NEAR/3 network\*) OR (classification\* NEAR/3 (algorithm OR binary OR multiclass OR multilabel)) OR (classifier\*) OR (data-mining\*) OR (feature NEAR/3 detection\*) OR (feature\* NEAR/3 (extraction OR learning OR ranking OR selection OR analysis OR fusion\*)) OR (k-nearest\* NEAR/3 neighbo\*) OR (kernel\* NEAR/3 method\*) OR (learning\* NEAR/3 algorithm\*) OR (least\* NEAR/3 absolute\* NEAR/3 shrinkage\* NEAR/3 selection\* NEAR/3 operator\*) OR (Markov\* NEAR/3 model\*) OR (memristor\*) OR (network\* NEAR/3 learning\*) OR (perceptron\*) OR (radial\* NEAR/3 basis\* NEAR/3 function\*) OR (random\* NEAR/3 forest\*) OR (recursive\* NEAR/3 feature\* NEAR/3 elimination\*) OR (recursive\* NEAR/3 partitioning\*) OR (support\* NEAR/3 vector\* NEAR/3 machine\*) OR ((recognition\* OR detection\* OR classification\* OR predict\* OR comput\* OR diagnos\*) NEAR/3 (algorithm\* OR network\* OR computer-aided\* OR automatic\* OR automated\*)) OR bayesian\* OR radiomic\* OR pattern-recognit\* OR ((AI) NEXT/1 (tool\* OR model\*))):ab,ti,kw OR AI:ti) AND ('musculoskeletal tumor'/exp OR 'bone cyst'/exp OR 'fibrous dysplasia'/exp OR 'lipoma'/exp OR 'hibernoma'/exp OR 'mesenchymoma'/exp OR 'lymphoma'/exp OR 'histiocytosis'/exp OR 'sinus histiocytosis'/exp OR 'sarcoma'/exp OR 'soft tissue tumor'/exp OR 'nerve tumor'/exp OR 'lymphangioma'/exp OR 'lipoblastoma'/exp OR 'ganglion cyst'/exp OR (GCTB OR DDLS OR GIST OR GISTs OR ((soft-tissue\* OR adipos\*-tissue\* OR glomus\* OR gastrointeststroma\* OR gastr\*-intest\*-stroma\* OR spinal\* OR rib OR skull OR sternal\* OR tibial\* OR sacrum\* OR jaw OR maxillar\* OR mandibular\* OR odontogenic\* OR connective-tissue\* OR subcutan\*-tissue\* OR vein\* OR muscle\* OR musculoskeletal\* OR bone\* OR benign-notochordal-cell OR fibrous\* OR osteoblast\* OR osteoclast\* OR synov\* OR granular-cell\* OR cartilag\* OR joint\* OR femoral\* OR humerus\* OR lympho\* OR rhabdoid OR non-ossifying OR extramedullary-myeloid\* OR atypical-lipmatous\* OR nerve\* OR giantcell\* OR schwann-cell\* OR desmoplastic\* OR myofibroblastic\*) NEAR/3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((vascular\* OR arter\* OR vessel\* OR venal\*) NEXT/1 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((lymph-node\*) NEAR/3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\*)) OR adamantin\* OR plasma-cell-granulom\* OR

<sup>\*\*</sup> Manually deleted abstracts from trial registries

<sup>\*\*\*</sup>Google Scholar was searched via "Publish or Perish" to download the results in EndNote.

glomangiom\* OR myoma\* OR desmoid\* OR Bessel-Hagen OR diaphyseal-aclas\* OR ((subungual OR multipl\* OR dysplas\* OR familial\*) NEAR/3 (exosto\*)) OR osteocyst\* OR ecchondrosis-ossificans OR chondrodysplasia OR adenosarcom\* OR sarcom\* OR gliosarcoma\* OR adenosarcom\* OR osteosarcom\* OR chondrosarcom\* OR chondrom\* OR enchondrom\* OR chondroblastom\* OR chondromatosis\* OR osteom\* OR osteoblastom\* OR osteochondrom\* OR maffucci\* OR hemangiom\* OR haemangiom\* OR hemangioendotheliom\* OR angiosarcom\* OR bone-cyst\* OR osseous-cyst\* OR intraosseous-gangli\* OR intra-osseous-gangli\* OR ganglion-cyst\* OR jaw-cyst\* OR subchondral-cyst\* OR chordom\* OR synoviom\* OR ((fibro\*) NEAR/2 (dysplas\* OR dystroph\* OR osteodys\*)) OR cherubism\* OR osteofibrousdysplasi\* OR lipom\* OR angiolipom\* OR angiom\* OR lipomatos\* OR fetal-lipoma\* OR Bannayan OR fatty-kidney OR fatty-pancreas\* OR hibernom\* OR mesenchym\* OR adamantinom\* OR hodgkin\* OR erdheim-Chester\* OR chester-erdheim\* OR eosinophil\*-granulom\* OR histiocytos\* OR dorfman-rosaidisease\* OR nora-s-lesion\* OR chondromesenchymal-hamartoma-of-chest-wall\* OR lymphom\* OR fibroma\* OR osteoclastom\* OR histioblastom\* OR histiosarcom\* OR leiomyosarcom\* OR angioendotheliom\* OR angioendotheliosarcom\* OR hemangiosarcom\* OR haemangiosarcom\* OR haemangioendotheliom\* OR hemangio-endotheliosarcom\* OR hemangioendotheliom\* OR hemangioendotheliosarcom\* OR hemangio-endotheliom OR haemangio-endotheliom\* OR lymphangiosarcom\* OR Stewart-Treves OR rhabdomysarcom\* OR myxofibrosarcom\* OR myxosarcom\* OR myofibrom\* OR myofibroblastom\* OR synoviom\* OR myxom\* OR myopericytom\* OR fibrosarcom\* OR fibroadenosarcom\* OR dermatofibrosarcom\* OR neurofibrosarcom\* OR chloroma\* OR extramedullary-leukaemia\* OR extramedullary-leukemia\* OR leukosarcom\* OR liposarcom\* OR neurom\* OR perineurom\* OR ganglionneurom\* OR neurilemom\* OR neurofibrom\* OR neurothekeom\* OR leiomyom\* OR rhabdomyom\* OR elastofibroma\* OR lymphangiom\* OR hemangiopericytom\* OR haemangiopericytom\* OR pericytom\* OR myopericytom\* OR glomangiopericytom\* OR lipoblastom\* OR schwannom\* OR neurilemmom\* OR neurinom\* OR neurolemmom\* OR neurilemom\* OR neurolilemmon\* OR ((pigment\* OR arthritis\*) NEAR/3 (villonodular\* OR villous\*)) OR ((arthritis\*) NEAR/3 (pigment\* OR schueller\*)) OR ((synovitis\*) NEAR/3 (pigment\* OR dendritic\* OR villonodular\*)) OR lymphosarcom\* OR reticulosarcom\* OR rhabdomyosarcom\* OR ameloblastom\* OR myosarcom\* OR fibrosarcom\* OR myoblastom\* OR fibrous-histiocytom\* OR histiomatos\* OR reticulohistiocyt\*):ab,ti,kw) AND ('radiomics'/exp OR 'radiogenomics'/exp OR 'diagnostic imaging'/de OR 'radiodiagnosis'/exp OR 'nuclear magnetic resonance imaging'/exp OR 'diffusion coefficient'/de OR 'diffusion weighted imaging'/de OR 'Doppler flowmetry'/de OR 'echography'/exp OR (radiogenomic\* OR ((radio OR radiat\*) NEXT/1 (genomic\* OR diagnos\*)) OR radiomic\* OR ((diagnos\* OR medical\*) NEAR/3 imag\*) OR radiogenomic\* OR radiomic\* OR (diagnos\* NEAR/3 imag\*) OR radiodiagnos\* OR ((comput\* OR positron) NEAR/3 tomogra\*) OR spect OR ct OR pet OR mri OR (magnetic NEAR/3 resonance) OR ((nuclear OR mr OR multimodalit\*) NEAR/3 imaging\*) OR rontgen OR roentgen OR ultraso\* OR scintigra\* OR (diffusion\* NEAR/3 (coefficient\* OR weighted OR tensor)) OR dwi OR dti OR Doppler OR echogra\*):ab,ti,kw) NOT ([Conference Abstract]/lim AND [1800-2020]/py) NOT ('case report'/de OR (case-report):ti) NOT ((animal/exp OR animal\*:de OR nonhuman/de) NOT ('human'/exp))

# Medline

(exp Artificial Intelligence/ OR exp Machine Learning/ OR Pattern Recognition, Automated/ OR (CNN OR (artificial\* ADJ3 intelligen\*) OR ((machine OR deep) ADJ3 learning) OR (neural\* ADJ3 network\*) OR (classification\* ADJ3 (algorithm OR binary OR multiclass OR multilabel)) OR (classifier\*) OR (data-

mining\*) OR (feature ADJ3 detection\*) OR (feature\* ADJ3 (extraction OR learning OR ranking OR selection OR analysis OR fusion\*)) OR (k-nearest\* ADJ3 neighbo\*) OR (kernel\* ADJ3 method\*) OR (learning\* ADJ3 algorithm\*) OR (least\* ADJ3 absolute\* ADJ3 shrinkage\* ADJ3 selection\* ADJ3 operator\*) OR (Markov\* ADJ3 model\*) OR (memristor\*) OR (network\* ADJ3 learning\*) OR (perceptron\*) OR (radial\* ADJ3 basis\* ADJ3 function\*) OR (random\* ADJ3 forest\*) OR (recursive\* ADJ3 feature\* ADJ3 elimination\*) OR (recursive\* ADJ3 partitioning\*) OR (support\* ADJ3 vector\* ADJ3 machine\*) OR ((recognition\* OR detection\* OR classification\* OR predict\* OR comput\* OR diagnos\*) ADJ3 (algorithm\* OR network\* OR computer-aided\* OR automatic\* OR automated\*)) OR bayesian\* OR radiomic\* OR pattern-recognit\* OR ((AI) ADJ (tool\* OR model\*))).ab,ti,kf. OR Al.ti.) AND (exp Bone Cysts/ OR exp Fibrous Dysplasia of Bone/ OR exp Lipoma/ OR exp Mesenchymoma/ OR exp Lymphoma/ OR exp Histiocytosis/ OR exp Histiocytosis, Sinus/ OR exp Sarcoma/ OR exp Soft Tissue Neoplasms/ OR exp Neuroma/ OR exp Lymphangioma/ OR exp Ganglion Cysts/ OR (GCTB OR DDLS OR GIST OR GISTS OR ((soft-tissue\* OR adipos\*-tissue\* OR glomus\* OR gastrointest-stroma\* OR gastr\*-intest\*-stroma\* OR spinal\* OR rib OR skull OR sternal\* OR tibial\* OR sacrum\* OR jaw OR maxillar\* OR mandibular\* OR odontogenic\* OR connective-tissue\* OR subcutan\*-tissue\* OR vein\* OR muscle\* OR musculoskeletal\* OR bone\* OR benign-notochordal-cell OR fibrous\* OR osteoblast\* OR osteoclast\* OR synov\* OR granular-cell\* OR cartilag\* OR joint\* OR femoral\* OR humerus\* OR lympho\* OR rhabdoid OR nonossifying OR extramedullary-myeloid\* OR atypical-lipmatous\* OR nerve\* OR giant-cell\* OR schwanncell\* OR desmoplastic\* OR myofibroblastic\*) ADJ3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((vascular\* OR arter\* OR vessel\* OR venal\*) ADJ (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((lymph-node\*) ADJ3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\*)) OR adamantin\* OR plasma-cell-granulom\* OR glomangiom\* OR myoma\* OR desmoid\* OR Bessel-Hagen OR diaphyseal-aclas\* OR ((subungual OR multipl\* OR dysplas\* OR familial\*) ADJ3 (exosto\*)) OR osteocyst\* OR ecchondrosis-ossificans OR chondrodysplasia OR adenosarcom\* OR sarcom\* OR gliosarcoma\* OR adenosarcom\* OR osteosarcom\* OR chondrosarcom\* OR chondrom\* OR enchondrom\* OR chondroblastom\* OR chondromatosis\* OR osteom\* OR osteoblastom\* OR osteochondrom\* OR maffucci\* OR hemangiom\* OR haemangiom\* OR hemangioendotheliom\* OR angiosarcom\* OR bone-cyst\* OR osseous-cyst\* OR intraosseous-gangli\* OR intra-osseous-gangli\* OR ganglion-cyst\* OR jaw-cyst\* OR subchondral-cyst\* OR chordom\* OR synoviom\* OR ((fibro\*) ADJ2 (dysplas\* OR dystroph\* OR osteodys\*)) OR cherubism\* OR osteofibrous-dysplasi\* OR lipom\* OR angiolipom\* OR angiom\* OR lipomatos\* OR fetal-lipoma\* OR Bannayan OR fatty-kidney OR fattypancreas\* OR hibernom\* OR mesenchym\* OR adamantinom\* OR hodgkin\* OR erdheim-Chester\* OR chester-erdheim\* OR eosinophil\*-granulom\* OR histiocytos\* OR dorfman-rosai-disease\* OR nora-slesion\* OR chondromesenchymal-hamartoma-of-chest-wall\* OR lymphom\* OR fibroma\* OR osteoclastom\* OR histioblastom\* OR histiosarcom\* OR leiomyosarcom\* OR angioendotheliom\* OR angioendotheliosarcom\* OR hemangiosarcom\* OR haemangiosarcom\* OR haemangioendotheliom\* OR hemangio-endotheliosarcom\* OR hemangioendotheliom\* OR hemangioendotheliosarcom\* OR hemangio-endotheliom OR haemangio-endotheliom\* OR lymphangiosarcom\* OR Stewart-Treves OR rhabdomysarcom\* OR myxofibrosarcom\* OR myxosarcom\* OR myofibrom\* OR myofibroblastom\* OR synoviom\* OR myxom\* OR myopericytom\* OR fibrosarcom\* OR fibroadenosarcom\* OR dermatofibrosarcom\* OR neurofibrosarcom\* OR chloroma\* OR extramedullary-leukaemia\* OR

extramedullary-leukemia\* OR leukosarcom\* OR liposarcom\* OR neurom\* OR perineurom\* OR ganglionneurom\* OR neurilemom\* OR neurofibrom\* OR neurothekeom\* OR leiomyom\* OR rhabdomyom\* OR elastofibroma\* OR lymphangiom\* OR hemangiopericytom\* OR haemangiopericytom\* OR pericytom\* OR myopericytom\* OR glomangiopericytom\* OR lipoblastom\* OR schwannom\* OR neurilemmom\* OR neurinom\* OR neurolemmom\* OR neurilemom\* OR neurolilemmon\* OR ((pigment\* OR arthritis\*) ADJ3 (villonodular\* OR villous\*)) OR ((arthritis\*) ADJ3 (pigment\* OR schueller\*)) OR ((synovitis\*) ADJ3 (pigment\* OR dendritic\* OR villonodular\*)) OR lymphosarcom\* OR reticulosarcom\* OR rhabdomyosarcom\* OR ameloblastom\* OR myosarcom\* OR fibrosarcom\* OR myoblastom\* OR fibrous-histiocytom\* OR histiomatos\* OR reticulohistiocyt\*).ab,ti,kf.) AND (exp Radiation Genomics/ OR Diagnostic Imaging/ OR exp Magnetic Resonance Imaging/ OR Laser-Doppler Flowmetry/ OR exp Ultrasonography/ OR (radiogenomic\* OR ((radio OR radiat\*) ADJ1 (genomic\* OR diagnos\*)) OR radiomic\* OR ((diagnos\* OR medical\*) ADJ3 imag\*) OR radiodiagnos\* OR ((comput\* OR positron) ADJ3 tomogra\*) OR spect OR ct OR pet OR mri OR (magnetic ADJ3 resonance) OR ((nuclear OR mr OR multimodalit\*) ADJ3 imaging\*) OR rontgen OR roentgen OR ultraso\* OR scintigra\* OR (diffusion\* ADJ3 (coefficient\* OR weighted OR tensor)) OR dwi OR dti OR Doppler OR echogra\*).ab,ti,kf.) NOT (news OR congres\* OR abstract\* OR book\* OR chapter\* OR dissertation abstract\*).pt. NOT (Case Reports/ OR (case-report).ti.) NOT (exp animals/ NOT humans/)

#### Cochrane

((CNN OR (artificial\* NEAR/3 intelligen\*) OR ((machine OR deep) NEAR/3 learning) OR (neural\* NEAR/3 network\*) OR (classification\* NEAR/3 (algorithm OR binary OR multiclass OR multilabel)) OR (classifier\*) OR (data NEXT/1 mining\*) OR (feature NEAR/3 detection\*) OR (feature\* NEAR/3 (extraction OR learning OR ranking OR selection OR analysis OR fusion\*)) OR (k NEXT/1 nearest\* NEAR/3 neighbo\*) OR (kernel\* NEAR/3 method\*) OR (learning\* NEAR/3 algorithm\*) OR (least\* NEAR/3 absolute\* NEAR/3 shrinkage\* NEAR/3 selection\* NEAR/3 operator\*) OR (Markov\* NEAR/3 model\*) OR (memristor\*) OR (network\* NEAR/3 learning\*) OR (perceptron\*) OR (radial\* NEAR/3 basis\* NEAR/3 function\*) OR (random\* NEAR/3 forest\*) OR (recursive\* NEAR/3 feature\* NEAR/3 elimination\*) OR (recursive\* NEAR/3 partitioning\*) OR (support\* NEAR/3 vector\* NEAR/3 machine\*) OR ((recognition\* OR detection\* OR classification\* OR predict\* OR comput\* OR diagnos\*) NEAR/3 (algorithm\* OR network\* OR computer NEXT/1 aided\* OR automatic\* OR automated\*)) OR bayesian\* OR radiomic\* OR pattern NEXT/1 recognit\* OR ((AI) NEXT/1 (tool\* OR model\*))):ab,ti,kw OR AI:ti) AND ((GCTB OR DDLS OR GIST OR GISTS OR ((soft NEXT/1 tissue\* OR adipos\* NEXT/1 tissue\* OR glomus\* OR gastrointest NEXT/1 stroma\* OR gastr\* NEXT/1 intest\* NEXT/1 stroma\* OR spinal\* OR rib OR skull OR sternal\* OR tibial\* OR sacrum\* OR jaw OR maxillar\* OR mandibular\* OR odontogenic\* OR connective NEXT/1 tissue\* OR subcutan\* NEXT/1 tissue\* OR vein\* OR muscle\* OR musculoskeletal\* OR bone\* OR benign NEXT/1 notochordal NEXT/1 cell OR fibrous\* OR osteoblast\* OR osteoclast\* OR synov\* OR granular NEXT/1 cell\* OR cartilag\* OR joint\* OR femoral\* OR humerus\* OR lympho\* OR rhabdoid OR non NEXT/1 ossifying OR extramedullary NEXT/1 myeloid\* OR atypical NEXT/1 lipmatous\* OR nerve\* OR giant NEXT/1 cell\* OR schwann NEXT/1 cell\* OR desmoplastic\* OR myofibroblastic\*) NEAR/3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((vascular\* OR arter\* OR vessel\* OR venal\*) NEXT/1 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((lymph NEXT/1 node\*) NEAR/3 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR

lesion\* OR plasmacytom\*)) OR adamantin\* OR plasma NEXT/1 cell NEXT/1 granulom\* OR glomangiom\* OR myoma\* OR desmoid\* OR Bessel NEXT/1 Hagen OR diaphyseal NEXT/1 aclas\* OR ((subungual OR multipl\* OR dysplas\* OR familial\*) NEAR/3 (exosto\*)) OR osteocyst\* OR ecchondrosis NEXT/1 ossificans OR chondrodysplasia OR adenosarcom\* OR sarcom\* OR gliosarcoma\* OR adenosarcom\* OR osteosarcom\* OR chondrosarcom\* OR chondrom\* OR enchondrom\* OR chondroblastom\* OR chondromatosis\* OR osteom\* OR osteoblastom\* OR osteochondrom\* OR maffucci\* OR hemangiom\* OR haemangiom\* OR hemangioendotheliom\* OR angiosarcom\* OR bone NEXT/1 cyst\* OR osseous NEXT/1 cyst\* OR intraosseous NEXT/1 gangli\* OR intra NEXT/1 osseous NEXT/1 gangli\* OR ganglion NEXT/1 cyst\* OR jaw NEXT/1 cyst\* OR subchondral NEXT/1 cyst\* OR chordom\* OR synoviom\* OR ((fibro\*) NEAR/2 (dysplas\* OR dystroph\* OR osteodys\*)) OR cherubism\* OR osteofibrous NEXT/1 dysplasi\* OR lipom\* OR angiolipom\* OR angiom\* OR lipomatos\* OR fetal NEXT/1 lipoma\* OR Bannayan OR fatty NEXT/1 kidney OR fatty NEXT/1 pancreas\* OR hibernom\* OR mesenchym\* OR adamantinom\* OR hodgkin\* OR erdheim NEXT/1 Chester\* OR chester NEXT/1 erdheim\* OR eosinophil\* NEXT/1 granulom\* OR histiocytos\* OR dorfman NEXT/1 rosai NEXT/1 disease\* OR nora NEXT/1 s NEXT/1 lesion\* OR chondromesenchymal NEXT/1 hamartoma NEXT/1 of NEXT/1 chest NEXT/1 wall\* OR lymphom\* OR fibroma\* OR osteoclastom\* OR histioblastom\* OR histiosarcom\* OR leiomyosarcom\* OR angioendotheliom\* OR angioendotheliosarcom\* OR hemangiosarcom\* OR haemangiosarcom\* OR haemangioendotheliom\* OR hemangio NEXT/1 endotheliosarcom\* OR hemangioendotheliom\* OR hemangioendotheliosarcom\* OR hemangio NEXT/1 endotheliom OR haemangio NEXT/1 endotheliom\* OR lymphangiosarcom\* OR Stewart NEXT/1 Treves OR rhabdomysarcom\* OR myxofibrosarcom\* OR myxosarcom\* OR myofibrom\* OR myofibroblastom\* OR synoviom\* OR myxom\* OR myopericytom\* OR fibrosarcom\* OR fibroadenosarcom\* OR dermatofibrosarcom\* OR neurofibrosarcom\* OR chloroma\* OR extramedullary NEXT/1 leukaemia\* OR extramedullary NEXT/1 leukemia\* OR leukosarcom\* OR liposarcom\* OR neurom\* OR perineurom\* OR ganglionneurom\* OR neurilemom\* OR neurofibrom\* OR neurothekeom\* OR leiomyom\* OR rhabdomyom\* OR elastofibroma\* OR lymphangiom\* OR hemangiopericytom\* OR haemangiopericytom\* OR pericytom\* OR myopericytom\* OR glomangiopericytom\* OR lipoblastom\* OR schwannom\* OR neurilemmom\* OR neurinom\* OR neurolemmom\* OR neurilemom\* OR neurolilemmon\* OR ((pigment\* OR arthritis\*) NEAR/3 (villonodular\* OR villous\*)) OR ((arthritis\*) NEAR/3 (pigment\* OR schueller\*)) OR ((synovitis\*) NEAR/3 (pigment\* OR dendritic\* OR villonodular\*)) OR lymphosarcom\* OR reticulosarcom\* OR rhabdomyosarcom\* OR ameloblastom\* OR myosarcom\* OR fibrosarcom\* OR myoblastom\* OR fibrous NEXT/1 histiocytom\* OR histiomatos\* OR reticulohistiocyt\*):ab,ti,kw) AND ((radiogenomic\* OR ((radio OR radiat\*) NEXT/1 (genomic\* OR diagnos\*)) OR radiomic\* OR ((diagnos\* OR medical\*) NEAR/3 imag\*) OR radio NEXT/1 genomic\* OR radiomic\* OR (diagnos\* NEAR/3 imag\*) OR radiodiagnos\* OR ((comput\* OR positron) NEAR/3 tomogra\*) OR spect OR ct OR pet OR mri OR (magnetic NEAR/3 resonance) OR ((nuclear OR mr OR multimodalit\*) NEAR/3 imaging\*) OR rontgen OR roentgen OR ultraso\* OR scintigra\* OR (diffusion\* NEAR/3 (coefficient\* OR weighted OR tensor)) OR dwi OR dti OR Doppler OR echogra\*):ab,ti,kw) NOT "conference abstract":pt

## **Web of Science**

TS=(((CNN OR (artificial\* NEAR/2 intelligen\*) OR ((machine OR deep) NEAR/2 learning) OR (neural\* NEAR/2 network\*) OR (classification\* NEAR/2 (algorithm OR binary OR multiclass OR multilabel)) OR (classifier\*) OR (data-mining\*) OR (feature NEAR/2 detection\*) OR (feature\* NEAR/2 (extraction OR learning OR ranking OR selection OR analysis OR fusion\*)) OR (k-nearest\* NEAR/2 neighbo\*) OR

(kernel\* NEAR/2 method\*) OR (learning\* NEAR/2 algorithm\*) OR (least\* NEAR/2 absolute\* NEAR/2 shrinkage\* NEAR/2 selection\* NEAR/2 operator\*) OR (Markov\* NEAR/2 model\*) OR (memristor\*) OR (network\* NEAR/2 learning\*) OR (perceptron\*) OR (radial\* NEAR/2 basis\* NEAR/2 function\*) OR (random\* NEAR/2 forest\*) OR (recursive\* NEAR/2 feature\* NEAR/2 elimination\*) OR (recursive\* NEAR/2 partitioning\*) OR (support\* NEAR/2 vector\* NEAR/2 machine\*) OR ((recognition\* OR detection\* OR classification\* OR predict\* OR comput\* OR diagnos\*) NEAR/2 (algorithm\* OR network\* OR computer-aided\* OR automatic\* OR automated\*)) OR bayesian\* OR radiomic\* OR pattern-recognit\* OR ((AI) NEAR/1 (tool\* OR model\*))) OR AI:ti) AND ((GCTB OR DDLS OR GIST OR GISTs OR ((soft-tissue\* OR adipos\*-tissue\* OR glomus\* OR gastrointest-stroma\* OR gastr\*-intest\*-stroma\* OR spinal\* OR rib OR skull OR sternal\* OR tibial\* OR sacrum\* OR jaw OR maxillar\* OR mandibular\* OR odontogenic\* OR connective-tissue\* OR subcutan\*-tissue\* OR vein\* OR muscle\* OR musculoskeletal\* OR bone\* OR benign-notochordal-cell OR fibrous\* OR osteoblast\* OR osteoclast\* OR synov\* OR granular-cell\* OR cartilag\* OR joint\* OR femoral\* OR humerus\* OR lympho\* OR rhabdoid OR non-ossifying OR extramedullary-myeloid\* OR atypical-lipmatous\* OR nerve\* OR giant-cell\* OR schwann-cell\* OR desmoplastic\* OR myofibroblastic\*) NEAR/2 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((vascular\* OR arter\* OR vessel\* OR venal\*) NEAR/1 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\* OR metasta\*)) OR ((lymph-node\*) NEAR/2 (tumor\* OR tumour\* OR cancer\* OR neoplas\* OR maligna\* OR lesion\* OR plasmacytom\*)) OR adamantin\* OR plasma-cell-granulom\* OR glomangiom\* OR myoma\* OR desmoid\* OR Bessel-Hagen OR diaphyseal-aclas\* OR ((subungual OR multipl\* OR dysplas\* OR familial\*) NEAR/2 (exosto\*)) OR osteocyst\* OR ecchondrosis-ossificans OR chondrodysplasia OR adenosarcom\* OR sarcom\* OR gliosarcoma\* OR adenosarcom\* OR osteosarcom\* OR chondrosarcom\* OR chondrom\* OR enchondrom\* OR chondroblastom\* OR chondromatosis\* OR osteom\* OR osteoblastom\* OR osteochondrom\* OR maffucci\* OR hemangiom\* OR haemangiom\* OR hemangioendotheliom\* OR angiosarcom\* OR bone-cyst\* OR osseous-cyst\* OR intraosseous-gangli\* OR intra-osseous-gangli\* OR ganglion-cyst\* OR jaw-cyst\* OR subchondral-cyst\* OR chordom\* OR synoviom\* OR ((fibro\*) NEAR/2 (dysplas\* OR dystroph\* OR osteodys\*)) OR cherubism\* OR osteofibrous-dysplasi\* OR lipom\* OR angiolipom\* OR angiom\* OR lipomatos\* OR fetal-lipoma\* OR Bannayan OR fatty-kidney OR fattypancreas\* OR hibernom\* OR mesenchym\* OR adamantinom\* OR hodgkin\* OR erdheim-Chester\* OR chester-erdheim\* OR eosinophil\*-granulom\* OR histiocytos\* OR dorfman-rosai-disease\* OR nora-slesion\* OR chondromesenchymal-hamartoma-of-chest-wall\* OR lymphom\* OR fibroma\* OR osteoclastom\* OR histioblastom\* OR histiosarcom\* OR leiomyosarcom\* OR angioendotheliom\* OR angioendotheliosarcom\* OR hemangiosarcom\* OR haemangiosarcom\* OR haemangioendotheliom\* OR hemangio-endotheliosarcom\* OR hemangioendotheliom\* OR hemangioendotheliosarcom\* OR hemangio-endotheliom OR haemangio-endotheliom\* OR lymphangiosarcom\* OR Stewart-Treves OR rhabdomysarcom\* OR myxofibrosarcom\* OR myxosarcom\* OR myofibrom\* OR myofibroblastom\* OR synoviom\* OR myxom\* OR myopericytom\* OR fibrosarcom\* OR fibroadenosarcom\* OR dermatofibrosarcom\* OR neurofibrosarcom\* OR chloroma\* OR extramedullary-leukaemia\* OR extramedullary-leukemia\* OR leukosarcom\* OR liposarcom\* OR neurom\* OR perineurom\* OR ganglionneurom\* OR neurilemom\* OR neurofibrom\* OR neurothekeom\* OR leiomyom\* OR rhabdomyom\* OR elastofibroma\* OR lymphangiom\* OR hemangiopericytom\* OR haemangiopericytom\* OR pericytom\* OR myopericytom\* OR glomangiopericytom\* OR lipoblastom\* OR schwannom\* OR neurilemmom\* OR neurinom\* OR neurolemmom\* OR neurilemom\* OR neurolilemmon\* OR ((pigment\* OR arthritis\*) NEAR/2 (villonodular\* OR villous\*)) OR ((arthritis\*)

NEAR/2 (pigment\* OR schueller\*)) OR ((synovitis\*) NEAR/2 (pigment\* OR dendritic\* OR villonodular\*)) OR lymphosarcom\* OR reticulosarcom\* OR rhabdomyosarcom\* OR ameloblastom\* OR myosarcom\* OR fibrosarcom\* OR myoblastom\* OR fibrous-histiocytom\* OR histiomatos\* OR reticulohistiocyt\*)) AND ((radiogenomic\* OR ((radio OR radiat\*) NEAR/1 (genomic\* OR diagnos\*)) OR radiomic\* OR ((diagnos\* OR medical\*) NEAR/2 imag\*) OR radio-genomic\* OR radiomic\* OR (diagnos\* NEAR/2 imag\*) OR radiodiagnos\* OR ((comput\* OR positron) NEAR/2 tomogra\*) OR spect OR ct OR pet OR mri OR (magnetic NEAR/2 resonance) OR ((nuclear OR mr OR multimodalit\*) NEAR/2 imaging\*) OR rontgen OR roentgen OR ultraso\* OR scintigra\* OR (diffusion\* NEAR/2 (coefficient\* OR weighted OR tensor)) OR dwi OR dti OR Doppler OR echogra\*)) NOT ((animal\* OR rat OR rats OR mouse OR mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows OR bovine OR rodent\* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar\* OR chick\* OR zebrafish\* OR baboon\* OR nonhuman\* OR primate\* OR cattle\* OR goose OR geese OR duck OR macaque\* OR avian\* OR bird\* OR fish\*) NOT (human\* OR patient\* OR women OR woman OR men OR man))) NOT DT=(Meeting Abstract OR Meeting Summary) NOT TI=(case-report)

# **Google Scholar**

"artificial intelligence" | "machine | deep learning" | "neural network" | radiomics "musculoskeletal | bone | nerve tumor | tumour | neoplasm | cancer" | "soft tissue tumor | tumour | neoplasm | cancer" radiomics | radiogenomics | "diagnostic imaging" | "radio diagnosis" | MRI | doppler

# Appendix 2

# **WELCOME**

This document contains checklists based on the CLAIM [1] and FUTURE-AI [2] guidelines. These checklists were used to assess the quality of research using AI in the diagnosis and prognosis of soft tissue and bone tumours. A completed checklist, used in the study "AI in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against CLAIM and FUTURE-AI guidelines" can be found at: https://douwe-spaanderman.github.io/AI-STTandBoneTumour-Review [3].

The second page in this document (general information) records basic information about each paper and the intial of the reviewer. The third page (FUTURE-AI) gives the checklist based on FUTURE-AI. As well as having a scoring system for each item it is divided into each principle and indiates if an item is "recommended" or "highly-recommended" by the FUTURE-AI guidelines. The fourth page gives the checklist based on CLAIM guidelines. Each item is placed within in its corresponding topic.

The CLAIM checklist has been adapted from the checklist initially developed by Si et al. [4], which used the original version of CLAIM [5] rather than the updated one. The checklist in this document has adapted the checklist created by Si et al. to reflect the 2024 update of CLAIM [1].

### REFERENCES

- [1] Tejani AS, Klontzas ME, Gatti AA, Mongan JT, Moy L, Park SH, Kahn CE Jr; CLAIM 2024 Update Panel. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): 2024 Update. Radiol Artif Intell. 2024 Jul;6(4):e240300. doi: 10.1148/ryai.240300. PMID: 38809149; PMCID: PMC11304031.
- [2] Lekadir K, Feragen A, Fofanah AJ, et al. FUTURE-AI: International consensus guideline for trustworthy and deployable artificial intelligence in healthcare. arXiv 2024; published online July. DOI:https://doi.org/10.48550/arXiv.2309.12325
- [3] Spaanderman D, Marzetti M, Wan X, Starmans M, Klein S. Al in radiological imaging of soft-tissue and bone tumours: a systematic review evaluating against best-practice guidelines. Github. 2024; published online Aug 21. https://douwe-spaanderman.github.io/Al-STTandBoneTumour-Review
- [4] Si L, Zhong J, Huo J, Xuan K, Zhuang Z, Hu Y, Wang Q, Zhang H, Yao W. Deep learning in knee imaging: a systematic review utilizing a Checklist for Artificial Intelligence in Medical Imaging (CLAIM). European Radiology. 2022 Feb 1:1-9
- [5] Mongan J, Moy L, Kahn CE Jr. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiol Artif Intell. 2020 Mar 25;2(2):e200029. doi: 10.1148/ryai.2020200029. PMID: 33937821; PMCID: PMC8017414.

General Information			
(sub)Section	Values		
Rater			
Year			
Journal			
Type imaging			
prognosis / diagnosis	0. Diagnosis 1. Prognosis 2. Both		
Which disease?	Soft tissue tumour/ Bone tumour/ GIST		
Used publicly available dataset	0. No 1. Yes 2. Both		
Retrospective vs prospective	0. Retrospective 1. Prospective		
Signle centre vs multi-centre	0. Single-centre 1. Multi-centre		
Data available	0. No 1. Upon request 2. Yes		
Code Available	0. No 1. Upon request 2. Yes		
Methods	0. Not learning 1. Hand crafted features 2. Model-learned features 3.  Combined		

	FUTURE-AI Checklist								
Principle	no.	Recommendations	Low ML-TRL	High ML-TRL	Description  Bias in medical AI is application-specific. At the design phase, the development team should identify possible types and sources	Scoring criteria  0) No potential biases were discussed prior to AI development,			
	1	Define any potential sources of bias from an early stage	++	++	of bias for their Al tool. These may include group attributes (e.g. sex, gender, age, ethnicity, socioeconomics, geography), the modical profiles of the individuals (e.g. with comorbidities or disability), as well as human biases (e.g. data abelling, data cuation, or the selection of the input features). To identify biases and apply measures for increased fairness, relevant attributes of the individuals, such as sex, gender, age,	To Specialisation of which with a second prior to discrepancing of the control of			
F 2		Collect data on individuals' attributes, when possible	+	+	ethnicity, risk factors, comorbidities or disabilities, should be collected. This should be subject to informed consent and approval by ethics committees to ensure an appropriate balance between the benefits for non-discrimination and risks for re-identification.	0.3) At reast the two attributes in the its concern, this loss Or gener, age, elimenty, risk factors(as I item), comorbidities of disabilities)  1) More than two attributes in the list were collected, OR with other attributes			
	3 Evaluate potential biases and bias correction measures		+	++	When possible, i.e the individuals' attributes are included in the dain, bias detection methods should be applied by using fainness matter. To course for any identified biases, mitigation measures should be applied to glar ansampling, biased are purposentations, equalized odds post-processing) and tested to verify their impact on both the tool's fairness and the model's accuracy. Importantly, any potential bias should be documented and reported to inform the end-users and citizens (see Traccobility 2).	Blases were neither investigated nor corrected for,     S) Blases were investigated and reported,     I) Blases were site corrected for by mitigation measures (In case of no biases found, 3 also applies)			
1		Define intended clinical settings and cross-setting variations	++	++	At the design phase, the development team should specify the clinical settings in which the AI tool will be applied (e.g. primary healthcare centres, hospitals, home care, low vs. high-resource settings, one or multiple countries), and anticipate potential obstacles to universality (e.g. differences in clinical definitions, medical equipment or IT inflastructures across settings)	0) The clinical setting was not reported (o) 5. Clinical setting outlined (e.g. primary healthcare centres, hospitals, horne care, low vs. high resource settings, one or multiple countries) 1) Clinical setting outlined and potential obstacles to universality discussed (e.g. differences in clinical definitions, medical equipment or IT infrastructures across settings)			
U	2	Use community-defined standards (e.g. clinical definitions, technical standards)	+	+	To ensure the quality and interoperability of the AI tool, it should be developed based on cristing community-defined standards. These may include clinical definitions, medical ontologies (e.g. SNOMED CT, 10 0MOP11), interface standards (e.g. DECOM, FIIR III.7), data amoutations, evaluation criteria, and technical standards (e.g. IEEE13 or SOVI4). To assess geomalisability, technical validations of the AI tools should be performed with external datasets that are distinct from	Are community defined standards used: (1) No (1) Yes			
	3	Evaluate using external datasets and/or multiple sites	++	++	If access generations, recurring a situation or use in a tools solution be passioned with extension transitions and extension to allow used for training. These may include reference or benchmarking datasets which are representative for the task in question (i. expression file approximating the expected real-world variations). Except for Al tools intended for single contras, the clinical evaluation studies should be performed an intelligent section superformance and interoposibility around involved world from the original variations. If the original contrast is a simple situation of the contrast of t	This study only used single center data -> no external validation;     Si livaluation was performed using external dataset from one other site (or same source, e.g., public available);     I) Evaluation was performed using external dataset from multiple sites;			
	4	Evaluate and demonstrate local clinical validity	+	++	Clinical settings vary in many aspects, such as populations, equipment, clinical workflows, and end-users. Hence to ensure trust a each site, the AI tools should be evaluated for their local clinical validity. In particular, the AI tool should fit the local clinical workflows and perform well can the local populations. If the performance is decrused when evaluated locally, re-calibration of the AI model should be performed (e.g., through model fine-tuning or retaining).	(i) local dinical validity has not been discussed, or was not applicable (e.g., Al tool was not staplyoed outside for exemb setting-internally) 6.5) local clinical validity has been discussed and evaluated, 1) local clinical validity has been discussed and evaluated and if needed, mitigation strategies have been deployed to deal with this local clinical validity.			
	1	Implement a risk management process throughout the AI lifecycle	+	++	Transplace the At tool's lifecycle, the development team should analyze potential ricks, more cost in it's likelihood, effects and school-unfel balance, deficin rick mitigation measures, monitor the ricks and mitigations commissed, and manistrate as rick management file. The risks may include those explicitly owned by the EUTUREA guiding principles (e.g. bits, harm), but also polygication-specific ricks. Other inks to consider include human factors that may lead to misses of the AE old e.g. for following the instructions, receiving insufficient training), applications of the AI tool to invitivabile who are not within the target population of the AI tool to mixed and physication, behave false, incorrect data anonation or input values, and adversarial makes. Minigation measures may include warmage to the user, system shadown, responsing of the topes dist, the equations of one department of the species of the expensions of one being which are to the cort of anomalous precisions of manipulation for the cort of the characteristic department of the cort of the cort of the characteristic department of the cort of the cort of the characteristic department of the cort of the cort of the characteristic department of the cort of the cort of the characteristic department of the cort of the cor	0.5) Risks regarding the AI lifecycle have been described, <ol> <li>A risk management plan has been described in order to circumvent risks during the AI</li> </ol>			
	2	Provide documentation (e.g. technical, clinical)	++	++	To increase transparency, transcability, and accountability, adequate documentations should be created and minimized for the AI count, which may include (i) and Infinemation leaflet to inform citizen and healthcare professional should the told visiteded use, risks (e.g. blaces) and instructions for use, (ii) a technical document to inform AI developers, health organizations and regulators down the AI model's properties (e.g. byperquarteers), training and esting date, evaluation critical and results bases and other limitations, and periodic audits and updates; (iii) a publication based on existing AI reporting standards, and (iv) a risk management file (see Transchility 1).	(1) No documentation has been provided, 0.51 Documentation about 1-2 points (see decription) have been provided, 1) Documentation about 3-4 points (see decription have been provided)			
Т	3	Define mechanisms for quality control of the AI inputs and outputs	+	++	The AI total docted by developed and deployed with mediations for continuous monitoring and quality control of the AI inputs and opposits, who is to identify intuiting or not of ragging plays arrivables, insonitated that demonst or units, incontrol and another or units, incontrol and another or monitorino of hada proprocessing, and ermonous or implansible AI outputs. For quality control of the AI decisions, incentiarily estimates should be provided (and califorated) to infinite the evaluace one the degree of confidence in the neutrin. Finally, when necessary, moded updates should be applied to address any identified limitations and enhance the AI models over time.	6) No monitoring or quality control measures of either inputs or outputs have beenimplemented 0.5) Monitoring or quality control measures have been implemented for either the inputs or outputs 1) Monitoring or quality control measures have been implemented for both inputs and outputs.			
	4	Implement a system for periodic auditing and updating	+	++	The AI tool should be developed and deployed with a configurable system for portical malting, which should define site-specific datasets and timelines for periodic valuations (e.g. every year). The periodic auditing should enable the identification of data or concept drifts, newly occurring biases, performance degradation or changes in the decision making of the end-overs. Accordingly, necessary updates to the AI models or AI tools should be applied.  To incrues transcribing and accountability, as AI logging systems should be implemented to trace the user's manu actions in a	No discussion of audit or future updating;     S) Need of audit or potential updates is discussed;     Methods for auditing or updating are discussed.			
	5	Implement a logging system for usage recording	+	++	privacy-preserving manner, specify the data that is accessed and used, record the AI predictions and clinical decisions, and log any encountered issues. Time-series statistics and visualisations should be used to inspect the usage of the AI tool over time.	No system has been devised for logging usage of the AI tool;     A system has been devised for logging usage of the AI tool			
	6	Establish mechanisms for Al governance	+	++	After deployment, the governance of the AI tool should be specified. In particular, the noise of risk management, periodic andiring maintenance, and specivion should be assigned, such as 10 IT leaves no behilter and ministerance. Furthermore, responsibilities for AI-related errors should be clearly specified among distincians, beathboare centres, AI developers, and manufacturers. Accountability mechanisms should be established, incorporating both individual and collective liability, alongside compensation and support structures for guitatis impacted by AI errors.	0) Al has no governance mechanism (see question for examples), 1) There is at least 1 governance mechanism implemented described			
	1	Define intended use and user requirements from an early stage	++	++	The AI developers should engage clinical experts, end-users (e.g. patients, physicians) and other relevant stakeholders (e.g. data managers, administrators) from an early stage, to compile information on the AI tool's intended use and end-user requirements (e.g. human-AI interfece, as well as on human factors that may impact the usage of the AI tool (e.g. ergoromics, intuitiveness, experience, learnability)	9) Oak J I type of siakeholder (e.g. Al developen-departments) was present for Al development, and no intended used user requirement was described, (e.g. Al developen-department) was present for Al development, and one intended user and end user requirement was described. (Nr. milliple development, however intended tone and ende ere requirements was described. (Nr. milliple development, however intended tone and ender requirement was described.) (Nr. milliple (e.g. milliple) (e.g. milli			
U	2	Establish mechanisms for human-AI interactions and oversight	+	++	Band on the user requirements, the All developers about implement interfaces to enable used-seen to effectively utilise the All model, amounts the input data in a standardised manusce, and verify the All imputs and results. Given the high-staken nature of model, All imputs and results described in the interface of the control of the c	The Al tool has no human oversight,     The Al tool provides at feast one interface or human-in-the-loop mechanism to involve human oversight.			
	3	Provide training materials and activities (e.g. tutorials, hands-on sessions)	+	++	To facilitate best usage of the AI tool, minimise errors and ham, and increase AI literacy, the developers should provide training materials (e.g. tutorials, manuls, examples) in accessible language and/or training activities (e.g. hands-on sessions), taking into account the diversity of end-users (e.g. clinical specialists, nurses, technicians, citizens or administrators).	Has any training material been provided: 0) No 1) Yes			
	4	Evaluate user experience and acceptance with independent end-users	+	++	To facilitate adoption, the usability of the Al Isool should be evaluated in the real world with representative and diverse end-users (e.g. with respect to sex, gender, age, clinical role, digital proficiency, (disjability). The usability tests should gather evidence on the user's satisfaction, performance and productivity. These tests should also verify whether the Al tool impacts the behaviour and	The AI tool was not evaluated for user experience,     S.5) The AI tool was evaluated for user experience by I user     The AI tool was evaluated for user experience by multiple independent end-users.			
	5	Evaluate clinical utility and safety (e.g. effectiveness, harm, cost- benefit)	+	++	dexistor making of the end-users.  The At not dotable the evaluate for its clinical utility and safety. The clinical evaluations of the At tool should show benefits for the clinical reg. incremely productivity, improved case, for the patient (e.g. entire diagnosis, better outcomes), and/or for the architecture comparisons (e.g. inchead costs, e.g. injunities of which who compared to the current standard or care. Additionally, it is important to show that the At I tool is safe and does not cause harm to individuals (or specific groups), such as through a mandonised clinical transfer.	0) The All tool was not evaluated for clinical utility and safety.  1) The All tool was evaluated for clinical utility and safety.  1) The All tool was evaluated for clinical utility and safety in a Randomized Control Trial (RCT).			
	1	Define sources of data variation from an early stage	++	++	At the design phase, an inventory should be made of the application-specific sources of variation that may impact the AI tool's obstateness in the real world. These may include differences in equipment, technical fault of a machine, data betrengeneities during data acquisition or amoutation, and/or adversarial attacks.	Date requisition and possible variation of the data source to the real would has not been discussed.  8.5) Date acquisition and possible variation of the data source to the real world has been discussed.  1) Extensive reporting, including reference to the literature and other primary sources, about how the data may vary of does not vary to the real world data.			
R	2	Train with representative real-world data	++	++	Clinicians, citizens and other stakeholders are more likely to trust the Al tool if it is trained on data that adequately represents the variations encountered in real-world clinical practice. Hence, the training datasets should be carefully selected, analysed and enriched according to the sources of variation identified at the design phase (see Robustness 1).	9) The representative of the training data to the real-world data was not valuated; 0.5) The representative of the training data to the real-world data was evaluated; 1) The representative of the training data to the real-world data was evaluated and enriched accordingly; Note "real world data" has to be data taken from a cinical settine			
	3	Evaluate and optimise robustness against real-world variations	++	++	Evaluation studies should be implemented to evaluate the AI tool's robustness (including atress tests and repeatability tests), by considering all potential sources of variation (see Robustness 1), such as data, conjumente, clinicians, patient- and centre-related variations. Depending on the results, mitigation measures should be implemented to optimise the robustness of the AI model, such as regularisation, data augmentation, data harmonisation, or domain adaptation.	The AI tool has not been evaluated against real-world data (test data),     O.5 The AI tool has been evaluated against real-world data (test data),     The AI tool has been evaluated against real-world data (test data) and     The AI tool has been evaluated against real-world data (test data) and the AI tool's robustness has been optimized (if applicable) using mitigation methods.			
E	1	Define the need and requirements for explainability with end-users	++	++	At the design phase, it should be established if explainability is required for the AI tool. In this case, the specific requirements for explainability should be defined with representative experts and end-users, including (i) the goal of the explainations (e.g. global description of the model's behaviour vs. local explanation of each AI decision), (ii) the most suitable approach for AI explainability, and (iii) the potential limitations to anticipate and monitor (e.g. over-reluxor of the end-users on the AI decision).	0) Explainability has not been defined at the design phase, 0.5 At least once of the following areas is discussed: (i) the, 0.5 At least once of the following areas is discussed: (ii) the, discreption of the model's behaviours vs. lead explanation of each Al decision, (ii) the most satisfied genouch for Al explainability and (iii) the potential limitations to anticipate and monitor (e.g. over-defined or of the end-serves on the Al decision).  1) more than one of the arean has been identified and discussed			
	2	Evaluate explainability with end-users (e.g. correctness, impact on users)	+	+	The explainable AI methods should be evaluated, first quantitatively by using in silico methods to assess the correctness of the explanations, then qualitatively with end-users to assess their impact on user satisfaction, confidence and clinical performance. The ordations should also identify any institutions of the AI explanations (e.g. they are clinically incoherent or sensitive to noise or adversarial attacks, they unreasonably increase the confidence in the AI-generated results).	Explainability has not been defined or not evaluated with end-users,     S. Explainability has been evaluated in silico OR with end users involved in the development     Explainability has been evaluated with end-users not involved in the development (e.g.     clinical users - radiologists/clinicians, radiographers etc)			
	1	Engage inter-disciplinary stakeholders throughout the AI lifecycle	++	++	Throughout the Al tool's lifecycle, the Al developers should continuously engage with inter-disciplinary stakeholders, such as healthcare professionals, critizens, patient representatives, expert ethicists, data managers and legal experts. This interaction will facilitate the understanding and anticipation of the needs, obstacles and pathways towards acceptance and adoption.	Was a multi-disciplinary team involved in AI development (more than 1 department) 0) No 1) Yes			
	2	Implement measures for data privacy and security	++	++	adequate mensures to ensure data privacy and security abouth to part in place fromglose the Al Efcycle. These may include privacy-embroaring techniques for a efforted privacy, exceptional data protections impair assessment and appropriet data partners and set deployment (e.g. logging system for data axcess, see Teacobility 5). If de-destrification is implemented (e.g. pendeolymistation, keep comparing the hardners between the health benefits for exitations after that for re-destination should be carefully assessed and considered. Furthermore, the manufacturers and deployers should implement and regularly evaluate measure for protecting the Al too against malicious tacks, such as by using system-level cybersecurity solutions or application-specific defence mechanisms (e.g. attack detection or mitigation)	His data privacy and security been discussed (e.g. data anonymization, cleanance from medical estitudi committee, (warved) informed consents)?  (9) No  1) Yes			
General	3	Implement measures to address identified AI risks	++	++	At the development stage, the development team should define an AI modelling plan that is aligned with the application-specific requirements. After implementing and testing a baseline AI model, the AI modelling plan should include mitigation measures to adares the challenge and rissis identified at the design stage (see Fixmes 1 to Explanishilty). These may include measures to enhance rebustness to real-world variations (e.g. regulariation, data augmentation, data harmonisation, domain adaptation), ensuranteed and according to the control of the control o	1) I'wo or more mitigation measures (F3, R2, R3) to enhance robusteness to real-world variation and/or ensure generalisability across settings and/or correct for biases across subgroups have been taken.			
	4	Define adequate evaluation plan (e.g. datasets, metrics, reference methods)	++	++	To increase trust and adoption, an appropriate evaluation plan should be defined (including test data, metrics and reference methods). First, adequate test data should be selected for associning each dimension of trustworthy A. In particular, the test data should be well-equated from the training to present data leading "Harthennee, adequate evaluation metrics should be carefully edected, taking timo account their benefits and present aftens. Finally, inculturating with respect to reference Al tools or standard practics which be performed to middle emporative associators of model performance of models performed to middle emporative associations of model performance of models performed to middle preformed to middle profession during the supervision of models performed to middle profession during the supervision of medium dependence of models performed to middle emporative association of models performed to middle emporative association of models performed to middle emporation association of models performed to middle emporative association of middle emporative association of models performed to middle emporative association of middle emp	OF Evaluation was not conducted using standardized and best practices, 0.5) a separate lest set was used to evaluate the Al I tool and reported on using appropriate evaluation metrics (e.g. sensitivity and specificity) 1) The Al I tool was compared to current standard practice (e.e. evaluation metrics on test set should be compared to same metrics for current clinical tests - so for example how did it compare to andiologists)			
	5	Identify and comply with applicable AI regulatory requirements	+	++	The development team should identify the applicable AI regulations depending on the relevant jurisdictions. This should be done at an early stage to anticipate regulatory obligations based on the medical AI tool's intended classification and risks.	Have AI regulatory requirements been identified?  (1) No  1) Yes			
	6	Investigate and address ethical issues	+	++	In addition to the well-known ethical issues that arise in medical AI (e.g. privacy, transparency, equity, autonomy), AI developers, domain specialists and professional ethicists should identify, discuss and address all application-specific ethical, social and societal issues as an integral part of the development and deployment of the AI too.	1) No 1) Yes			
	7	Investigate and address social and societal issues	+	+	Sociation stocks an integral pair to the development and authorized to the CF of the C	Have social and societal implications been investigated? 0) No 1) Yes			
					•				

CLAIM Checklist						
(sub)section	CLAIM item#	Criterion	Explanation	Values		
Title or Abstract	1	The study identifies the Al methodology, or specifies the category of technology used (eg.	Specify the AI techniques used in the study—such as "vision transformers" or "deep learning"—in the article's title and/or abstract; use judgment regarding the level of	Not specified     Specified		
Abstract	2	deep learning).  Summary of study design, methods, results, and conclusions	specificity.  The abstract should present a succinct structured summary of the study's design, methods, results, and conclusions. Include relevant detail about the study population, such as data source and use of publicly available datasets, number of patients or examinations, number of studies per data source, modalities and relevant series or sequences. Provide information about data partitions and level of data splitting (eg., patient- or image-level). Clearly state if the study is prospective or retrospective and summarize the statistical analysis that was performed. The reader should clearly understand the primary outcomes and implication of the study's findings, including relevant clinical impact. Indicate whether the software, data, and/or resulting model are publicly available (including where to find more details, if applicable).	0. Not included 1. Included		
Introduction	3	Scientific and/or clinical background, including the intended use and role of the Al approach	Considered as complete if at least a simple sentence was provided to introduce the medical context and rationale for developing/validating the model: The current practice should be explicitly mentioned. (1) Describe the study's rationale, goals, and anticipated impact. (2) resent a focused summary of the pertinent literature to describe current practice and highlight how the investigation changes or builds on that work. Guide readers to understand the context for the study, the underlying science, the assumptions underlying the methodology, and the nuances of the study.	0. Not provided 1. Provided		
	4a	Study aims and objectives	Define clearly the clinical or scientific question to be answered; avoid vague statements or descriptions of a process. Limit the chance of post hoc data dredging by specifying the study's hypothesis apriori. The study's hypothesis and objectives	Not provided     Provided		
	4b	Study hypothesis	by operaning the study's hypothesis a prior. The study's hypothesis and objectives should guide appropriate statistical analyses, sample size calculations, and whether the hypothesis will be supported or not.	Not provided     Provided		
Methods	5	Prospective or retrospective study	Indicate if the study is retrospective or prospective. Evaluate predictive models in a	Not documented		
			prospective setting, if possible.  Considered as complete if at least a simple sentence was provided involving	1. Documented		
Study Design	6	Study goal	one of the points below: (1) Define the study's goal, such as model creation, exploratory study, feasibility study, or noninferiently trial. For classification systems, state the intended use, such as diagnosis, screening, staging, monitoring, surveillance, prediction, or prognosis. (2) Describe the type of predictive modeling to be performed, the target of predictions, and how it will solve the clinical or scientific question.	Not documented     Documented		
	7a	Data source	State the source(s) of data including publicly available datasets and/or synthetic	0: Not documented 1: Documented		
	7b	Data collection institutions	images; provide links to data sources and/or images, if available. Describe how well the data align with the intended use and target population of the model. Provide	Not documented     Documented		
	7c	Institutional review board approval	links to data sources and/or images, if available. Authors are strongly encouraged to deposit data and/or software used for modeling or data analysis in a publicly	Not documented     Documented		
	7d	Participant consent	accessible repository.	Not documented     Documented		
	8	Inclusion and exclusion criteria	Specify inclusion and exclusion criteria, such as location, dates, patient-care setting, demographics (eg, age, sex, race), pertinent follow-up, and results from prior tests. Define how, where, and when potentially eligible participants or studies were identified. Indicate whether a consecutive, random, or convenience series was selected.	Not provided     Provided		
	9a	Data pre-processing steps with details		Not provided     Provided		
	9b	Normalization / resampling in preprocessing		Not documented     Documented		
	9c	Whether data have been rescaled, threshold- limited ("binarized"), and/or standardized	Describe preprocessing steps to allow other investigators to reproduce them.  Specify the use of normalization, resampling of image size, change in bit depth,	Not documented     Documented		
Data	9d	Specify how the following issues were handled: regional format, manual input, inconsistent data, missing data, wrong data types, file manipulations, and missing anonymization.	and/or adjustment of window/level settings. If applicable, state whether the data have been rescaled, threshold-limited ("binarized"), and/or standardized. Specify processes used to address regional formatting, manual input, inconsistent data, missing data, incorrect data type, file manipulations, and missing anonymization. State any oriteria used to remove outliers. When applicable, include description for libraries, software (including manufacturer name and location and version numbers),	Not documented     Documented		
	9e	Define any criteria to remove outliers	and all option and configurations settings.	Not documented     Documented		
	9f	Specify the libraries, software (including manufacturer name and location), and version numbers, and all option and configuration settings employed.		Not documented     Documented		
	10	Selection of data subsets	State whether investigators selected subsets of raw extracted data during preprocessing. For example, describe whether investigators selected a subset of the images, cropped portions of images, or extracted segments of a report. If this process is automated, describe the tools and parameters used. If performed manually, describe the training of the personnel and criteria used in their instruction. Justify how this manual step would be accommodated in context of the clinical or scientific problem, describing methods of scaling processes, when applicable.	Not documented     Documented		
	11	De-identification methods	Describe the methods used to de-identify data and how protected health information has been removed to meet U.S. (HIPAA), EU (AI Act, EU Health Data Space, GDPR), or other relevant regulations	Not defined     Defined		
	12	How missing data were handled	Clearly describe how missing data were handled. For example, describe processes to replace them with approximate, predicted, or proxy values. Discuss biases that imputed data may introduce.	Not defined     Defined		
	13	Image acquisition protocol	Describe the image acquisition protocol, such as manufacturer, MRI sequence, ultrasoundfrequency, maximum CT energy, tube current, slice thickness,scan range, and scan resolution; include all relevant parametersto enable reproducibility of the stated methods.	0. Not defined 1. Defined		
	14	Definition of method(s) used to obtain reference standard	Include a clear, detailed description of methods used to obtain the reference standard; readers should be able to replicate the reference standard based on this description. Include specific, standard guidelines provided to all annotators. Avoid vague descriptions, such as "white matter lesion burden," and use precise definitions, such as "lesion location (periventricular, juxtacortical, infratentorial), size measured in three dimensions, and number of lesions as measured on T2/FLAIR MR brain images." Provide an atlas of examples to annotators to illustrate subjective grading schemes (eg, mild, moderate, severe) and make that information available for review.	0. Not defined 1. Defined		
	15	Rationale for choosing the reference standard	Describe the rationale for choice of the reference standard versus any alternatives. Include information on potential errors, biases, and limitations of that reference standard.	Not documented     Documented		

Ground Truth	and Truth 16 Source of reference standard annotations		Considered as complete if all points below were provided: (1) Specify the source of reference standard annotations, citing relevant literature if annotations from existing data resources are used (2)Specify the number of human annotators and their qualifications (eg, level of expertise, subspecialty training). (3) Describe the instructions and training given to annotators; include training materials as a supplement	Not documented     Documented
	17	Annotation of test set	Detail the steps taken to annotate the test set with sufficient detail so that another investigator could replicate the annotation. Include any standard instructions provided to annotators for a given task. Specify software used for manual annotation, including the version number. Describe if and how imaging labels were extracted from imaging reports or electronic health records using natural language processing or recurrent neural networks. This information should be included for any step involving manual annotation, in addition to any semiautomated or automated annotation.	Not documented     Documented
	18	Measurement of inter- and intrarater variability of features described by annotators	Describe the methods to measure inter- and intra- rater variability, and any steps taken to reduce or mitigate this variability and/or resolve discrepancies between annotators.	Not documented     Documented
Data Partitions	19	How data were assigned to partitions; specify proportions	Specify how data were partitioned for training, model optimization (often termed "tuning" or "validation"), and testing. Indicate the proportion of data in each partition (eg. 80/10/10) and justify that selection. Indicate if there are any systematic differences between the data in each partition, and if so, why and how potential class imbalance was addressed. If using openly available data, use established splits to improve comparison to the literature. If freely sharing data, provide data splits so that others can perform model training and testing comparably.	Not documented     Documented
	20	Level at which partitions are disjoint	Describe the level at which the partitions are disjoint (eg, patient-, series-, image- level). Sets of medical images generally should be disjoint at the patient level or higher so that images of the same patient do not appear in each partition.	Not documented     Documented
Testing Data	21	Intended sample size	Describe the size of the testing set and how it was determined. Use traditional power calculation methods, if applicable, to estimate the required sample size. For classification problems, in cases where there is no algorithm-specific sample size estimation method available, sample size can be estimated for a given area under the curve and confidence interval width	Not documented     Documented
Model	22	<b>Detailed</b> description of model	If novel model architecture is used, provide a complete and detailed structure of the model, including inputs, outputs, and all intermediate layers, in sufficient detail that another investigator could exactly reconstruct the network. For neural network models, include all details of pooling, normalization, regularization, and activation in the layer descriptions. Model inputs must match the form of the preprocessed data. Model outputs must correspond to the requirements of the stated clinical problem, and for supervised learning should match the form of the reference standard annotations. If a previously published model architecture is employed, cite a reference that meets the preceding standards and fully describe every modification made to the model. Cite a reference for any proprietary model described previously, as well. In some cases, if may be more convenient to provide the structure of the model in code as supplemental data.	Not documented     Documented
	23	Software libraries, frameworks, and packages	Specify the names and version numbers of all software libraries, frameworks, and packages. A detailed hardware description may be helpful, especially if computational performance benchmarking is a focus of the work.	Not documented     Documented
	24	Initialization of model parameters	Indicate how the parameters of the model were initialized. Describe the distribution from which random values were drawn for randomly initialized parameters. Specify the source of the starting weights if transfer learning is employed to initialize parameters. When there is a combination of random initialization and transfer learning, make it clear which portions of the model were initialized with which strategies.	Not documented     Documented
Training	25	Details of training approach	Describe the training procedures and hyperparameters in sufficient detail to enable another investigator to replicate the experiment. To fully document training, a manuscript should: (a) describe how training data were augmented (eg, types and ranges of transformations for images), (b) state how convergence of training of each model was monitored and what the criteria for stopping training were, and (c) indicate the values that were used for every hyperparameter, including which of these were varied between models, over what range, and using what search strategy. For neural networks, descriptions of hyperparameters should include at least the learning rate schedule, optimization algorithm, minibatch size, dropout rates (if any), and regularization parameters (if any). Discuss what objective function was employed, why it was selected, and to what extent it matches the performance required for the clinical or scientific use case. Define criteria used to select the best-performing model. If some model parameters are froze or restricted from modification, for example in transfer learning, clearly indicate which parameters are involved, the method by which they are restricted, and the portion of the training for which the restriction applies. It may be more concise to describe these details in code in the form of a succinct training script, particularly for neural network models when using a standard framework.	Not documented     Documented
	26	Method of selecting the final model	Describe the method and metrics used to select the best-performing model among all the models trained for evaluation against the held-out test set. If more than one model was selected, justify why this was appropriate.	Not documented     Documented
	27	Ensembling techniques	If the final algorithm involves an ensemble of models, describe each model comprising the ensemble in complete detail in accordance with the preceding recommendations. Indicate how the outputs of the component models are weighted and/or combined.	Not documented     Documented
	28	Metrics of model performance	Describe the metrics used to assess the model's performance and indicate how they address the performance characteristics most important to the clinical or scientific problem. Compare the presented model to previously published models.	Not documented     Documented
Statistical measures of significance and uncertainty			Considered as complete if all points below were provided: (1) Indicate the uncertainty of the performance metrics' values, such as with standard deviation and/or confidence intervals. (2) Compute appropriate tests of statistical significance to compare metrics. (3) Specify the statistical software, including version.	Not documented     Documented
	30	Robustness or sensitivity analysis	Analyze the robustness or sensitivity of the model to various assumptions or initial conditions.	Not documented     Documented
Standard   Standard		Methods for explainability or interpretability	If applied, describe the methods that allow one to explain or interpret the model's results and provide the parameters used to generate them. Describe how any such methods were validated in the current study.	Not documented / NA     Documented
		Document and describe evaluation performed on internal data. If there are systematic differences in the structure of annotations or data between the training set and the internal test set, explain the differences, and describe the approach taken to accommodate the differences. Document whether there is consistency in performance on the training and internal test sets.	0. Not described 1. Employed internal test data	
		Testing on external data	Describe the external data used to evaluate the completed algorithm. If no external testing is performed, note and justify this limitation. If there are differences in structure of annotations or data between the training set and the external testing set, explain the differences, and describe the approach taken to accommodate the differences.	Not described     Employed external test data

•				
	34	Clinical trial registration	If applicable, comply with the clinical trial registration statement from the International Committee of Medical Journal Editors (ICMJE). ICMJE recommends that all medical journal editors require registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. Registration of the study protocol in a clinical trial registry, such as ClinicalTrials.gov or WHO Primary Registries, helps avoid overlapping or redundant studies and allows interested parties to contact the study coordinators.	Not documented     Documented
Results				
	35	Flow of participants or cases, using a diagram to indicate inclusion and exclusion	Document the numbers of patients, examinations, or images included and excluded based on each of the study's inclusion and exclusion criteria. Include a flowchart or alternative diagram to show selection of the initial patient population and those excluded for any reason.	Not documented     Documented
Data	36	Demographic and clinical characteristics of cases in each partition	Specify the demographic and clinical characteristics of cases in each partition and dataset. Identify sources of potential bias that may originate from differences in demographic or clinical characteristics, such as sex distribution, underrepresented racial or ethnic groups, phenotypic variations, or differences in treatment.	Not documented     Documented
	37	Performance metrics and measures of statistical uncertainty	Considered as complete if at least two points below were provided: (1) Report the final model's performance on the test partition. (2) Benchmark the performance of the Al model against current standards, such as histopathologic identification of disease or a panel of medical experts with an explicit method to resolve disagreements. (3) State the performance metrics on all data partitions and datasets, including any demographic subgroups.	Not documented     Documented
Model Performance	38	Estimates of diagnostic accuracy and their precision	Considered as complete if at least three points below were provided: For classification tasks, (1) include estimates of diagnostic accuracy and their precision, such as 95% confidence intervals. (2) Apply appropriate methodology such as receiver operating characteristic analysis and/or calibration curves. When the direct calculation of confidence intervals is not possible, report non-parametric estimates from bootstrap samples. (3) State which variables were shown to be predictive of the response variable. (4) Identify the subpopulation(s) for which the prediction model worked most and least effectively. (5) If applicable, recognize the presence of class imbalance (uneven distribution across data classes within or between datasets) and provide appropriate metrics to reflect algorithm performance	Not documented     Documented
	39	Failure analysis of incorrectly classified cases	Considered as complete if at least one points below were provided: Provide information to help understand incorrect results. (1) If the task entails classification into two or more categories, provide a confusion matrix that shows tallies for predicted versus actual categories. (2) Consider presenting examples of incorrectly classified cases to help readers better understand the strengths and limitations of the algorithm. (3) Provide sufficient detail to frame incorrect results in the appropriate medical context.	Not documented     Documented
	40	Study limitations	Identify the study's limitations, including those involving the study's methods, materials, biases, statistical uncertainty, unexpected results, and generalizability. This discussion should follow succinct summarization of the results with appropriate context and explanation of how the current work advances our knowledge and the state of the art.	Not discussed     Discussed
Discussion	41	Implications for practice, including the intended use and/or clinical role	Considered as complete if at least three points below were provided: (1) Describe the implications for practice, including the intended use and possible clinical role of the Al model. (2) Describe the key impact the work may have on the field. (3) Envision the next steps that one might take to build upon the results. (4) Discuss any issues that would impede successful translation of the model into practice.	Not discussed     Discussed
	42	Provide a reference to the full study protocol or to additional technical details	preclinical studies, include reference to details of the AI methodology, if not fully	Not access to the full study protocol     Provided access to the full study protocol
Other information	43	Statement about the availability of software, trained model, and/or data	Describe the algorithms and software in sufficient detail to allowreplication of the study. Authors should deposit all computercode used for modeling and/or data analysis into a publiclyaccessible repository.	Not discussed     Discussed
	44	Sources of funding and other support; role of funders	Specify the sources of funding and other support and the exact role of the funders in performing the study. Indicate whether the authors had independence in each phase of the study.	Not documented     Documented

# **Appendix 3**

- 1. Alabdulkreem E, Saeed MK, Alotaibi SS, Allafi R, Mohamed A, Hamza MA. Bone Cancer Detection and Classification Using Owl Search Algorithm With Deep Learning on X-Ray Images. *Ieee Access* 2023; **11**: 109095-103.
- 2. Alaoui EA, Tekouabou SCK, Hartini S, Rustam Z, Silkan H, Agoujil S. Improvement in Automated Diagnosis of Soft Tissues Tumors Using Machine Learning. *Biq Data Min Anal* 2021; **4**(1): 33-46.
- 3. Alge O, Lu L, Li Z, Hua Y, Gryak J, Najarian K. Automated Classification of Osteosarcoma and Benign Tumors using RNA-seq and Plain X-ray. *Annu Int Conf IEEE Eng Med Biol Soc* 2020; **2020**: 1165-8.
- 4. Altameem T. Fuzzy rank correlation-based segmentation method and deep neural network for bone cancer identification. *Neural Computing and Applications* 2020.
- 5. Amini B, Chenglei L, Duran-Sierra E, Wang WL, Canjirathinkal MA, Moradi H, et al. Role of Apparent Diffusion Coefficient Map-Based First- and High-Order Radiomic Features for the Discrimination of Sacral Chordomas and Chondrosarcomas With Overlapping Conventional Imaging Features. *JCO precis oncol* 2023; **7**: e2300243.
- 6. Ao W, Cheng G, Lin B, Yang R, Liu X, Zhou C, et al. A novel CT-based radiomic nomogram for predicting the recurrence and metastasis of gastric stromal tumors. *Am J Cancer Res* 2021; **11**(6): 3123-34.
- 7. Arthur A, Orton MR, Emsley R, Vit S, Kelly-Morland C, Strauss D, et al. A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis. *Lancet Oncol* 2023; **24**(11): 1277-86.
- 8. Ba-Ssalamah A, Muin D, Schernthaner R, Kulinna-Cosentini C, Bastati N, Stift J, et al. Texture-based classification of different gastric tumors at contrast-enhanced CT. *Eur J Radiol* 2013; **82**(10): e537-43.
- 9. Bandyopadhyay O, Biswas A, Bhattacharya BB. Bone-Cancer Assessment and Destruction Pattern Analysis in Long-Bone X-ray Image. *J Digit Imaging* 2019; **32**(2): 300-13.
- 10. Banerjee I, Crawley A, Bhethanabotla M, Daldrup-Link HE, Rubin DL. Transfer learning on fused multiparametric MR images for classifying histopathological subtypes of rhabdomyosarcoma. *Comput Med Imaging Graph* 2018; **65**: 167-75.
- 11. Baskaran K, Malathi R, Thirusakthimurugan P. Feature Fusion for FDG-PET and MRI for Automated Extra Skeletal Bone Sarcoma Classification. *Mater Today-Proc* 2018; **5**(1): 1879-89.
- 12. Blackledge MD, Winfield JM, Miah A, Strauss D, Thway K, Morgan VA, et al. Supervised Machine-Learning Enables Segmentation and Evaluation of Heterogeneous Post-treatment Changes in Multi-Parametric MRI of Soft-Tissue Sarcoma. *Front oncol* 2019; **9**: 941.
- 13. Bouhamama A, Leporq B, Khaled W, Nemeth A, Brahmi M, Dufau J, et al. Prediction of Histologic Neoadjuvant Chemotherapy Response in Osteosarcoma Using Pretherapeutic MRI Radiomics. *Radiol Imaging Cancer* 2022; **4**(5): e210107.

- 14. Breden S, Hinterwimmer F, Consalvo S, Neumann J, Knebel C, von Eisenhart-Rothe R, et al. Deep Learning-Based Detection of Bone Tumors around the Knee in X-rays of Children. *J Clin Med* 2023; **12**(18).
- 15. Cao C, Yi Z, Xie M, Xie Y, Tang X, Tu B, et al. Machine learning-based radiomics analysis for predicting local recurrence of primary dermatofibrosarcoma protuberans after surgical treatment. *Radiother Oncol* 2023; **186**: 109737.
- 16. Cao Y, Wang Z, Ren J, Liu W, Da H, Yang X, Bao H. Differentiation of retroperitoneal paragangliomas and schwannomas based on computed tomography radiomics. *Sci rep* 2023; **13**(1): 9253.
- 17. Cappello G, Giannini V, Cannella R, Tabone E, Ambrosini I, Molea F, et al. A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST). *Eur J Radiol Open* 2023; **11**: 100505.
- 18. Casale R, De Angelis R, Coquelet N, Mokhtari A, Bali MA. The Impact of Edema on MRI Radiomics for the Prediction of Lung Metastasis in Soft Tissue Sarcoma. *Diagnostics* 2023; **13(19)**.
- 19. Casale R, Varriano G, Santone A, Messina C, Casale C, Gitto S, et al. Predicting risk of metastases and recurrence in soft-tissue sarcomas via Radiomics and Formal Methods. *Jamia Open* 2023; **6**(2): ooad025.
- 20. Cay N, Mendi BAR, Batur H, Erdogan F. Discrimination of lipoma from atypical lipomatous tumor/well-differentiated liposarcoma using magnetic resonance imaging radiomics combined with machine learning. *Jpn J Radiol* 2022; **40**(9): 951-60.
- 21. Chen CY, Chiou HJ, Chou SY, Chiou SY, Wang HK, Chou YH, Chiang HK. Computer-aided diagnosis of soft-tissue tumors using sonographic morphologic and texture features. *Acad Radiol* 2009; **16**(12): 1531-8.
- 22. Chen G, Fan L, Liu J, Wu S. Machine learning-based predictive model for the differential diagnosis of <= 5 cm gastric stromal tumor and gastric schwannoma based on CT images. *Discov Oncol* 2023; **14**(1): 186.
- 23. Chen H, Liu J, Cheng Z, Lu X, Wang X, Lu M, et al. Development and external validation of an MRI-based radiomics nomogram for pretreatment prediction for early relapse in osteosarcoma: A retrospective multicenter study. *Eur J Radiol* 2020; **129**: 109066.
- 24. Chen H, Zhang X, Wang X, Quan X, Deng Y, Lu M, et al. MRI-based radiomics signature for pretreatment prediction of pathological response to neoadjuvant chemotherapy in osteosarcoma: a multicenter study. *Eur Radiol* 2021; **31**(10): 7913-24.
- 25. Chen S, Li N, Tang Y, Chen B, Fang H, Qi S, et al. Radiomics Analysis of Fat Saturated T2-Weighted MRI Sequences for Prognostic Prediction to Soft-Tissue Sarcoma of the Extremities and Trunk Treated With Neoadjuvant Radiotherapy. *Int J Radiat Oncol Biol Phys* 2021; **111**(3): e315.
- 26. Chen T, Liu S, Li Y, Feng X, Xiong W, Zhao X, et al. Developed and validated a prognostic nomogram for recurrence-free survival after complete surgical resection of local primary gastrointestinal stromal tumors based on deep learning. *EBioMedicine* 2019; **39**: 272-9.

- 27. Chen T, Ning Z, Xu L, Feng X, Han S, Roth HR, et al. Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively. *Eur Radiol* 2019; **29**(3): 1074-82.
- 28. Chen W, Ayoub M, Liao M, Shi R, Zhang M, Su F, et al. A fusion of VGG-16 and ViT models for improving bone tumor classification in computed tomography. *J Bone Oncol* 2023; **43**: 100508.
- 29. Chen X, Huang Y, He L, Zhang T, Zhang L, Ding H. CT-Based Radiomics to Differentiate Pelvic Rhabdomyosarcoma From Yolk Sac Tumors in Children. *Front oncol* 2020; **10**: 584272.
- 30. Chen Z, Xu L, Zhang C, Huang C, Wang M, Feng Z, Xiong Y. CT Radiomics Model for Discriminating the Risk Stratification of Gastrointestinal Stromal Tumors: A Multi-Class Classification and Multi-Center Study. *Front oncol* 2021; **11**: 654114.
- 31. Cheng Y, Yang L, Wang Y, Kuang L, Pan X, Chen L, et al. Development and validation of a radiomics model based on T2-weighted imaging for predicting the efficacy of high intensity focused ultrasound ablation in uterine fibroids. *Quant Imaging Med Surg* 2024; **14**(2): 1803-19.
- 32. Chianca V, Cuocolo R, Gitto S, Albano D, Merli I, Badalyan J, et al. Radiomic Machine Learning Classifiers in Spine Bone Tumors: A Multi-Software, Multi-Scanner Study. *Eur J Radiol* 2021; **137**: 109586.
- 33. Chiappa V, Interlenghi M, Salvatore C, Bertolina F, Bogani G, Ditto A, et al. Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors. *Gynecol Oncol* 2021; **161**(3): 838-44.
- 34. Chiou HJ, Chen CY, Liu TC, Chiou SY, Wang HK, Chou YH, Chiang HK. Computer-aided diagnosis of peripheral soft tissue masses based on ultrasound imaging. *Comput Med Imaging Graph* 2009; **33**(5): 408-13.
- 35. Chu H, Pang P, He J, Zhang D, Zhang M, Qiu Y, et al. Value of radiomics model based on enhanced computed tomography in risk grade prediction of gastrointestinal stromal tumors. *Sci rep* 2021; **11**(1): 12009.
- 36. Cilengir AH, Evrimler S, Serel TA, Uluc E, Tosun O. The diagnostic value of magnetic resonance imaging-based texture analysis in differentiating enchondroma and chondrosarcoma. *Skeletal Radiol* 2023; **52**(5): 1039-49.
- 37. Consalvo S, Hinterwimmer F, Neumann J, Steinborn M, Salzmann M, Seidl F, et al. Two-Phase Deep Learning Algorithm for Detection and Differentiation of Ewing Sarcoma and Acute Osteomyelitis in Paediatric Radiographs. *Anticancer Res* 2022; **42**(9): 4371-80.
- 38. Corino VDA, Montin E, Messina A, Casali PG, Gronchi A, Marchiano A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. *J Magn Reson Imaging* 2018; **47**(3): 829-40.
- 39. Crombe A, Fadli D, Buy X, Italiano A, Saut O, Kind M. High-Grade Soft-Tissue Sarcomas: Can Optimizing Dynamic Contrast-Enhanced MRI Postprocessing Improve Prognostic Radiomics Models? *J Magn Reson Imaging* 2020; **52**(1): 282-97.

- 40. Crombe A, Lucchesi C, Bertolo F, Kind M, Spalato-Ceruso M, Toulmonde M, et al. Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis. *NPJ Precis Oncol* 2024; **8**(1): 129.
- 41. Crombe A, Perier C, Kind M, De Senneville BD, Le Loarer F, Italiano A, et al. T2 -based MRI Deltaradiomics improve response prediction in soft-tissue sarcomas treated by neoadjuvant chemotherapy. *J Magn Reson Imaging* 2019; **50**(2): 497-510.
- 42. Dai M, Liu Y, Hu Y, Li G, Zhang J, Xiao Z, Lv F. Combining multiparametric MRI features-based transfer learning and clinical parameters: application of machine learning for the differentiation of uterine sarcomas from atypical leiomyomas. *Eur Radiol* 2022; **32**(11): 7988-97.
- 43. Dai Y, Yin P, Mao N, Sun C, Wu J, Cheng G, Hong N. Differentiation of Pelvic Osteosarcoma and Ewing Sarcoma Using Radiomic Analysis Based on T2-Weighted Images and Contrast-Enhanced T1-Weighted Images. *Biomed Res Int* 2020; **2020**: 9078603.
- 44. Deng J, Zeng W, Shi Y, Kong W, Guo S. Fusion of FDG-PET Image and Clinical Features for Prediction of Lung Metastasis in Soft Tissue Sarcomas. *Comput math methods med* 2020; **2020**: 8153295.
- 45. Deng KH, Wang B, Ma SS, Xue Z, Cao XH. A Bone Lesion Identification Network (BLIN) in CT Images with Weakly Supervised Learning. 2024; **14349**: 243-52.
- 46. Ding Y, Wang Z, Xu P, Ma Y, Yao W, Li K, Gong Y. MRI-based radiomics in distinguishing Kaposiform hemangioendothelioma (KHE) and fibro-adipose vascular anomaly (FAVA) in extremities: A preliminary retrospective study. *J Pediatr Surg* 2022; **57**(7): 1228-34.
- 47. Djuricic GJ, Ahammer H, Rajkovic S, Kovac JD, Milosevic Z, Sopta JP, Radulovic M. Directionally Sensitive Fractal Radiomics Compatible With Irregularly Shaped Magnetic Resonance Tumor Regions of Interest: Association With Osteosarcoma Chemoresistance. *J Magn Reson Imaging* 2023; **57**(1): 248-58.
- 48. Do BH, Langlotz C, Beaulieu CF. Bone Tumor Diagnosis Using a Naïve Bayesian Model of Demographic and Radiographic Features. *J Digit Imaging* 2017; **30**(5): 640-7.
- 49. Do NT, Jung ST, Yang HJ, Kim SH. Multi-level seg-unet model with global and patch-based x-ray images for knee bone tumor detection. *Diagn* 2021; **11**(4).
- 50. Dong J, Yu M, Miao Y, Shen H, Sui Y, Liu Y, et al. Differential Diagnosis of Solitary Fibrous Tumor/Hemangiopericytoma and Angiomatous Meningioma Using Three-Dimensional Magnetic Resonance Imaging Texture Feature Model. *Biomed Res Int* 2020; **2020**: 5042356.
- 51. Dong Z, Zhao X, Zheng H, Zheng H, Chen D, Cao J, et al. Efficacy of real-time artificial intelligence-aid endoscopic ultrasonography diagnostic system in discriminating gastrointestinal stromal tumors and leiomyomas: a multicenter diagnostic study. *EclinicalMedicine* 2024; **73**: 102656.
- 52. Dou Y, Li X, Tao J, Dong Y, Xu N, Wang S. Prediction of high-grade soft-tissue sarcoma using a combined intratumoural and peritumoural MRI-based radiomics nomogram. *Clin Radiol* 2023; **78**(12): e1032-e40.
- 53. Erdem F, Tamsel I, Demirpolat G. The use of radiomics and machine learning for the differentiation of chondrosarcoma from enchondroma. *J Clin Ultrasound* 2023; **51**(6): 1027-35.

- 54. Escobars T, Vauclin S, Orlhac F, Nioche C, Pineau P, Buvat I. An original voxel-wise supervised analysis of tumors with multimodal radiomics to highlight predictive biological patterns. *J Nucl Med* 2021; **62**(SUPPL 1).
- 55. Eweje FR, Bao B, Wu J, Dalal D, Liao WH, He Y, et al. Deep Learning for Classification of Bone Lesions on Routine MRI. *EBioMedicine* 2021; **68**: 103402.
- 56. Fadli D, Kind M, Michot A, Le Loarer F, Crombe A. Natural Changes in Radiological and Radiomics Features on MRIs of Soft-Tissue Sarcomas Naive of Treatment: Correlations With Histology and Patients' Outcomes. *J Magn Reson Imaging* 2022; **56**(1): 77-96.
- 57. Fan L, Gong X, Zheng C, Li J. Data pyramid structure for optimizing EUS-based GISTs diagnosis in multi-center analysis with missing label. *Comput Biol Med* 2024; **169**.
- 58. Fares R, Atlan LD, Druckmann I, Factor S, Gortzak Y, Segal O, et al. Imaging-Based Deep Learning for Predicting Desmoid Tumor Progression. *J Imaging* 2024; **10**(5).
- 59. Farhidzadeh H, Goldgof DB, Hall LO, Scott JG, Gatenby RA, Gillies RJ, Raghavan M. A Quantitative Histogram-based Approach to Predict Treatment Outcome for Soft Tissue Sarcomas Using Pre- and Post-treatment MRIs. 2016: 4549-54.
- 60. Feng N, Chen HY, Wang XJ, Lu YF, Zhou JP, Zhou QM, et al. A CT-based nomogram established for differentiating gastrointestinal heterotopic pancreas from gastrointestinal stromal tumor: compared with a machine-learning model. *BMC med imaging* 2023; **23**(1): 131.
- 61. Feng Q, Tang B, Zhang Y, Liu X. Prediction of the Ki-67 expression level and prognosis of gastrointestinal stromal tumors based on CT radiomics nomogram. *Int j comput assist radiol surg* 2022; **17**(6): 1167-75.
- 62. Fichera G, Giraudo C, Stramare R, Bisogno G, Motta R, Evangelista L, et al. Radiomic features as biomarkers of soft tissue paediatric sarcomas: results of a PET/MR study. *Insights Imaging* 2022; **14**: 112.
- 63. Fields BKK, Demirjian NL, Cen SY, Varghese BA, Hwang DH, Lei X, et al. Predicting Soft Tissue Sarcoma Response to Neoadjuvant Chemotherapy Using an MRI-Based Delta-Radiomics Approach. *Mol Imaging Biol* 2023; **25**(4): 776-87.
- 64. Fields BKK, Demirjian NL, Hwang DH, Varghese BA, Cen SY, Lei X, et al. Whole-tumor 3D volumetric MRI-based radiomics approach for distinguishing between benign and malignant soft tissue tumors. *Eur Radiol* 2021; **31**(11): 8522-35.
- 65. Findlay MC, Yost S, Bauer SZ, Cole KL, Henson JC, Lucke-Wold B, et al. Application of Radiomics to the Differential Diagnosis of Temporal Bone Skull Base Lesions: A Pilot Study. *World Neurosurg* 2023; **172**: e540-e54.
- 66. Foreman SC, Llorián-Salvador O, David DE, Rösner VKN, Rischewski JF, Feuerriegel GC, et al. Development and Evaluation of MR-Based Radiogenomic Models to Differentiate Atypical Lipomatous Tumors from Lipomas. *Cancers (Basel)* 2023; **15**(7).

- 67. Fradet G, Ayde R, Bottois H, El Harchaoui M, Khaled W, Drape JL, et al. Prediction of lipomatous soft tissue malignancy on MRI: comparison between machine learning applied to radiomics and deep learning. *Eur Radiol Exp* 2022; **6**(1): 41.
- 68. Gao Y, Ghodrati V, Kalbasi A, Fu J, Ruan D, Cao M, et al. Prediction of soft tissue sarcoma response to radiotherapy using longitudinal diffusion MRI and a deep neural network with generative adversarial network-based data augmentation. *Med Phys* 2021; **48**(6): 3262-372.
- 69. Gao Y, Kalbasi A, Hsu W, Ruan D, Fu J, Shao J, et al. Treatment effect prediction for sarcoma patients treated with preoperative radiotherapy using radiomics features from longitudinal diffusion-weighted MRIs. *Phys Med Biol* 2020; **65**(17): 175006.
- 70. Gawade S, Bhansali A, Patil K, Shaikh D. Application of the convolutional neural networks and supervised deep-learning methods for osteosarcoma bone cancer detection. *Healthc Anal* 2023; **3**.
- 71. George A, Ayshwarya B. Adaptive FLAME based segmentation and classification for bone cancer detection. ... Conference on Artificial Intelligence ... 2023.
- 72. Georgeanu V, Mamuleanu ML. Convolutional neural networks for automated detection and classification of bone tumors in magnetic resonance imaging. ... on Artificial Intelligence ... 2021.
- 73. Georgeanu VA, Mămuleanu M, Ghiea S, Selișteanu D. Malignant Bone Tumors Diagnosis Using Magnetic Resonance Imaging Based on Deep Learning Algorithms. *Medicina (Kaunas)* 2022; **58**(5).
- 74. Gitto S, Annovazzi A, Nulle K, Interlenghi M, Salvatore C, Anelli V, et al. X-rays radiomics-based machine learning classification of atypical cartilaginous tumour and high-grade chondrosarcoma of long bones. *EBioMedicine* 2024; **101**: 105018.
- 75. Gitto S, Bologna M, Corino VDA, Emili I, Albano D, Messina C, et al. Diffusion-weighted MRI radiomics of spine bone tumors: feature stability and machine learning-based classification performance. *Radiol Med (Torino)* 2022; **127**(5): 518-25.
- 76. Gitto S, Corino VDA, Annovazzi A, Milazzo Machado E, Bologna M, Marzorati L, et al. 3D vs. 2D MRI radiomics in skeletal Ewing sarcoma: Feature reproducibility and preliminary machine learning analysis on neoadjuvant chemotherapy response prediction. *Front oncol* 2022; **12**: 1016123.
- 77. Gitto S, Cuocolo R, Albano D, Chianca V, Messina C, Gambino A, et al. MRI radiomics-based machine-learning classification of bone chondrosarcoma. *Eur J Radiol* 2020; **128**: 109043.
- 78. Gitto S, Cuocolo R, Annovazzi A, Anelli V, Acquasanta M, Cincotta A, et al. CT radiomics-based machine learning classification of atypical cartilaginous tumours and appendicular chondrosarcomas. *EBioMedicine* 2021; **68**: 103407.
- 79. Gitto S, Cuocolo R, van Langevelde K, van de Sande MAJ, Parafioriti A, Luzzati A, et al. MRI radiomics-based machine learning classification of atypical cartilaginous tumour and grade II chondrosarcoma of long bones. *EBioMedicine* 2022; **75**: 103757.
- 80. Gitto S, Interlenghi M, Cuocolo R, Salvatore C, Giannetta V, Badalyan J, et al. MRI radiomics-based machine learning for classification of deep-seated lipoma and atypical lipomatous tumor of the extremities. *Radiol Med (Torino)* 2023; **128**(8): 989-98.

- 81. Gruber L, Gruber H, Luger AK, Glodny B, Henninger B, Loizides A. Diagnostic hierarchy of radiological features in soft tissue tumours and proposition of a simple diagnostic algorithm to estimate malignant potential of an unknown mass. *Eur J Radiol* 2017; **95**: 102-10.
- 82. Grueneisen J, Schaarschmidt B, Demircioglu A, Chodyla M, Martin O, Bertram S, et al. (18)F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. *J Nucl Med* 2019; **60**(11): 1537-42.
- 83. Guo C, Zhou H, Chen X, Feng Z. Computed tomography texture-based models for predicting KIT exon 11 mutation of gastrointestinal stromal tumors. *Heliyon* 2023; **9**(10): e20983.
- 84. Guo J, Li YM, Guo H, Hao DP, Xu JX, Huang CC, et al. Parallel CNN-Deep Learning Clinical-Imaging Signature for Assessing Pathologic Grade and Prognosis of Soft Tissue Sarcoma Patients. *J Magn Reson Imaging* 2024.
- 85. Hajianfar G, Sabouri M, Salimi Y, Amini M, Bagheri S, Jenabi E, et al. Artificial intelligence-based analysis of whole-body bone scintigraphy: The quest for the optimal deep learning algorithm and comparison with human observer performance. *Z Med Phys* 2024; **34**(2): 242-57.
- 86. Hao J, Liu S, Wang T, Han X, Gao A, Wang H, Hao D. Differentiation of malignant from benign soft tissue tumors using radiomics based on pharmacokinetic parameter maps obtained from dynamic contrast-enhanced magnetic resonance imaging data. *Chin J Acad Radiol* 2024.
- 87. He F, Xie L, Sun X, Xu J, Li Y, Liu R, et al. A Scoring System for Predicting Neoadjuvant Chemotherapy Response in Primary High-Grade Bone Sarcomas: A Multicenter Study. *Orthop Surg* 2022; **14**(10): 2499-509.
- 88. He J, Bi X. Automatic classification of spinal osteosarcoma and giant cell tumor of bone using optimized DenseNet. *J Bone Oncol* 2024; **46**: 100606.
- 89. He Q, Bano S, Liu J, Liu W, Stoyanov D, Zuo S. Query2: Query over queries for improving gastrointestinal stromal tumour detection in an endoscopic ultrasound. *Comput Biol Med* 2023; **152**: 106424.
- 90. He Y, Guo J, Ding X, van Ooijen PMA, Zhang Y, Chen A, et al. Convolutional neural network to predict the local recurrence of giant cell tumor of bone after curettage based on pre-surgery magnetic resonance images. *Eur Radiol* 2019; **29**(10): 5441-51.
- 91. He Y, Pan I, Bao B, Halsey K, Chang M, Liu H, et al. Deep learning-based classification of primary bone tumors on radiographs: A preliminary study. *EBioMedicine* 2020; **62**.
- 92. Hermessi H, Mourali O, Zagrouba E. Deep feature learning for soft tissue sarcoma classification in MR images via transfer learning. *Expert Syst Appl* 2019; **120**: 116-27.
- 93. Hu P, Chen L, Zhou Z. Machine Learning in the Differentiation of Soft Tissue Neoplasms: Comparison of Fat-Suppressed T2WI and Apparent Diffusion Coefficient (ADC) Features-Based Models. *J Digit Imaging* 2021; **34**(5): 1146-55.

- 94. Hu Y, Tang J, Zhao SH, Li Y. Diffusion-Weighted Imaging-Magnetic Resonance Imaging Information under Class-Structured Deep Convolutional Neural Network Algorithm in the Prognostic Chemotherapy of Osteosarcoma. *Sci Program* 2021; **2021**.
- 95. Hu Y, Wang H, Yue Z, Wang X, Wang Y, Luo Y, Jiang W. A contrast-enhanced MRI-based nomogram to identify lung metastasis in soft-tissue sarcoma: A multi-centre study. *Med Phys* 2023; **50**(5): 2961-70.
- 96. Hu Z, Liang H, Zhao H, Hou F, Hao D, Ji Q, et al. Preoperative contrast-enhanced CT-based radiomics signature for predicting hypoxia-inducible factor 1alpha expression in retroperitoneal sarcoma. *Clin Radiol* 2023; **78**(8): e543-e51.
- 97. Huang B, Wang J, Sun M, Chen X, Xu D, Li ZP, et al. Feasibility of multi-parametric magnetic resonance imaging combined with machine learning in the assessment of necrosis of osteosarcoma after neoadjuvant chemotherapy: a preliminary study. *BMC Cancer* 2020; **20**(1): 322.
- 98. Iwai T, Kida M, Okuwaki K, Watanabe M, Adachi K, Ishizaki J, et al. Deep learning analysis for differential diagnosis and risk classification of gastrointestinal tumors. *Scand J Gastroenterol* 2024: 1-8.
- 99. Jansma C, Wan X, Acem I, Spaanderman DJ, Visser JJ, Hanff D, et al. Preoperative Classification of Peripheral Nerve Sheath Tumors on MRI Using Radiomics. *Cancers (Basel)* 2024; **16**(11).
- 100. Jayachandran JJB, Ambigapathy S. X-Ray Image Analysis in Identification of Bone Cancer Using Laws Features and Machine Learning Model. ... Artificial Intelligence ... 2022.
- 101. Jeong SY, Kim W, Byun BH, Kong CB, Song WS, Lim I, et al. Prediction of Chemotherapy Response of Osteosarcoma Using Baseline 18F-FDG Textural Features Machine Learning Approaches with PCA. *Contrast Media Mol Imaging* 2019; **2019**: 3515080.
- 102. Ji X, Shang Y, Tan L, Hu Y, Liu J, Song L, et al. Prediction of High-Risk Gastrointestinal Stromal Tumor Recurrence Based on Delta-CT Radiomics Modeling: A 3-Year Follow-up Study After Surgery. *Clin Med Insights Oncol* 2024; **18**: 11795549241245698.
- 103. Jia X, Wan L, Chen X, Ji W, Huang S, Qi Y, et al. Risk stratification for 1- to 2-cm gastric gastrointestinal stromal tumors: visual assessment of CT and EUS high-risk features versus CT radiomics analysis. *Eur Radiol* 2023; **33**(4): 2768-78.
- 104. Joo DC, Kim GH, Lee MW, Lee BE, Kim JW, Kim KB. Artificial Intelligence-Based Diagnosis of Gastric Mesenchymal Tumors Using Digital Endosonography Image Analysis. *J Clin Med* 2024; **13**(13).
- 105. Juntu J, Sijbers J, De Backer S, Rajan J, Van Dyck D. Machine learning study of several classifiers trained with texture analysis features to differentiate benign from malignant soft-tissue tumors in T1-MRI images. *J Magn Reson Imaging* 2010; **31**(3): 680-9.
- 106. Kang B, Yuan X, Wang H, Qin S, Song X, Yu X, et al. Preoperative CT-Based Deep Learning Model for Predicting Risk Stratification in Patients With Gastrointestinal Stromal Tumors. *Front oncol* 2021; **11**: 750875.
- 107. Kim BC, Kim J, Kim K, Byun BH, Lim I, Kong CB, et al. Preliminary Radiogenomic Evidence for the Prediction of Metastasis and Chemotherapy Response in Pediatric Patients with Osteosarcoma Using (18)F-FDF PET/CT, EZRIN and KI67. *Cancers (Basel)* 2021; **13**(11).

- 108. Kim H, Rha SE, Shin YR, Kim EH, Park SY, Lee SL, et al. Differentiating Uterine Sarcoma From Atypical Leiomyoma on Preoperative Magnetic Resonance Imaging Using Logistic Regression Classifier: Added Value of Diffusion-Weighted Imaging-Based Quantitative Parameters. *Korean J Radiol* 2024; **25**(1): 43-54.
- 109. Kim J, Jeong SY, Kim BC, Byun BH, Lim I, Kong CB, et al. Prediction of Neoadjuvant Chemotherapy Response in Osteosarcoma Using Convolutional Neural Network of Tumor Center (18)F-FDG PET Images. *Diagnostics (Basel)* 2021; **11**(11).
- 110. Kim W, Park J, Sheen H, Byun BH, Lim I, Kong CB, et al. Development of deep learning model for prediction of chemotherapy response using PET images and radiomics features. 2018.
- 111. Kim YH, Kim GH, Kim KB, Lee MW, Lee BE, Baek DH, et al. Application of A Convolutional Neural Network in The Diagnosis of Gastric Mesenchymal Tumors on Endoscopic Ultrasonography Images. *J Clin Med* 2020; **9**(10).
- 112. Kumar R, Suhas MV. Classification of Benign and Malignant bone lesions on CT ImagesUsing Support Vector Machine: A Comparison of Kernel Functions. 2016: 821-4.
- 113. Kumar VDA. Bone Cancer Detection Using Feature Extraction with Classification Using K-Nearest Neighbor and Decision Tree Algorithm. *Smart Intelligent Computing and Communication ...* 2021.
- 114. Lee S, Jung JY, Nam Y, Jung CK, Lee SY, Lee J, et al. Diagnosis of Marginal Infiltration in Soft Tissue Sarcoma by Radiomics Approach Using T2-Weighted Dixon Sequence. *J Magn Reson Imaging* 2023; **57**(3): 752-60.
- 115. Lee S, Lee SY, Jung JY, Nam Y, Jeon HJ, Jung CK, et al. Ensemble learning-based radiomics with multi-sequence magnetic resonance imaging for benign and malignant soft tissue tumor differentiation. *PLoS ONE* 2023; **18**(5): e0286417.
- 116. Lee SE, Jung JY, Nam Y, Lee SY, Park H, Shin SH, et al. Radiomics of diffusion-weighted MRI compared to conventional measurement of apparent diffusion-coefficient for differentiation between benign and malignant soft tissue tumors. *Sci rep* 2021; **11**(1): 15276.
- 117. Leporq B, Bouhamama A, Pilleul F, Lame F, Bihane C, Sdika M, et al. MRI-based radiomics to predict lipomatous soft tissue tumors malignancy: a pilot study. *Cancer Imaging* 2020; **20**(1): 78.
- 118. Li A, Hu Y, Cui XW, Ye XH, Peng XJ, Lv WZ, Zhao CK. Predicting the malignancy of extremity soft-tissue tumors by an ultrasound-based radiomics signature. *Acta Radiol* 2024; **65**(5): 470-81.
- 119. Li J, Li S, Li X, Miao S, Dong C, Gao C, et al. Primary bone tumor detection and classification in full-field bone radiographs via YOLO deep learning model. *Eur Radiol* 2023; **33**(6): 4237-48.
- 120. Li L, Wang K, Ma X, Liu Z, Wang S, Du J, et al. Radiomic analysis of multiparametric magnetic resonance imaging for differentiating skull base chordoma and chondrosarcoma. *Eur J Radiol* 2019; **118**: 81-7.
- 121. Li Q, Wang N, Wang Y, Li X, Su Q, Zhang J, et al. Intratumoral and peritumoral CT radiomics in predicting prognosis in patients with chondrosarcoma: a multicenter study. *Insights imaging* 2024; **15**(1): 9.

- 122. Li X, Jiang F, Guo Y, Jin Z, Wang Y. Computer-aided diagnosis of gastrointestinal stromal tumors: a radiomics method on endoscopic ultrasound image. *Int j comput assist radiol surg* 2019; **14**(10): 1635-45.
- 123. Li X, Lan M, Wang X, Zhang J, Gong L, Liao F, et al. Development and validation of a MRI-based combined radiomics nomogram for differentiation in chondrosarcoma. *Front oncol* 2023; **13**: 1090229.
- 124. Li X, Shi X, Wang Y, Pang J, Zhao X, Xu Y, et al. A CT-based radiomics nomogram for predicting histologic grade and outcome in chondrosarcoma. *Cancer Imaging* 2024; **24**(1): 50.
- 125. Li X, Zhang J, Leng Y, Liu J, Li L, Wan T, et al. Preoperative prediction of histopathological grading in patients with chondrosarcoma using MRI-based radiomics with semantic features. *BMC med imaging* 2024; **24**(1): 171.
- 126. Liang HY, Yang SF, Zou HM, Hou F, Duan LS, Huang CC, et al. Deep Learning Radiomics Nomogram to Predict Lung Metastasis in Soft-Tissue Sarcoma: A Multi-Center Study. *Front oncol* 2022; **12**: 897676.
- 127. Lin JX, Wang FH, Wang ZK, Wang JB, Zheng CH, Li P, et al. Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features. *Radiol Med (Torino)* 2023; **128**(6): 644-54.
- 128. Lin P, Yang PF, Chen S, Shao YY, Xu L, Wu Y, et al. A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma. *Cancer Imaging* 2020; **20**(1): 7.
- 129. Lingappa E, Parvathy LR. Image Classification with Deep Learning Methods for Detecting and Staging Bone Cancer from MRI. 2023 International Conference on ... 2023.
- 130. Liu B, Liu H, Zhang L, Song Y, Yang S, Zheng Z, et al. Value of contrast-enhanced CT based radiomic machine learning algorithm in differentiating gastrointestinal stromal tumors with KIT exon 11 mutation: a two-center study. *Diagn Interv Radiol* 2022; **28**(1): 29-38.
- 131. Liu C, Guo Y, Jiang F, Xu L, Shen F, Jin Z, Wang Y. Gastrointestinal stromal tumors diagnosis on multi-center endoscopic ultrasound images using multi-scale image normalization and transfer learning. *Technol Health Care* 2022; **30**(S1): 47-59.
- 132. Liu C, Qiao M, Jiang F, Guo Y, Jin Z, Wang Y. TN-USMA Net: Triple normalization-based gastrointestinal stromal tumors classification on multicenter EUS images with ultrasound-specific pretraining and meta attention. *Med Phys* 2021; **48**(11): 7199-214.
- 133. Liu H, Jiao M, Yuan Y, Ouyang H, Liu J, Li Y, et al. Benign and malignant diagnosis of spinal tumors based on deep learning and weighted fusion framework on MRI. *Insights imaging* 2022; **13**(1): 87.
- 134. Liu J, Huang J, Song Y, He Q, Fang W, Wang T, et al. Differentiating Gastrointestinal Stromal Tumors From Leiomyomas of Upper Digestive Tract Using Convolutional Neural Network Model by Endoscopic Ultrasonography. *J Clin Gastroenterol* 2024; **58**(6): 574-9.
- 135. Liu J, Lian T, Chen H, Wang X, Quan X, Deng Y, et al. Pretreatment Prediction of Relapse Risk in Patients with Osteosarcoma Using Radiomics Nomogram Based on CT: A Retrospective Multicenter Study. *Biomed Res Int* 2021; **2021**: 6674471.

- 136. Liu L, Chen J, Shan J, Sun X. Development and validation of an EUS-based nomogram for prediction of the malignant potential in gastrointestinal stromal tumors. *Scand J Gastroenterol* 2023; **58**(7): 830-7.
- 137. Liu M, Bian J. Radiomics signatures based on contrast-enhanced CT for preoperative prediction of the Ki-67 proliferation state in gastrointestinal stromal tumors. *Jpn J Radiol* 2023; **41**(7): 741-51.
- 138. Liu R, Pan D, Xu Y, Zeng H, He Z, Lin J, et al. A deep learning—machine learning fusion approach for the classification of benign, malignant, and intermediate bone tumors. *Eur Radiol* 2022; **32**(2): 1371-83.
- 139. Liu S, Sun W, Yang S, Duan L, Huang C, Xu J, et al. Deep learning radiomic nomogram to predict recurrence in soft tissue sarcoma: a multi-institutional study. *Eur Radiol* 2022; **32**(2): 793-805.
- 140. Liu X, Guo L, Wang H, Guo J, Yang S, Duan L. Research on imbalance machine learning methods for MR[Formula: see text]WI soft tissue sarcoma data. *BMC med imaging* 2022; **22**(1): 149.
- 141. Liu X, Yin Y, Wang X, Yang C, Wan S, Yin X, et al. Gastrointestinal stromal tumors: associations between contrast-enhanced CT images and KIT exon 11 gene mutation. *Ann transl med* 2021; **9**(19): 1496.
- 142. Liu Y, He C, Fang W, Peng L, Shi F, Xia Y, et al. Prediction of Ki-67 expression in gastrointestinal stromal tumors using radiomics of plain and multiphase contrast-enhanced CT. *Eur Radiol* 2023; **33**(11): 7609-17.
- 143. Liu Y, Yin P, Cui J, Sun C, Chen L, Hong N. Postoperative Relapse Prediction in Patients With Ewing Sarcoma Using Computed Tomography-Based Radiomics Models Covering Tumor Per Se and Peritumoral Signatures. *J Comput Assist Tomogr* 2023; **47**(5): 766-73.
- 144. Liu Y, Yin P, Cui J, Sun C, Chen L, Hong N, Li Z. Radiomics analysis based on CT for the prediction of pulmonary metastases in ewing sarcoma. *BMC med imaging* 2023; **23**(1): 147.
- 145. Lombardi A, Arezzo F, Di Sciascio E, Ardito C, Mongelli M, Di Lillo N, et al. A human-interpretable machine learning pipeline based on ultrasound to support leiomyosarcoma diagnosis. *Artif Intell Med* 2023; **146**: 102697.
- 146. Long B, Zhang H, Zhang H, Chen W, Sun Y, Tang R, et al. Deep learning models of ultrasonography significantly improved the differential diagnosis performance for superficial soft-tissue masses: a retrospective multicenter study. *BMC Med* 2023; **21**(1): 405.
- 147. Lu Y, Chen L, Wu J, Er L, Shi H, Cheng W, et al. Artificial intelligence in endoscopic ultrasonography: risk stratification of gastric gastrointestinal stromal tumors. *Therap adv in gastroenterol* 2023; **16**: 17562848231177156.
- 148. Lu Y, Wu J, Hu M, Zhong Q, Er L, Shi H, et al. Artificial Intelligence in the Prediction of Gastrointestinal Stromal Tumors on Endoscopic Ultrasonography Images: Development, Validation and Comparison with Endosonographers. *Gut Liver* 2023; **17**(6): 874-83.

- 149. Luo Z, Li J, Liao Y, Huang W, Li Y, Shen X. Prediction of response to preoperative neoadjuvant chemotherapy in extremity high-grade osteosarcoma using X-ray and multiparametric MRI radiomics. *JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY* 2023; **31**(3): 611-26.
- 150. Luo Z, Li J, Liao Y, Liu R, Shen X, Chen W. Radiomics Analysis of Multiparametric MRI for Prediction of Synchronous Lung Metastases in Osteosarcoma. *Front oncol* 2022; **12**: 802234.
- 151. Lv C, Chen H, Huang P, Chen Y, Liu B. Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors. *Turk J Gastroenterol* 2024; **35**(5): 366-73.
- 152. Malek M, Gity M, Alidoosti A, Oghabian Z, Rahimifar P, Seyed Ebrahimi SM, et al. A machine learning approach for distinguishing uterine sarcoma from leiomyomas based on perfusion weighted MRI parameters. *Eur J Radiol* 2019; **110**: 203-11.
- 153. Malinauskaite I, Hofmeister J, Burgermeister S, Neroladaki A, Hamard M, Montet X, Boudabbous S. Radiomics and Machine Learning Differentiate Soft-Tissue Lipoma and Liposarcoma Better than Musculoskeletal Radiologists. *SARCOMA* 2020; **2020**: 7163453.
- 154. Mao H, Zhang B, Zou M, Huang Y, Yang L, Wang C, et al. MRI-Based Radiomics Models for Predicting Risk Classification of Gastrointestinal Stromal Tumors. *Front oncol* 2021; **11**: 631927.
- 155. Martin-Carreras T, Li H, Cooper K, Fan Y, Sebro R. Radiomic features from MRI distinguish myxomas from myxofibrosarcomas. *BMC med imaging* 2019; **19**(1): 67.
- 156. Mayerhoefer ME, Breitenseher M, Amann G, Dominkus M. Are signal intensity and homogeneity useful parameters for distinguishing between benign and malignant soft tissue masses on MR images? Objective evaluation by means of texture analysis. *Magn Reson Imaging* 2008; **26**(9): 1316-22.
- 157. Mazumder MH, Singh MP. Bone Cancer Detection Using Deep Learning. ... on Innovations in Computer Science and ... 2022.
- 158. Megala G, Swarnalatha P, Venkatesan R. Detecting Bone Tumor on Applying Edge Computational Deep Learning Approach. *International Conference on ...* 2023.
- 159. Minoda Y, Ihara E, Fujimori N, Nagatomo S, Esaki M, Hata Y, et al. Efficacy of ultrasound endoscopy with artificial intelligence for the differential diagnosis of non-gastric gastrointestinal stromal tumors. *Sci rep* 2022; **12**(1): 16640.
- 160. Minoda Y, Ihara E, Komori K, Ogino H, Otsuka Y, Chinen T, et al. Efficacy of endoscopic ultrasound with artificial intelligence for the diagnosis of gastrointestinal stromal tumors. *J Gastroenterol* 2020; **55**(12): 1119-26.
- 161. Mutlu IN, Kocak B, Kus EA, Ulusan MB, Kilickesmez O. Machine Learning-Based Computed Tomography Texture Analysis of Lytic Bone Lesions Needing Biopsy: A Preliminary Study. *Istanb Med J* 2021; **22**(3): 223-31.
- 162. Nakagawa M, Nakaura T, Namimoto T, Iyama Y, Kidoh M, Hirata K, et al. A multiparametric MRI-based machine learning to distinguish between uterine sarcoma and benign leiomyoma: comparison with 18F-FDG PET/CT. *Clin Radiol* 2019; **74**(2): 167.e1-e.

- 163. Nakagawa M, Nakaura T, Namimoto T, Iyama Y, Kidoh M, Hirata K, et al. Machine Learning to Differentiate T2-Weighted Hyperintense Uterine Leiomyomas from Uterine Sarcomas by Utilizing Multiparametric Magnetic Resonance Quantitative Imaging Features. *Acad Radiol* 2019; **26**(10): 1390-9.
- 164. Nakagawa M, Nakaura T, Yoshida N, Azuma M, Uetani H, Nagayama Y, et al. Performance of Machine Learning Methods Based on Multi-Sequence Textural Parameters Using Magnetic Resonance Imaging and Clinical Information to Differentiate Malignant and Benign Soft Tissue Tumors. *Acad Radiol* 2023; **30**(1): 83-92.
- 165. Navarro F, Dapper H, Asadpour R, Knebel C, Spraker MB, Schwarze V, et al. Development and External Validation of Deep-Learning-Based Tumor Grading Models in Soft-Tissue Sarcoma Patients Using MR Imaging. *Cancers (Basel)* 2021; **13**(12).
- 166. Nguyen VX, Nguyen CC, Li B, Das A. Digital image analysis is a useful adjunct to endoscopic ultrasonographic diagnosis of subepithelial lesions of the gastrointestinal tract. *J Ultrasound Med* 2010; **29**(9): 1345-51.
- 167. Nie P, Zhao X, Wang N, Ma J, Zuo P, Hao D, Yu T. A Computed Tomography Radiomics Nomogram in Differentiating Chordoma From Giant Cell Tumor in the Axial Skeleton. *J Comput Assist Tomogr* 2023; **47**(3): 453-9.
- 168. Ning Z, Luo J, Li Y, Han S, Feng Q, Xu Y, et al. Pattern Classification for Gastrointestinal Stromal Tumors by Integration of Radiomics and Deep Convolutional Features. *IEEE j biomed health inform* 2019; **23**(3): 1181-91.
- 169. Oh CK, Kim T, Cho YK, Cheung DY, Lee BI, Cho YS, et al. Convolutional neural network-based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images. *J Gastroenterol Hepatol* 2021; **36**(12): 3387-94.
- 170. Ouyang H, Meng F, Liu J, Song X, Li Y, Yuan Y, et al. Evaluation of Deep Learning-Based Automated Detection of Primary Spine Tumors on MRI Using the Turing Test. *Front Oncol* 2022; **12**.
- 171. Pan D, Liu R, Zheng B, Yuan J, Zeng H, He Z, et al. Using Machine Learning to Unravel the Value of Radiographic Features for the Classification of Bone Tumors. *BioMed Res Int* 2021; **2021**.
- 172. Pan J, Zhang K, Le H, Jiang Y, Li W, Geng Y, et al. Radiomics Nomograms Based on Non-enhanced MRI and Clinical Risk Factors for the Differentiation of Chondrosarcoma from Enchondroma. *J Magn Reson Imaging* 2021; **54**(4): 1314-23.
- 173. Park CW, Oh SJ, Kim KS, Jang MC, Kim IS, Lee YK, et al. Artificial intelligence-based classification of bone tumors in the proximal femur on plain radiographs: System development and validation. *PLoS ONE* 2022; **17**(2 February).
- 174. Peeken JC, Asadpour R, Specht K, Chen EY, Klymenko O, Akinkuoroye V, et al. MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. *Radiother Oncol* 2021; **164**: 73-82.
- 175. Peeken JC, Bernhofer M, Spraker MB, Pfeiffer D, Devecka M, Thamer A, et al. CT-based radiomic features predict tumor grading and have prognostic value in patients with soft tissue sarcomas treated with neoadjuvant radiation therapy. *Radiother Oncol* 2019; **135**: 187-96.

- 176. Peeken JC, Neumann J, Asadpour R, Leonhardt Y, Moreira JR, Hippe DS, et al. Prognostic Assessment in High-Grade Soft-Tissue Sarcoma Patients: A Comparison of Semantic Image Analysis and Radiomics. *Cancers (Basel)* 2021; **13**(8).
- 177. Peeken JC, Spraker MB, Knebel C, Dapper H, Pfeiffer D, Devecka M, et al. Tumor grading of soft tissue sarcomas using MRI-based radiomics. *EBioMedicine* 2019; **48**: 332-40.
- 178. Peng Y, Bi L, Guo Y, Feng D, Fulham M, Kim J. Deep multi-modality collaborative learning for distant metastases predication in PET-CT soft-tissue sarcoma studies. *Annu Int Conf IEEE Eng Med Biol Soc* 2019; **2019**: 3658-88.
- 179. Peng Y, Bi L, Kumar A, Fulham M, Feng D, Kim J. Predicting distant metastases in soft-tissue sarcomas from PET-CT scans using constrained hierarchical multi-modality feature learning. *Phys Med Biol* 2021; **66**(24).
- 180. Pereira HM, Leite Duarte ME, Ribeiro Damasceno I, de Oliveira Moura Santos LA, Nogueira-Barbosa MH. Machine learning-based CT radiomics features for the prediction of pulmonary metastasis in osteosarcoma. *Br J Radiol* 2021; **94**(1124): 20201391.
- 181. Pressney I, Khoo M, Endozo R, Ganeshan B, O'Donnell P. Pilot study to differentiate lipoma from atypical lipomatous tumour/well-differentiated liposarcoma using MR radiomics-based texture analysis. *Skeletal Radiol* 2020; **49**(11): 1719-29.
- 182. Purnima S, Lashna V, Mahalakshmi R. An Approach to Detect and Classify Bone tumour using fast and Robust Fuzzy C Means Clustering technique. *Annals of the ...* 2021.
- 183. Ren C, Wang S, Zhang S. Development and validation of a nomogram based on CT images and 3D texture analysis for preoperative prediction of the malignant potential in gastrointestinal stromal tumors. *Cancer Imaging* 2020; **20**(1): 5.
- 184. Rengo M, Onori A, Caruso D, Bellini D, Carbonetti F, De Santis D, et al. Development and Validation of Artificial-Intelligence-Based Radiomics Model Using Computed Tomography Features for Preoperative Risk Stratification of Gastrointestinal Stromal Tumors. *J Pers Med* 2023; **13**(5).
- 185. Ristow I, Madesta F, Well L, Shenas F, Wright F, Molwitz I, et al. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1. *Neuro-oncol* 2022; **24**(10): 1790-8.
- 186. Roller LA, Wan Q, Liu X, Qin L, Chapel D, Burk KS, et al. MRI, clinical, and radiomic models for differentiation of uterine leiomyosarcoma and leiomyoma. *Abdom Radiol* 2024; **49**(5): 1522-33.
- 187. Sampath K, Rajagopal S, Chintanpalli A. A comparative analysis of CNN-based deep learning architectures for early diagnosis of bone cancer using CT images. *Sci rep* 2024; **14**(1): 2144.
- 188. Santoro M, Zybin V, Coada CA, Mantovani G, Paolani G, Di Stanislao M, et al. Machine Learning Applied to Pre-Operative Computed-Tomography-Based Radiomic Features Can Accurately Differentiate Uterine Leiomyoma from Leiomyosarcoma: A Pilot Study. *Cancers (Basel)* 2024; **16**(8).

- 189. Seven G, Silahtaroglu G, Kochan K, Ince AT, Arici DS, Senturk H. Use of Artificial Intelligence in the Prediction of Malignant Potential of Gastric Gastrointestinal Stromal Tumors. *Dig Dis Sci* 2022; **67**(1): 273-81.
- 190. Seven G, Silahtaroglu G, Seven OO, Senturk H. Differentiating Gastrointestinal Stromal Tumors from Leiomyomas Using a Neural Network Trained on Endoscopic Ultrasonography Images. *Dig Dis* 2022; **40**(4): 427-35.
- 191. Shang S, Sun J, Yue Z, Wang Y, Wang X, Luo Y, et al. Multi-parametric MRI based radiomics with tumor subregion partitioning for differentiating benign and malignant soft-tissue tumors. *Biomed Signal Process Control* 2021; **67**.
- 192. Shao J, Lin H, Ding L, Li B, Xu D, Sun Y, et al. Deep learning for differentiation of osteolytic osteosarcoma and giant cell tumor around the knee joint on radiographs: a multicenter study. *Insights imaging* 2024; **15**(1): 35.
- 193. Shao J, Wang C, Shu K, Zhou Y, Cheng N, Lai Z, et al. A contrast-enhanced CT-based radiomic nomogram for the differential diagnosis of intravenous leiomyomatosis and uterine leiomyoma. *Front oncol* 2023; **13**: 1239124.
- 194. Shao M, Niu Z, He L, Fang Z, He J, Xie Z, et al. Building Radiomics Models Based on Triple-Phase CT Images Combining Clinical Features for Discriminating the Risk Rating in Gastrointestinal Stromal Tumors. *Front oncol* 2021; **11**: 737302.
- 195. Sharma A, Yadav DP, Garg H, Kumar M, Sharma B, Koundal D. Bone Cancer Detection Using Feature Extraction Based Machine Learning Model. *Comput math methods med* 2021; **2021**: 7433186.
- 196. Sheen H, Kim W, Byun BH, Kong CB, Song WS, Cho WH, et al. Metastasis risk prediction model in osteosarcoma using metabolic imaging phenotypes: A multivariable radiomics model. *PLoS ONE* 2019; **14**(11): e0225242.
- 197. Shen R, Li Z, Zhang L, Hua Y, Mao M, Li Z, et al. Osteosarcoma Patients Classification Using Plain X-Rays and Metabolomic Data. *Conf Proc IEEE Eng Med Biol Soc* 2018; **2018**: 690-3.
- 198. Shrivastava A, Nag MK. Enhancing Bone Cancer Diagnosis Through Image Extraction and Machine Learning: A State-of-the-Art Approach. *Surg Innov* 2024; **31**(1): 58-70.
- 199. Sierra ED, Valenzuela R, Canjirathinkal MA, Costelloe CM, Moradi H, Madewell JE, et al. Cancer Radiomic and Perfusion Imaging Automated Framework: Validation on Musculoskeletal Tumors. *JCO Clin Cancer Inform* 2024; **8**: e2300118.
- 200. Singh M, Angurala M, Bala M. Bone Tumour detection Using Feature Extraction with Classification by Deep Learning Techniques. *Research Journal of Computer ...* 2020.
- 201. Skorpil M, Ryden H, Berglund J, Brynolfsson P, Brosjo O, Tsagozis P. Soft-tissue fat tumours: differentiating malignant from benign using proton density fat fraction quantification MRI. *Clin Radiol* 2019; **74**(7): 534-8.

- 202. Song Y, Li J, Wang H, Liu B, Yuan C, Liu H, et al. Radiomics Nomogram Based on Contrastenhanced CT to Predict the Malignant Potential of Gastrointestinal Stromal Tumor: A Two-center Study. *Acad Radiol* 2022; **29**(6): 806-16.
- 203. Spraker MB, Wootton LS, Hippe DS, Ball KC, Peeken JC, Macomber MW, et al. MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma. *Adv Radiat Oncol* 2019; **4**(2): 413-21.
- 204. Starmans MPA, Timbergen MJM, Vos M, Renckens M, Grunhagen DJ, van Leenders G, et al. Differential Diagnosis and Molecular Stratification of Gastrointestinal Stromal Tumors on CT Images Using a Radiomics Approach. *J Digit Imaging* 2022; **35**(2): 127-36.
- 205. Su Q, Wang N, Wang B, Wang Y, Dai Z, Zhao X, et al. Ct-based intratumoral and peritumoral radiomics for predicting prognosis in osteosarcoma: A multicenter study. *Eur J Radiol* 2024; **172**: 111350.
- 206. Sudjai N, Siriwanarangsun P, Lektrakul N, Saiviroonporn P, Maungsomboon S, Phimolsarnti R, et al. Robustness of Radiomic Features: Two-Dimensional versus Three-Dimensional MRI-Based Feature Reproducibility in Lipomatous Soft-Tissue Tumors. *Diagnostics (Basel)* 2023; **13**(2).
- 207. Sudjai N, Siriwanarangsun P, Lektrakul N, Saiviroonporn P, Maungsomboon S, Phimolsarnti R, et al. Tumor-to-bone distance and radiomic features on MRI distinguish intramuscular lipomas from well-differentiated liposarcomas. *J ORTHOP SURG* 2023; **18**(1): 255.
- 208. Sun K, Yu S, Wang Y, Jia R, Shi R, Liang C, et al. Development of a multi-phase CT-based radiomics model to differentiate heterotopic pancreas from gastrointestinal stromal tumor. *BMC med imaging* 2024; **24**(1): 44.
- 209. Sun W, Liu S, Guo J, Liu S, Hao D, Hou F, et al. A CT-based radiomics nomogram for distinguishing between benign and malignant bone tumours. *Cancer Imaging* 2021; **21**(1): 20.
- 210. Sun XF, Zhu HT, Ji WY, Zhang XY, Li XT, Tang L, Sun YS. Preoperative prediction of malignant potential of 2-5 cm gastric gastrointestinal stromal tumors by computerized tomography-based radiomics. *World J Gastrointest Oncol* 2022; **14**(5): 1014-26.
- 211. Tagliafico AS, Bignotti B, Rossi F, Valdora F, Martinoli C. Local recurrence of soft tissue sarcoma: a radiomic analysis. *RADIOL ONCOL* 2019; **53**(3): 300-6.
- 212. Tamehisa T, Sato S, Sakai T, Maekawa R, Tanabe M, Ito K, Sugino N. Establishment of Noninvasive Prediction Models for the Diagnosis of Uterine Leiomyoma Subtypes. *Obstet Gynecol* 2024; **143**(3): 358-65.
- 213. Tang Y, Cui J, Zhu J, Fan G. Differentiation Between Lipomas and Atypical Lipomatous Tumors of the Extremities Using Radiomics. *J Magn Reson Imaging* 2022; **56**(6): 1746-54.
- 214. Teo KY, Daescu O, Cederberg K, Sengupta A, Leavey PJ. Correlation of histopathology and multimodal magnetic resonance imaging in childhood osteosarcoma: Predicting tumor response to chemotherapy. *PLoS ONE* 2022; **17**(2): e0259564.
- 215. Thornhill RE, Golfam M, Sheikh A, Cron GO, White EA, Werier J, et al. Differentiation of lipoma from liposarcoma on MRI using texture and shape analysis. *Acad Radiol* 2014; **21**(9): 1185-94.

- 216. Tian L, Li X, Zheng H, Wang L, Qin Y, Cai J. Fisher discriminant model based on LASSO logistic regression for computed tomography imaging diagnosis of pelvic rhabdomyosarcoma in children. *Sci rep* 2022; **12**(1): 15631.
- 217. Tian L, Zhang D, Bao S, Nie P, Hao D, Liu Y, et al. Radiomics-based machine-learning method for prediction of distant metastasis from soft-tissue sarcomas. *Clin Radiol* 2021; **76**(2): 158.e19-.e25.
- 218. Tian Z, Cheng Y, Zhao S, Li R, Zhou J, Sun Q, Wang D. Deep learning radiomics-based prediction model of metachronous distant metastasis following curative resection for retroperitoneal leiomyosarcoma: a bicentric study. *Cancer Imaging* 2024; **24**(1): 52.
- 219. Timbergen MJM, Starmans MPA, Padmos GA, Grunhagen DJ, van Leenders G, Hanff DF, et al. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. *Eur J Radiol* 2020; **131**: 109266.
- 220. Toyohara Y, Sone K, Noda K, Yoshida K, Kato S, Kaiume M, et al. The automatic diagnosis artificial intelligence system for preoperative magnetic resonance imaging of uterine sarcoma. *J gynecol oncol* 2024; **35**(3): e24.
- 221. Toyohara Y, Sone K, Noda K, Yoshida K, Kurokawa R, Tanishima T, et al. Development of a deep learning method for improving diagnostic accuracy for uterine sarcoma cases. *Sci rep* 2022; **12**(1): 19612.
- 222. Usuff R, Kothandapani S, Rangan R. Enhancing radiographic image interpretation: WARES-PRS model for knee bone tumour detection. ... in Neural Systems 2024.
- 223. Vaiyapuri T, Balaji P, Shridevi S, Dharmarajlu SM, Alaseem NA. An attention-based bidirectional long short-term memory based optimal deep learning technique for bone cancer detection and classifications. *Aims Mathematics* 2024; **9**(6): 16704-20.
- 224. Vallieres M, Freeman CR, Skamene SR, El Naqa I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. *Phys Med Biol* 2015; **60**(14): 5471-96.
- von Schacky CE, Wilhelm NJ, Schäfer VS, Leonhardt Y, Gassert FG, Foreman SC, et al. Multitask deep learning for segmentation and classification of primary bone tumors on radiographs. *Radiology* 2021; **301**(2): 398-406.
- 226. von Schacky CE, Wilhelm NJ, Schafer VS, Leonhardt Y, Jung M, Jungmann PM, et al. Development and evaluation of machine learning models based on X-ray radiomics for the classification and differentiation of malignant and benign bone tumors. *Eur Radiol* 2022; **32**(9): 6247-57.
- 227. Vos M, Starmans MPA, Timbergen MJM, van der Voort SR, Padmos GA, Kessels W, et al. Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI. *Br J Surg* 2019; **106**(13): 1800-9.
- 228. Wahab CA, Jannot AS, Bonaffini PA, Bourillon C, Cornou C, Lefrere-Belda MA, et al. Diagnostic Algorithm to Differentiate Benign Atypical Leiomyomas from Malignant Uterine Sarcomas with Diffusion-weighted MRI (vol 297, pg 361, 2020). *Radiology* 2020; **297**(3): E347-E.

- 229. Wang B, Perronne L, Burke C, Adler RS. Artificial intelligence for classification of soft-tissue masses at us. *Radiology: Art Int* 2021; **3**(1).
- 230. Wang C, Li H, Jiaerken Y, Huang P, Sun L, Dong F, et al. Building CT Radiomics-Based Models for Preoperatively Predicting Malignant Potential and Mitotic Count of Gastrointestinal Stromal Tumors. *Transl Oncol* 2019; **12**(9): 1229-36.
- 231. Wang C, Zhang Z, Dou Y, Liu Y, Chen B, Liu Q, Wang S. Development of clinical and magnetic resonance imaging-based radiomics nomograms for the differentiation of nodular fasciitis from soft tissue sarcoma. *Acta Radiol* 2023; **64**(9): 2578-89.
- 232. Wang FH, Zheng HL, Li JT, Li P, Zheng CH, Chen QY, et al. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features. *Radiol Med (Torino)* 2022; **127**(10): 1085-97.
- 233. Wang H, Chen H, Duan S, Hao D, Liu J. Radiomics and Machine Learning With Multiparametric Preoperative MRI May Accurately Predict the Histopathological Grades of Soft Tissue Sarcomas. *J Magn Reson Imaging* 2020; **51**(3): 791-7.
- 234. Wang H, Nie P, Wang Y, Xu W, Duan S, Chen H, et al. Radiomics nomogram for differentiating between benign and malignant soft-tissue masses of the extremities. *J Magn Reson Imaging* 2020; **51**(1): 155-63.
- 235. Wang H, Zhang J, Bao S, Liu J, Hou F, Huang Y, et al. Preoperative MRI-Based Radiomic Machine-Learning Nomogram May Accurately Distinguish Between Benign and Malignant Soft-Tissue Lesions: A Two-Center Study. *J Magn Reson Imaging* 2020; **52**(3): 873-82.
- 236. Wang J, Shao M, Hu H, Xiao W, Cheng G, Yang G, et al. Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors. *BMC Cancer* 2024; **24**(1): 280.
- 237. Wang J, Xie Z, Zhu X, Niu Z, Ji H, He L, et al. Differentiation of gastric schwannomas from gastrointestinal stromal tumors by CT using machine learning. *Abdom Radiol* 2021; **46**(5): 1773-82.
- 238. Wang JK. Predictive value and modeling analysis of MSCT signs in gastrointestinal stromal tumors (GISTs) to pathological risk degree. *Eur Rev Med Pharmacol Sci* 2017; **21**(5): 999-1005.
- 239. Wang M, Feng Z, Zhou L, Zhang L, Hao X, Zhai J. Computed-Tomography-Based Radiomics Model for Predicting the Malignant Potential of Gastrointestinal Stromal Tumors Preoperatively: A Multi-Classifier and Multicenter Study. *Front oncol* 2021; **11**: 582847.
- 240. Wang P, Yan J, Qiu H, Huang J, Yang Z, Shi Q, Yan C. A radiomics-clinical combined nomogram-based on non-enhanced CT for discriminating the risk stratification in GISTs. *J Cancer Res Clin Oncol* 2023; **149**(14): 12993-3003.
- 241. Wang Q, Zhang Y, Zhang E, Xing X, Chen Y, Nie K, et al. A Multiparametric Method Based on Clinical and CT-Based Radiomics to Predict the Expression of p53 and VEGF in Patients With Spinal Giant Cell Tumor of Bone. *Front oncol* 2022; **12**: 894696.

- 242. Wang Q, Zhang Y, Zhang E, Xing X, Chen Y, Su MY, Lang N. Prediction of the early recurrence in spinal giant cell tumor of bone using radiomics of preoperative CT: Long-term outcome of 62 consecutive patients. *J Bone Oncol* 2021; **27**: 100354.
- 243. Wang S, Sun M, Sun J, Wang Q, Wang G, Wang X, et al. Advancing musculoskeletal tumor diagnosis: Automated segmentation and predictive classification using deep learning and radiomics. *Comput Biol Med* 2024; **175**: 108502.
- 244. Wang Y, Wang Y, Ren J, Jia L, Ma L, Yin X, et al. Malignancy risk of gastrointestinal stromal tumors evaluated with noninvasive radiomics: A multi-center study. *Front oncol* 2022; **12**: 966743.
- 245. Wei CJ, Yan C, Tang Y, Wang W, Gu YH, Ren JY, et al. Computed Tomography-Based Differentiation of Benign and Malignant Craniofacial Lesions in Neurofibromatosis Type I Patients: A Machine Learning Approach. *Front oncol* 2020; **10**: 1192.
- 246. Wei Y, Lu Z, Ren Y. Predictive Value of a Radiomics Nomogram Model Based on Contrast-Enhanced Computed Tomography for KIT Exon 9 Gene Mutation in Gastrointestinal Stromal Tumors. *Technol Cancer Res Treat* 2023; **22**: 15330338231181260.
- 247. White LM, Atinga A, Naraghi AM, Lajkosz K, Wunder JS, Ferguson P, et al. T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival. *Skeletal Radiol* 2023; **52**(3): 553-64.
- 248. Wu Y, Xu L, Yang P, Lin N, Huang X, Pan W, et al. Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography. *EBioMedicine* 2018; **34**: 27-34.
- 249. Xie H, Hu J, Zhang X, Ma S, Liu Y, Wang X. Preliminary utilization of radiomics in differentiating uterine sarcoma from atypical leiomyoma: Comparison on diagnostic efficacy of MRI features and radiomic features. *Eur J Radiol* 2019; **115**: 39-45.
- 250. Xie H, Zhang X, Ma S, Liu Y, Wang X. Preoperative Differentiation of Uterine Sarcoma from Leiomyoma: Comparison of Three Models Based on Different Segmentation Volumes Using Radiomics. *Mol Imaging Biol* 2019; **21**(6): 1157-64.
- 251. Xie H, Zhang Y, Dong L, Lv H, Li X, Zhao C, et al. Deep learning driven diagnosis of malignant soft tissue tumors based on dual-modal ultrasound images and clinical indexes. *Front oncol* 2024; **14**: 1361694.
- 252. Xie Z, Suo S, Zhang W, Zhang Q, Dai Y, Song Y, et al. Prediction of high Ki-67 proliferation index of gastrointestinal stromal tumors based on CT at non-contrast-enhanced and different contrast-enhanced phases. *Eur Radiol* 2024; **34**(4): 2223-32.
- 253. Xie Z, Zhao H, Song L, Ye Q, Zhong L, Li S, et al. A radiograph-based deep learning model improves radiologists' performance for classification of histological types of primary bone tumors: A multicenter study. *Eur J Radiol* 2024; **176**.
- 254. Xu F, Ma X, Wang Y, Tian Y, Tang W, Wang M, et al. CT texture analysis can be a potential tool to differentiate gastrointestinal stromal tumors without KIT exon 11 mutation. *Eur J Radiol* 2018; **107**: 90-7.

- 255. Xu J, Miao L, Wang CX, Wang HH, Wang QZ, Li M, et al. Preoperative Contrast-Enhanced CT-Based Deep Learning Radiomics Model for Distinguishing Retroperitoneal Lipomas and Well-Differentiated Liposarcomas. *Acad Radiol* 2024; **31**(12): 5042-53.
- 256. Xu L, Wang MY, Qi L, Zou YF, Fei-Yun WU, Sun XL. Radiomics approach to distinguish between benign and malignant soft tissue tumors on magnetic resonance imaging. *Eur J Radiol Open* 2024; **12**: 100555.
- 257. Xu L, Yang P, Hu K, Wu Y, Xu-Welliver M, Wan Y, et al. Prediction of neoadjuvant chemotherapy response in high-grade osteosarcoma: added value of non-tumorous bone radiomics using CT images. *Quant imaging med surg* 2021; **11**(4): 1184-95.
- 258. Xu R, Kido S, Suga K, Hirano Y, Tachibana R, Muramatsu K, et al. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions. *Ann Nucl Med* 2014; **28**(9): 926-35.
- 259. Xu W, Hao D, Hou F, Zhang D, Wang H. Soft Tissue Sarcoma: Preoperative MRI-Based Radiomics and Machine Learning May Be Accurate Predictors of Histopathologic Grade. *AJR Am J Roentgenol* 2020; **215**(4): 963-9.
- 260. Xu Z, Niu K, Tang S, Song T, Rong Y, Guo W, He Z. Bone tumor necrosis rate detection in few-shot X-rays based on deep learning. *Comput Med Imaging Graph* 2022; **102**.
- 261. Yamazawa E, Takahashi S, Shin M, Tanaka S, Takahashi W, Nakamoto T, et al. MRI-Based Radiomics Differentiates Skull Base Chordoma and Chondrosarcoma: A Preliminary Study. *Cancers (Basel)* 2022; **14**(13).
- 262. Yan J, Zhao X, Han S, Wang T, Miao F. Evaluation of Clinical Plus Imaging Features and Multidetector Computed Tomography Texture Analysis in Preoperative Risk Grade Prediction of Small Bowel Gastrointestinal Stromal Tumors. *J Comput Assist Tomogr* 2018; **42**(5): 714-20.
- 263. Yan M, Liu Y, You H, Zhao Y, Jin J, Wang J. Differentiation of Small Gastrointestinal Stromal Tumor and Gastric Leiomyoma with Contrast-Enhanced CT. *J healthc eng* 2023; **2023**: 6423617.
- 264. Yan R, Hao D, Li J, Liu J, Hou F, Chen H, et al. Magnetic Resonance Imaging-Based Radiomics Nomogram for Prediction of the Histopathological Grade of Soft Tissue Sarcomas: A Two-Center Study. *J Magn Reson Imaging* 2021; **53**(6): 1683-96.
- 265. Yang F, Feng Y, Sun P, Traverso A, Dekker A, Zhang B, et al. Preoperative prediction of high-grade osteosarcoma response to neoadjuvant therapy based on a plain CT radiomics model: A dual-center study. *J Bone Oncol* 2024; **47**: 100614.
- 266. Yang J, Chen Z, Liu W, Wang X, Ma S, Jin F, Wang X. Development of a Malignancy Potential Binary Prediction Model Based on Deep Learning for the Mitotic Count of Local Primary Gastrointestinal Stromal Tumors. *Korean J Radiol* 2021; **22**(3): 344-53.
- 267. Yang L, Du D, Zheng T, Liu L, Wang Z, Du J, et al. Deep learning and radiomics to predict the mitotic index of gastrointestinal stromal tumors based on multiparametric MRI. *Front oncol* 2022; **12**: 948557.

- 268. Yang L, Ma CF, Li Y, Zhang CR, Ren JL, Shi GF. Application of radiomics in predicting the preoperative risk stratification of gastric stromal tumors. *Diagn Interv Radiol* 2022; **28**(6): 532-9.
- 269. Yang L, Zhang D, Zheng T, Liu D, Fang Y. Predicting the progression-free survival of gastrointestinal stromal tumors after imatinib therapy through multi-sequence magnetic resonance imaging. *Abdom Radiol* 2024; **49**(3): 801-13.
- 270. Yang L, Zheng T, Dong Y, Wang Z, Liu D, Du J, et al. MRI Texture-Based Models for Predicting Mitotic Index and Risk Classification of Gastrointestinal Stromal Tumors. *J Magn Reson Imaging* 2021; **53**(4): 1054-65.
- 271. Yang P, Wu J, Liu M, Zheng Y, Zhao X, Mao Y. Preoperative CT-based radiomics and deep learning model for predicting risk stratification of gastric gastrointestinal stromal tumors. *Med Phys* 2024; **51**(10): 7257-68.
- 272. Yang X, Wang H, Dong Q, Xu Y, Liu H, Ma X, et al. An artificial intelligence system for distinguishing between gastrointestinal stromal tumors and leiomyomas using endoscopic ultrasonography. *Endoscopy* 2022; **54**(3): 251-61.
- 273. Yang Y, Ma X, Wang Y, Ding X. Prognosis prediction of extremity and trunk wall soft-tissue sarcomas treated with surgical resection with radiomic analysis based on random survival forest. *Updates Surg* 2022; **74**(1): 355-65.
- 274. Yang Y, Zhou Y, Zhou C, Ma X. Novel computer aided diagnostic models on multimodality medical images to differentiate well differentiated liposarcomas from lipomas approached by deep learning methods. *Orphanet J Rare Dis* 2022; **17**(1): 158.
- 275. Yang Y, Zhou Y, Zhou C, Zhang X, Ma X. MRI-Based Computer-Aided Diagnostic Model to Predict Tumor Grading and Clinical Outcomes in Patients With Soft Tissue Sarcoma. *J Magn Reson Imaging* 2022; **56**(6): 1733-45.
- 276. Ye Q, Yang H, Lin B, Wang M, Song L, Xie Z, et al. Automatic detection, segmentation, and classification of primary bone tumors and bone infections using an ensemble multi-task deep learning framework on multi-parametric MRIs: a multi-center study. *Eur Radiol* 2024; **34**(7): 4287-99.
- 277. Yildiz Potter I, Yeritsyan D, Mahar S, Wu J, Nazarian A, Vaziri A, Vaziri A. Automated Bone Tumor Segmentation and Classification as Benign or Malignant Using Computed Tomographic Imaging. *J Digit Imaging* 2023; **36**(3): 869-78.
- 278. Yin P, Mao N, Chen H, Sun C, Wang S, Liu X, Hong N. Machine and Deep Learning Based Radiomics Models for Preoperative Prediction of Benign and Malignant Sacral Tumors. *Front Oncol* 2020; **10**.
- 279. Yin P, Mao N, Liu X, Sun C, Wang S, Chen L, Hong N. Can clinical radiomics nomogram based on 3D multiparametric MRI features and clinical characteristics estimate early recurrence of pelvic chondrosarcoma? *J Magn Reson Imaging* 2020; **51**(2): 435-45.
- 280. Yin P, Mao N, Wang S, Sun C, Hong N. Clinical-radiomics nomograms for pre-operative differentiation of sacral chordoma and sacral giant cell tumor based on 3D computed tomography and multiparametric magnetic resonance imaging. *Br J Radiol* 2019; **92**(1101): 20190155.

- 281. Yin P, Mao N, Zhao C, Wu J, Chen L, Hong N. A Triple-Classification Radiomics Model for the Differentiation of Primary Chordoma, Giant Cell Tumor, and Metastatic Tumor of Sacrum Based on T2-Weighted and Contrast-Enhanced T1-Weighted MRI. *J Magn Reson Imaging* 2019; **49**(3): 752-9.
- 282. Yin P, Mao N, Zhao C, Wu J, Sun C, Chen L, Hong N. Comparison of radiomics machine-learning classifiers and feature selection for differentiation of sacral chordoma and sacral giant cell tumour based on 3D computed tomography features. *Eur Radiol* 2019; **29**(4): 1841-7.
- 283. Yin P, Sun C, Wang S, Chen L, Hong N. Clinical-Deep Neural Network and Clinical-Radiomics Nomograms for Predicting the Intraoperative Massive Blood Loss of Pelvic and Sacral Tumors. *Front Oncol* 2021; **11**.
- 284. Yin P, Wang W, Wang S, Liu T, Sun C, Liu X, et al. The potential for different computed tomography-based machine learning networks to automatically segment and differentiate pelvic and sacral osteosarcoma from Ewing's sarcoma. *Quant imaging med surg* 2023; **13**(5): 3174-84.
- 285. Yin P, Zhong J, Liu Y, Liu T, Sun C, Liu X, et al. Clinical-radiomics models based on plain X-rays for prediction of lung metastasis in patients with osteosarcoma. *BMC med imaging* 2023; **23**(1): 40.
- 286. Yin XN, Wang ZH, Zou L, Yang CW, Shen CY, Liu BK, et al. Computed tomography radiogenomics: A potential tool for prediction of molecular subtypes in gastric stromal tumor. *World J Gastrointest Oncol* 2024; **16**(4): 1296-308.
- 287. Yisheng X, Yueqin L, Ming Z. Diagnostic significance of multisequence MRI radiomics models in distinguishing benign and malignant spinal fractures. *J Radiat Res Appl Sci* 2024; **17**(3).
- 288. Yoon H, Choi WH, Joo MW, Ha S, Chung YA. SPECT/CT Radiomics for Differentiating between Enchondroma and Grade I Chondrosarcoma. *Tomography* 2023; **9**(5): 1868-75.
- 289. Yu Y, Guo H, Zhang M, Hou F, Yang S, Huang C, et al. Multi-institutional validation of a radiomics signature for identification of postoperative progression of soft tissue sarcoma. *Cancer Imaging* 2024; **24**(1): 59.
- 290. Yue Z, Wang X, Wang Y, Wang H, Jiang W. Clinical-Radiomics Nomogram from T1W, T1CE, and T2FS MRI for Improving Diagnosis of Soft-Tissue Sarcoma. *Mol Imaging Biol* 2022; **24**(6): 995-1006.
- 291. Yue Z, Wang X, Yu T, Shang S, Liu G, Jing W, et al. Multi-parametric MRI-based radiomics for the diagnosis of malignant soft-tissue tumor. *Magn Reson Imaging* 2022; **91**: 91-9.
- 292. Yuguang Y, Chen Y, Zhu D, Huang Y, Li X, Xiahou J. GHA-DenseNet prediction and diagnosis of malignancy in femoral bone tumors using magnetic resonance imaging. *J Bone Oncol* 2024; **44**: 100520.
- 293. Zhai Y, Bai J, Xue Y, Li M, Mao W, Zhang X, Zhang Y. Development and validation of a preoperative MRI-based radiomics nomogram to predict progression-free survival in patients with clival chordomas. *Front oncol* 2022; **12**: 996262.
- 294. Zhang C, Wang C, Mao G, Cheng G, Ji H, He L, et al. Radiomics analysis of contrast-enhanced computerized tomography for differentiation of gastric schwannomas from gastric gastrointestinal stromal tumors. *J Cancer Res Clin Oncol* 2024; **150**(2): 87.

- 295. Zhang C, Wang J, Yang Y, Dai B, Xu Z, Zhu F, Yu H. Machine learning for predicting the risk stratification of 1-5 cm gastric gastrointestinal stromal tumors based on CT. *BMC med imaging* 2023; **23**(1): 90.
- 296. Zhang L, Gao Q, Dou Y, Cheng T, Xia Y, Li H, Gao S. Evaluation of the neoadjuvant chemotherapy response in osteosarcoma using the MRI DWI-based machine learning radiomics nomogram. *Front oncol* 2024; **14**: 1345576.
- 297. Zhang L, Ge Y, Gao Q, Zhao F, Cheng T, Li H, Xia Y. Machine Learning-Based Radiomics Nomogram With Dynamic Contrast-Enhanced MRI of the Osteosarcoma for Evaluation of Efficacy of Neoadjuvant Chemotherapy. *Front oncol* 2021; **11**: 758921.
- 298. Zhang L, Kang L, Li G, Zhang X, Ren J, Shi Z, et al. Computed tomography-based radiomics model for discriminating the risk stratification of gastrointestinal stromal tumors. *Radiol Med (Torino)* 2020; **125**(5): 465-73.
- 299. Zhang L, Ren Z. Comparison of CT and MRI images for the prediction of soft-tissue sarcoma grading and lung metastasis via a convolutional neural networks model. *Clin Radiol* 2020; **75**(1): 64-9.
- 300. Zhang L, Yang Y, Wang T, Chen X, Tang M, Deng J, et al. Intratumoral and peritumoral MRI-based radiomics prediction of histopathological grade in soft tissue sarcomas: a two-center study. *Cancer Imaging* 2023; **23**(1): 103.
- 301. Zhang M, Tong E, Hamrick F, Lee EH, Tam LT, Pendleton C, et al. Machine-Learning Approach to Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors: A Multicenter Study. *Neurosurgery* 2021; **89**(3): 509-17.
- 302. Zhang M, Tong E, Wong S, Hamrick F, Mohammadzadeh M, Rao V, et al. Machine learning approach to differentiation of peripheral schwannomas and neurofibromas: A multi-center study. *Neuro-oncol* 2022; **24**(4): 601-9.
- 303. Zhang QW, Gao YJ, Zhang RY, Zhou XX, Chen SL, Zhang Y, et al. Personalized CT-based radiomics nomogram preoperative predicting Ki-67 expression in gastrointestinal stromal tumors: a multicenter development and validation cohort. *Clin Transl Med* 2020; **9**(1): 12.
- 304. Zhang QW, Zhang RY, Yan ZB, Zhao YX, Wang XY, Jin JZ, et al. Personalized radiomics signature to screen for KIT-11 mutation genotypes among patients with gastrointestinal stromal tumors: a retrospective multicenter study. *J transl med* 2023; **21**(1): 726.
- 305. Zhang QW, Zhou XX, Zhang RY, Chen SL, Liu Q, Wang J, et al. Comparison of malignancy-prediction efficiency between contrast and non-contract CT-based radiomics features in gastrointestinal stromal tumors: A multicenter study. *Clin Transl Med* 2020; **10**(3): e291.
- 306. Zhang XD, Zhang L, Gong TT, Wang ZR, Guo KL, Li J, et al. A combined radiomic model distinguishing GISTs from leiomyomas and schwannomas in the stomach based on endoscopic ultrasonography images. *J appl clin med phys* 2023; **24**(7): e14023.
- 307. Zhang Y, Yue X, Zhang P, Zhang Y, Wu L, Diao N, et al. Clinical-radiomics-based treatment decision support for KIT Exon 11 deletion in gastrointestinal stromal tumors: a multi-institutional retrospective study. *Front oncol* 2023; **13**: 1193010.

- 308. Zhang Y, Zhao H, Liu Y, Zeng M, Zhang J, Hao D. Diagnostic Performance of Dynamic Contrast-Enhanced MRI and 18F-FDG PET/CT for Evaluation of Soft Tissue Tumors and Correlation with Pathology Parameters. *Academic Radiology* 2022.
- 309. Zhang Y, Zhu Y, Shi X, Tao J, Cui J, Dai Y, et al. Soft Tissue Sarcomas: Preoperative Predictive Histopathological Grading Based on Radiomics of MRI. *Acad Radiol* 2019; **26**(9): 1262-8.
- 310. Zhao K, Zhang M, Xie Z, Yan X, Wu S, Liao P, et al. Deep Learning Assisted Diagnosis of Musculoskeletal Tumors Based on Contrast-Enhanced Magnetic Resonance Imaging. *J Magn Reson Imaging* 2022; **56**(1): 99-107.
- 311. Zhao S, Su Y, Duan J, Qiu Q, Ge X, Wang A, Yin Y. Radiomics signature extracted from diffusion-weighted magnetic resonance imaging predicts outcomes in osteosarcoma. *J Bone Oncol* 2019; **19**: 100263.
- 312. Zhao Y, Feng M, Wang M, Zhang L, Li M, Huang C. CT Radiomics for the Preoperative Prediction of Ki67 Index in Gastrointestinal Stromal Tumors: A Multi-Center Study. *Front oncol* 2021; **11**: 689136.
- 313. Zheng F, Yin P, Liang K, Wang Y, Hao W, Hao Q, Hong N. Fusion Radiomics-Based Prediction of Response to Neoadjuvant Chemotherapy for Osteosarcoma. *Acad Radiol* 2024; **31**(6): 2444-55.
- 314. Zheng F, Yin P, Liang KW, Liu T, Wang YJ, Hao WH, et al. Comparison of Different Fusion Radiomics for Predicting Benign and Malignant Sacral Tumors: A Pilot Study. *Journal of Imaging Informatics in Medicine* 2024.
- 315. Zheng J, Liao Q, Chen X, Hong M, Mazzocca A, Urbini M, et al. Development and validation of a computed tomography-based radiomics signature to predict "highest-risk" from patients with high-risk gastrointestinal stromal tumor. *J gastrointest oncol* 2024; **15**(1): 125-33.
- 316. Zheng J, Xia Y, Xu A, Weng X, Wang X, Jiang H, et al. Combined model based on enhanced CT texture features in liver metastasis prediction of high-risk gastrointestinal stromal tumors. *Abdom Radiol* 2022; **47**(1): 85-93.
- 317. Zheng Y, Chen L, Liu M, Wu J, Yu R, Lv F. Prediction of Clinical Outcome for High-Intensity Focused Ultrasound Ablation of Uterine Leiomyomas Using Multiparametric MRI Radiomics-Based Machine Leaning Model. *Front oncol* 2021; **11**: 618604.
- 318. Zheng Y, Chen L, Liu M, Wu J, Yu R, Lv F. Nonenhanced MRI-based radiomics model for preoperative prediction of nonperfused volume ratio for high-intensity focused ultrasound ablation of uterine leiomyomas. *Int J Hyperthermia* 2021; **38**(1): 1349-58.
- 319. Zhong J, Zhang C, Hu Y, Zhang J, Liu Y, Si L, et al. Automated prediction of the neoadjuvant chemotherapy response in osteosarcoma with deep learning and an MRI-based radiomics nomogram. *Eur Radiol* 2022; **32**(9): 6196-206.
- 320. Zhou Y, Zhang J, Chen J, Yang C, Gong C, Li C, Li F. Prediction using T2-weighted magnetic resonance imaging-based radiomics of residual uterine myoma regrowth after high-intensity focused ultrasound ablation. *Ultrasound Obstet Gynecol* 2022; **60**(5): 681-92.

- 321. Zhou Z, Xie P, Dai Z, Wu J. Self-supervised tumor segmentation and prognosis prediction in osteosarcoma using multiparametric MRI and clinical characteristics. *Comput Methods Programs Biomed* 2024; **244**: 107974.
- 322. Zhu MP, Ding QL, Xu JX, Jiang CY, Wang J, Wang C, Yu RS. Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs). *Abdom Radiol* 2022; **47**(9): 3161-73.
- 323. Zhuo M, Chen X, Guo J, Qian Q, Xue E, Chen Z. Deep Learning-Based Segmentation and Risk Stratification for Gastrointestinal Stromal Tumors in Transabdominal Ultrasound Imaging. *J Ultrasound Med* 2024; **43**(9): 1661-72.
- 324. Zhuo M, Guo J, Tang Y, Tang X, Qian Q, Chen Z. Ultrasound radiomics model-based nomogram for predicting the risk Stratification of gastrointestinal stromal tumors. *Front oncol* 2022; **12**: 905036.
- 325. Zhuo M, Tang Y, Guo J, Qian Q, Xue E, Chen Z. Predicting the risk stratification of gastrointestinal stromal tumors using machine learning-based ultrasound radiomics. *J Med Ultrason (2001)* 2024; **51**(1): 71-82.